

DocMode Health Technologies Limited

Reg Office : 307, Shivai Plaza,
Marol Cooperative Industrial Estate
Road, Sagbag, Marol, Andheri East,
Mumbai - 400059, Maharashtra.
CIN : L74999MH2017PLC297413
Contact no : +91 90821 70046
Email : support@docmode.org
Website : www.docmode.org



Date: 29.08.2025

To,
The Manager / Secretary – Listing,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: **DHTL**

Subject: Notice of the 8th Annual General Meeting (AGM) and Annual Report for financial year 2024-2025.

Dear Sir/ Madam,

Please find enclosed herewith the Notice of the 8th Annual General Meeting of the Company scheduled to be held on Tuesday, 30th September, 2025 at 02:00 p.m. at 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India, alongwith the Annual Report for financial year 2024-2025.

The schedule of the 8th AGM of the Company is set out below:

Particulars	Details
Day, Date & Time of AGM	Tuesday, 30 th September, 2025
Cut-off for attending AGM	Tuesday, 23 rd September, 2025

The Annual Report for year ended 31st March, 2025 will be available on the Company's website at <https://docmode.org/annual-report/> under section "Investors", on the website of NSE Limited at www.nseindia.com and is being dispatched to all shareholders whose email IDs are registered with the Company/Depositories as on record date of 29th August, 2025.

Kindly take the same on record.

Thanking you,

Yours faithfully,

FOR DOCMODE HEALTH TECHNOLOGIES LIMITED

PAULSON PAUL THAZHATHEDATH
WHOLETIME DIRECTOR
DIN: 02301881



Transforming Learning and Practice

CIN: L74999MH2017PLC297413

2024 - 25

ANNUAL REPORT

**Registered Office Address: 307, Shivai Plaza, Marol Cooperative Industrial
Estate Road, Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India**

INDEX

Sr. No.	Particulars	Page Number
1.	Company Overview	3
2.	Company's Unique Selling Propositions (USPs)	5
3.	MD, Founder & Chairman's Letter	7
4.	Strategic Outlook & Growth Initiatives	10
5.	Board of Directors	11
6.	Corporate Information	12
7.	Products & Services	13
8.	Review of Performance	15
9.	Directors' Report and Annexures to Directors' Report	16
10.	Management Discussion and Analysis	30
11.	Independent Auditors Report on Standalone Financials	44
12.	Standalone Financial Statements	53
13.	Independent Auditors Report on Consolidated Financials	73
14.	Consolidated Financial Statements	79
15.	Notice of Annual General Meeting to Shareholders	98

1. COMPANY OVERVIEW:

I am pleased to present the updated Annual Report of DocMode Health Technologies Limited for the financial year 2025-26. This report highlights the company's strategic transformation toward comprehensive healthcare research and data-driven solutions, positioning us as a leader in the evolving healthcare ecosystem.

DocMode is a pioneering healthcare technology company that has strategically evolved into a comprehensive healthcare ecosystem encompassing medical education, clinical research, contract research services, and practice enhancement solutions. With our enhanced vision to "Transform Learning & Practice" in the medical fraternity while establishing leadership in healthcare research and data analytics, the company has positioned itself as India's premier integrated healthcare research and technology provider focused on building a robust healthcare ecosystem.

Originally incorporated as "Docmode Health Technologies Private Limited" in Mumbai, Maharashtra in 2017, the company was converted to a public limited company in December 2022 and renamed "Docmode Health Technologies Limited." Under the experienced leadership of our founders with over 25 years of collective expertise in healthcare advertising, health IT, healthcare communications, and event management, DocMode has evolved into a multi-faceted organization serving diverse stakeholders across the global healthcare ecosystem.

Expanded Product & Services Portfolio:

DocMode's comprehensive healthcare ecosystem now encompasses six key business segments focused on research and data-driven solutions:

DocMode LERN Platform: Our flagship learning environment serves 2,45,736 registered healthcare professionals through increasing associations and partnerships with leading medical institutions and universities globally. The platform has conducted a 15% increase in national and international speaker programs since last year, with enhanced focus on hybrid models incorporating fellowships to provide comprehensive professional development pathways.

DocMode SURE Platform: Our research platform has achieved a milestone with 25,000 registered healthcare professionals, making it the largest group of HCPs registered for conducting real-world studies and post-marketing surveillance studies in clinical research. This verified network provides unparalleled capabilities for evidence-based research initiatives under independent ethical committee supervision.

DocMode CARE: Our practice enhancement segment features the Nutritional Management Software focused on providing standalone providers access and integrating with AI capabilities, alongside our AI-powered Clinical Decision Support system serving the healthcare professional community with advanced clinical decision-making tools.

Clinical Research & CRO Services: Our expanded Contract Research Organization capabilities offer comprehensive Phase I-IV clinical trial management, post-marketing surveillance, and regulatory submissions, supported by our CDSCO-approved Ethics Committee.

CRAMS Services: Our Contract Research and Manufacturing Services provide analytical services, method development, stability studies, and regulatory support for pharmaceutical research and development activities.

DocMode KNOW: Our knowledge marketing services assist medico-marketing organizations with scientific promotional literature and customized learning initiatives.

Strategic Evolution and Market Position:

The past year has marked a pivotal transformation for DocMode as we strategically expanded beyond medical education technology into comprehensive pharmaceutical research services focused on advancing the healthcare ecosystem through research and data-driven solutions. This evolution positions

us to capture substantial opportunities in both domestic and international clinical research markets while maintaining our core strengths in healthcare professional education and technology solutions.

Our strategic shift toward traditional pharmaceutical business models, combined with our technology-driven approach, creates a unique competitive advantage in the rapidly growing clinical research sector. The company now serves as a bridge between innovative healthcare technology and established pharmaceutical research methodologies, offering clients integrated solutions within a comprehensive healthcare ecosystem.

With a current team of 75 employees spanning senior executives to specialized technical personnel, DocMode maintains operational agility while scaling capabilities across multiple business verticals. Our ISO 27001:2013 certification for Information Security Management System and "ready" status from Skill India underscore our commitment to quality and compliance in building a robust healthcare ecosystem.

Market Expansion and Global Vision:

DocMode aspires to establish itself as India's comprehensive answer to global healthcare ecosystem leaders, competing through our unique combination of technology innovation, research excellence, and data analytics capabilities. Our expanded international focus, particularly in CRO and CRAMS services, positions us to serve global pharmaceutical companies while contributing to the advancement of the global healthcare ecosystem.

The company's asset-light, technology-driven business model, combined with strong network effects and our experienced management team, enables rapid scalability and market expansion without substantial capital requirements. Our comprehensive ecosystem approach differentiates us from specialized players by offering integrated research and data solutions across the entire healthcare value chain, ultimately strengthening the overall healthcare ecosystem.

2. COMPANY'S UNIQUE SELLING PROPOSITIONS (USPs):

DocMode's competitive advantage stems from our unique position as an integrated healthcare ecosystem provider that combines cutting-edge technology with comprehensive pharmaceutical research capabilities. Our evolved value proposition addresses the full spectrum of healthcare industry needs through both innovative digital solutions and traditional research excellence.

Comprehensive Healthcare Ecosystem Integration

DocMode has established the industry's most comprehensive ecosystem that seamlessly integrates medical education, clinical practice enhancement, pharmaceutical research, contract research services, and evidence-based studies within a unified healthcare ecosystem. Unlike specialized providers who focus on single verticals, our integrated approach creates synergies that deliver superior value across all stakeholder groups while generating multiple revenue streams from interconnected services that strengthen the overall healthcare ecosystem.

Clinical Research & CRO Leadership

Our expanded clinical research capabilities position DocMode as a leading Contract Research Organization with end-to-end clinical trial management services spanning Phase I through Phase IV studies. The CDSCO approval of our Ethics Committee provides independent research oversight capability, while our comprehensive CRAMS services offer pharmaceutical companies complete research and manufacturing support. This focus on traditional pharmaceutical research creates substantial revenue opportunities in established, high-value market segments while contributing valuable data to the healthcare ecosystem.

International Market Penetration Strategy

DocMode's strategic expansion into international CRO and CRAMS markets leverages our regulatory compliance capabilities and cost-effective service delivery model to serve the global healthcare ecosystem. Our focus on building long-term relationships with multinational pharmaceutical companies creates sustainable competitive advantages in the global clinical research sector, while our specialized expertise in emerging therapeutic areas positions us for future leadership in healthcare research and data generation.

Technology-Driven Research Excellence

Our unique approach combines traditional pharmaceutical research methodologies with cutting-edge technology platforms, creating efficiency advantages in data collection and analysis that established players cannot easily replicate. The integration of AI-powered Clinical Decision Support, comprehensive learning management systems (LERN), and advanced research platforms (SURE) with traditional CRO services creates a differentiated position in the healthcare ecosystem.

Exclusive Distribution Network Model

The development of our exclusive reseller and distributor network creates competitive advantages through established healthcare relationships, enhanced market penetration, accelerated service delivery, and comprehensive geographic coverage. This strategic partnership approach leverages local market knowledge while maintaining centralized quality control and service standards across the healthcare ecosystem.

Verified Healthcare Professional Network for Research

Our community of 25,000 verified healthcare professionals on the SURE platform, representing the largest group of HCPs registered for conducting real-world studies, combined with 2,45,736 registered users across all platforms, creates unparalleled access to the medical community for research, education, and market intelligence purposes. This verified network provides authentic insights and research capabilities that contribute valuable data to the global healthcare ecosystem.

Regulatory Compliance and Quality Leadership

Our proactive approach to regulatory compliance, evidenced by ISO 27001:2013 certification and CDSCO Ethics Committee approval, positions DocMode as the preferred partner for pharmaceutical companies requiring rigorous quality standards. This compliance leadership creates barriers to entry and enables premium pricing for high-value services.

Scalable Asset-Light Business Model

DocMode's technology-driven infrastructure enables global service delivery without geographical constraints, while our cloud-based platforms support unlimited scaling without proportional infrastructure investments. The network effects generated across our ecosystem create sustainable competitive moats that strengthen with increased adoption.

3. MD, FOUNDER & CFO'S LETTER:

Paresh Sampat, Managing Director

Dear Respected Investors,

I am pleased to address you at this pivotal moment in DocMode's journey, where our transformation into a comprehensive healthcare research and technology ecosystem is delivering both strategic and financial strength.

While our Chairman has laid out the long-term vision and our CEO has articulated the execution roadmap, I wish to share how our management team is ensuring disciplined implementation, sound governance, and sustainable value creation for all stakeholders.

The expansion into Contract Research Organization (CRO) and CRAMS services marks a defining step for DocMode. With the approval of our Ethics Committee by CDSCO, we now possess the regulatory foundation to conduct clinical trials of the highest international standards. This regulatory credibility, combined with our technology-driven platforms, provides us with a unique edge in the highly competitive pharmaceutical research landscape.

From an operational perspective, our focus remains on:

- Execution Discipline - Ensuring every clinical and research project is delivered on time, with precision and uncompromising quality.
- Risk Management - Establishing rigorous compliance, data security, and ethical oversight frameworks aligned with both Indian and international requirements.
- Financial Prudence - Pursuing profitable growth by balancing high-margin opportunities with cost-optimized operations.
- Human Capital Development - Strengthening our talent pool of researchers, technologists, and healthcare professionals who are the backbone of our success.

We are particularly encouraged by the traction in our international CRO and CRAMS engagements, where our India-based operations provide both cost efficiency and world-class quality. The exclusive reseller and distributor partnerships being established across global markets will accelerate expansion without overstretching our internal resources, thereby safeguarding shareholder interests.

Our Q1 FY 2025-26 results reinforce this strategy, with robust performance across both traditional and new service lines. More importantly, the pipeline visibility we now have in pharmaceutical research gives us confidence in sustaining this momentum in the coming quarters.

As Managing Director, I view my role as ensuring that the bold vision of our leadership is matched with robust execution, transparent governance, and measurable outcomes. Together, these elements will secure DocMode's place as a credible, high-growth player in the global healthcare research market while delivering sustainable returns to you, our valued investors.

I extend my gratitude for your continued trust and support as we advance confidently on this exciting journey.

Paulson Paul Thazhathedath, Founder & Chairman

Dear Valued Investors,

I write to you today with tremendous confidence about DocMode's strategic transformation and the exceptional opportunities ahead. The past year has been transformational as we successfully evolved from a specialized med-ed-tech platform into a comprehensive healthcare research and technology ecosystem that addresses the full spectrum of pharmaceutical industry needs.

Our strategic expansion into clinical research and Contract Research Organization services represents a fundamental shift that positions DocMode to capture substantial value in traditional, high-margin pharmaceutical business segments. The CDSCO approval of our Ethics Committee and our comprehensive CRAMS capabilities establish us as a serious player in the global clinical research market, where demand continues to outpace supply.

The development of our international CRO and CRAMS strategy opens unprecedented opportunities in global pharmaceutical markets. Our cost-effective Indian operations, combined with world-class regulatory compliance and technology platforms, create competitive advantages that established international players cannot easily replicate. We are targeting long-term partnerships with multinational pharmaceutical companies that will provide sustainable, high-value revenue streams.

Our exclusive reseller and distributor network strategy will accelerate market penetration while leveraging established healthcare relationships across multiple geographies. This approach reduces our direct market development costs while expanding reach and revenue potential across all service lines. The strong Q1 performance for FY 2025-26 validates our strategic direction and operational execution capabilities. We are confident that our focus on increasing bottom-line profitability while maintaining aggressive revenue growth will deliver substantial returns to our investors.

DocMode's unique position as both a technology innovator and traditional pharmaceutical research provider creates multiple pathways for value creation. Our verified network of 15,000+ healthcare professionals, combined with our expanding clinical research capabilities, positions us to capture opportunities across the entire healthcare value chain.

I am particularly excited about our international expansion potential and the substantial market opportunities in contract research and manufacturing services. These traditional pharmaceutical business models, enhanced by our technology capabilities, provide clear pathways to significant revenue growth and market leadership.

With our experienced management team, robust operational capabilities, and strategic market positioning, DocMode is poised to deliver exceptional returns while transforming the healthcare research landscape.

Hans Albert Lewis, Founder Whole Time Director & Chief Executive Officer

Dear Esteemed Investors,

As CEO of DocMode Health Technologies, I am excited to share our strategic evolution and the remarkable growth opportunities we have created through our expansion into comprehensive pharmaceutical research services. Our transformation from a healthcare education platform into an integrated research and technology ecosystem represents a strategic leap that positions us for substantial value creation.

Our enhanced clinical research capabilities, centered around our Contract Research Organization and CRAMS services, create immediate access to high-value pharmaceutical research markets. The CDSCO approval of our Ethics Committee provides the regulatory foundation for conducting clinical studies that meet international standards, while our comprehensive service portfolio addresses the complete spectrum of pharmaceutical research needs.

The technology integration across our traditional research services creates operational efficiencies that provide competitive advantages in both domestic and international markets. Our AI-powered platforms, combined with proven pharmaceutical research methodologies, deliver superior results while maintaining cost leadership that international clients find compelling.

Our international CRO strategy focuses on building long-term partnerships with global pharmaceutical companies through demonstrated excellence in research delivery, regulatory compliance, and cost-effective service models. The initial market feedback has been exceptionally positive, with several multinational companies expressing interest in comprehensive research partnerships.

The development of our exclusive reseller and distributor network will accelerate market expansion while reducing direct sales costs. This partnership approach leverages established healthcare networks and local market expertise to expand our reach across multiple geographies and service categories.

Our financial outlook for FY 2025-26 reflects the substantial revenue potential of our expanded service portfolio. The clinical research and CRAMS markets offer significantly higher per-project values compared to our traditional education services, while our technology platforms enable efficient scaling without proportional cost increases.

The Q1 performance demonstrates strong momentum across all business segments, with particular strength in our clinical research initiatives. Our pipeline of potential projects, both domestic and international, provides confidence in sustained growth throughout the fiscal year.

Our commitment to operational excellence, combined with strategic market positioning in high-growth pharmaceutical research segments, creates multiple value creation opportunities. The integration of technology-driven efficiency with traditional pharmaceutical business models provides sustainable competitive advantages that will drive long-term investor returns.

DocMode's evolution into a comprehensive healthcare research ecosystem, supported by our technology platforms and experienced team, positions us to capture substantial market opportunities while delivering consistent, profitable growth. We are confident that our strategic initiatives will create significant value for all stakeholders.

4. STRATEGIC OUTLOOK & GROWTH INITIATIVES:

Enhanced Market Position: DocMode's strategic transformation establishes us as a unique hybrid organization that combines technology innovation with traditional pharmaceutical research excellence. Our comprehensive service portfolio addresses evolving industry needs while our international expansion strategy targets high-value global opportunities.

Revenue Diversification: Our multi-segment approach across education, clinical research, contract services, and technology platforms creates resilient revenue streams while reducing dependency on any single market segment. The focus on traditional pharmaceutical business models provides access to established, high-margin market opportunities.

Investment in Excellence: Continued investment in regulatory compliance, technology platforms, and international market development will drive sustainable competitive advantages while positioning DocMode for leadership in the evolving healthcare research landscape.

With our expanded capabilities, strategic market positioning, and commitment to operational excellence, DocMode Health Technologies Limited is poised to deliver exceptional value to investors while transforming the healthcare research and education ecosystem globally.

5. BOARD OF DIRECTORS:

Paresh Jaysih Sampat is the Managing Director of our company. He has completed his FCMA from Institute of Cost Accountants of India, he is Fellow member of the Institute of Company Secretaries of India (FCS), Chartered Management Accountant (C.I.M.A. from London, U.K.), LL.B. (Degree) from Mumbai University, Bachelor of Commerce (B.Com) from Mumbai University. He has extensive experience in the areas of Managing Commercial Operations, Fund raising, Public Issue (IPO), Capital structuring, Private Equity, Mergers, Company Secretarial and Corporate Compliances, Cost Audit, MIS development and managing the entire Operations and Corporate affairs of the Business.

Paulson Paul Thazhathedath, is the Promoter and Whole-time Director of our Company. He has completed his formal education. He has over 15 years of experience in the field of mass media and advertisement, and has been instrumental in shaping the strategic direction of the company.

Hans Albert Lewis, is the Promoter, Chief Financial Officer and Whole-time Director of our Company. He completed his graduation in mass media, advertising from Wilson College, Mumbai in the year 2004. He has over 15 years of experience in the field of mass media and advertisement, and plays a key role in the company's financial management and operations.

Monina Elizabeth Lewis is the Non-Executive Director of our Company. She completed degree of bachelor of science from Mumbai University in 2001. She has been on board of our Company since March 20, 2023. She has over 6 years of experience as an officer coordination and training follow-up employee in a foreign airline company

Sujit Nityanand Chakraborty is the Non-Executive Director of our Company. He completed degree of mast of computer applications from Indira Gandhi National Open University in 2008. Also he holds degree of international executive master of business administration in project management from Ulyanovsk State University of Russian Foundation. He has more than 25 years of experience in the field of information technology.

Nilay Shivnarayan Sharma is the Independent Non-Executive Director of our Company. He completed degree of bachelor of engineering from Shivaji University, Kolhapur. He has more than 30 years of experience in the field of information technology.

The diverse backgrounds and extensive experience of the Board members, coupled with their unwavering commitment to the company's vision, have been instrumental in guiding DocMode's growth and ensuring the effective oversight of its operations. The Board's strong leadership and strategic guidance have been crucial in positioning the company as a leading player in the healthcare technology ecosystem.

6. CORPORATE INFORMATION:

NAME AND DESIGNATION OF DIRECTORS:

Name of the Director	DIN	Designation
Mr. Paresh Jaysih Sampat	00410185	Managing Director
Mr. Paulson Paul Thazhathedath	02301881	Whole Time Director
Mr. Hans Albert Lewis	02301853	Whole Time Director
Mr. Sujit Nityanand Chakraborty	07275025	Independent Director
Mr. Nilay Shivnarayan Sharma	00231299	Independent Director
Ms. Monina Elizabeth Lewis	10147743	Non-Executive Director

* Mr. Krushang Rajenkumar Shah resigned as an Independent Director & Ms. Hiral Rushang Gandhi resigned as Non-Executive Director of the company respectively, w.e.f. 24th April, 2024.

KEY MANAGERIAL PEERSONNEL (KMP):

Name of the KMP	DIN / PAN	Designation
Mr. Paresh Jaysih Sampat	00410185	Managing Director
Mr. Hans Albert Lewis	ACOPL6883G	Chief Financial Officer
Mr. Hans Albert Lewis	02301853	Whole Time Director
Mr. Paulson Paul Thazhathedath	02301881	Whole Time Director

* Ms. Reshma Susan Thomas, Company Secretary and Compliance Officer resigned from the company, w.e.f. 30th April, 2024.

AUDIT COMMITTEE, NOMINATION AND REMUNERATION COMMITTEE AND
STAKEHOLDERS' RELATIONSHIP COMMITTEE:

Mr. Sujit Nityanand Chakraborty	Chairman
Mr. Nilay Shivnarayan Sharma	Member
Ms. Monina Elizabeth Lewis	Member

* Mr. Krushang Rajenkumar Shah resigned as an independent director of the company respectively, w.e.f. 24th April, 2024

INTERNAL AUDITOR: M/s. C.J.K. Associates Chartered Accountant (Firm Registration Number 117467W)	REGISTRAR AND TRANSFER AGENT: Bigshare Services Private Limited E-3, Ansa Industrial Estate, Saki Vihar Road, Sakinaka, Mumbai – 400072, Maharashtra, India
BANKERS: ICICI Bank	REGISTERED OFFICE: 307, Shivai Plaza, Marol Cooperative Industrial Estate Road, Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India
STATUTORY AUDITOR: M/s. R. Sundaresan Aiyar & Co., Chartered Accountant	LISTED ON: National Stock Exchange Registrar and Share Transfer Agent
SECRETARIAL AUDITORS: M/s. Vidhi Jobanputra & Co., Practicing Company Secretary (FCS No.: 11160 C. P. No.: 22293)	

7. PRODUCTS & SERVICES:

DocMode's comprehensive product suite caters to the diverse needs of healthcare professionals, spanning across our integrated healthcare ecosystem focused on research, data analytics, and evidence-based practice enhancement.

7.1 DocMode LERN:

Certification Programs: DocMode offers comprehensive certification programs through increasing associations and partnerships with leading medical institutions and universities globally, providing healthcare professionals with internationally recognized credentials and continuing education opportunities.

National & International Speaker Programs: The platform has conducted a 15% increase in national and international speaker programs since last year, with enhanced focus on hybrid models incorporating fellowships to provide comprehensive professional development pathways. These programs invite key opinion leaders and subject matter experts to facilitate learning and networking initiatives.

Live Interactive Case-Based Quiz Program with Polling: DocMode facilitates discussions on complicated clinical cases, where participants can share their answers through live polling with real-time results and expert analysis.

Gapsule: This platform aims to bridge the knowledge gap and ensure the uninterrupted flow of information between the pharmaceutical industry, medical practitioners, and healthcare providers through structured educational content and industry insights.

7.2 DocMode SURE:

Market Research: The SURE platform offers comprehensive market research services, including understanding knowledge gaps, product e-detailing, rating and feedback systems, competitor analysis, literature studies, and behavioral research for evidence-based decision making.

Clinical Research: The SURE platform facilitates clinical research initiatives including real-world studies, post-marketing surveillance studies, Phase IV clinical trials, and the development of electronic data capturing (EDC) tools for comprehensive data collection and analysis.

Real-World Evidence Generation: With 25,000 registered healthcare professionals, making it the largest group of HCPs registered for conducting real-world studies and post-marketing surveillance studies in clinical research, the platform provides unparalleled capabilities for generating authentic clinical evidence.

7.3 DocMode KNOW

Knowledge Marketing Services: This segment assists medico-marketing organizations through the creation of scientific promotional literature, medical writing services, regulatory documentation, and customization of learning initiatives.

CRM Solutions: Comprehensive customer relationship management solutions tailored for pharmaceutical and healthcare organizations to optimize their engagement with healthcare professionals.

Regulatory Support Services: Specialized support for regulatory submissions, compliance documentation, and strategic regulatory consulting for pharmaceutical and medical device companies.

7.4 DocMode CARE

Clinical Nutrition Management Tool: Our nutrition management solution focuses on providing standalone providers access to comprehensive nutritional assessment and planning capabilities while integrating with AI technologies for enhanced clinical decision support and patient care optimization.

AI-based Clinical Decision Support System (CDSS): Our advanced clinical decision support platform empowers doctors to make better-informed decisions by providing real-time access to comprehensive knowledge bases, clinical guidelines, evidence-based protocols, and intelligent decision support algorithms.

Practice Management Solutions: Integrated tools for healthcare providers to enhance patient care, streamline clinical workflows, and strengthen the HCP-Patient relationship through technology-driven practice enhancement.

7.5 Clinical Research & CRO Services

Phase I-IV Clinical Trial Management: Comprehensive clinical trial services including protocol development, site management, patient recruitment, data management, and regulatory submissions with full regulatory compliance.

Post-Marketing Surveillance: Specialized services for ongoing safety monitoring and effectiveness assessment of pharmaceutical products in real-world clinical settings.

Ethics Committee Services: Independent ethical review and oversight of clinical research protocols through our CDSCO-approved Ethics Committee, ensuring compliance with international research standards.

Electronic Data Capturing (EDC) Systems: Advanced digital platforms for clinical trial data collection, management, and analysis with real-time monitoring and quality assurance capabilities.

7.6 CRAMS Services

Analytical Services: Comprehensive analytical testing and validation services for pharmaceutical research and development, including method development and validation protocols.

Bioequivalence Studies: Specialized bioequivalence and bioavailability studies for generic drug development and regulatory submissions.

Stability Studies: Long-term and accelerated stability testing services supporting pharmaceutical product development and regulatory requirements.

Method Development & Validation: Custom analytical method development and validation services for pharmaceutical compounds and formulations.

Regulatory Strategy & Support: Strategic consulting and comprehensive regulatory support for drug development programs, including submission preparation and regulatory affairs management.

8. REVIEW OF PERFORMANCE

I am pleased to report that DocMode has strategically positioned itself for enhanced performance in FY 2025-26, with our expanded healthcare ecosystem approach and focus on research and data-driven solutions showing strong momentum across all business segments.

Key Performance Highlights:

8.1 Enhanced Research Capabilities & Market Position

DocMode's transformation into a comprehensive healthcare research ecosystem has significantly strengthened our market position. Our Clinical Research & CRO services expansion, supported by CDSCO Ethics Committee approval, positions us to capture substantial opportunities in both domestic and international pharmaceutical research markets.

8.2 Platform Growth & Network Expansion

DocMode LERN Growth: Our learning platform now serves 2,45,736 registered healthcare professionals, representing continued expansion of our educational ecosystem. The 15% increase in speaker programs with hybrid fellowship models demonstrates our commitment to comprehensive professional development.

DocMode SURE Leadership: With 25,000 registered healthcare professionals, we have established the largest HCP network for conducting real-world studies and post-marketing surveillance studies in clinical research, providing unparalleled research capabilities and market intelligence.

Technology-Enhanced Services: Our AI-based Clinical Decision Support System and Clinical Nutrition Management Tool continue to demonstrate strong adoption among healthcare providers, with enhanced AI integration improving clinical outcomes and provider satisfaction.

8.3 Revenue Diversification Strategy

Our strategic focus on traditional pharmaceutical business models, combined with technology-driven efficiency, has created multiple high-value revenue streams. The expansion into CRAMS services and international CRO partnerships provides access to established, high-margin market segments while our exclusive reseller and distributor network strategy accelerates market penetration.

8.4 Operational Excellence & Compliance

Our ISO 27001:2013 certification for Information Security Management and "ready" status from Skill India, combined with CDSCO Ethics Committee approval, underscore our commitment to operational excellence and regulatory compliance across all service offerings.

8.5 Strategic Partnerships & Market Expansion

The development of increasing associations and partnerships with medical institutions and universities globally strengthens our educational offerings, while our Master Service Agreements with major pharmaceutical companies establish long-term revenue relationships in clinical research and market intelligence.

8.6 Future Performance Outlook

The strong Q1 performance for FY 2025-26 validates our strategic direction toward research and data-driven healthcare ecosystem solutions. Our focus on increasing bottom-line profitability while maintaining aggressive revenue growth, combined with our expanded international CRO and CRAMS capabilities, positions DocMode for sustained high-performance results. Through our comprehensive healthcare ecosystem approach, spanning education, research, clinical services, and data analytics, DocMode has positioned itself as an integrated solution provider that addresses the complete spectrum of healthcare industry needs while contributing to the advancement of evidence-based medical practice globally.

DOCMODE HEALTH TECHNOLOGIES LIMITED
DIRECTORS' REPORT

**To,
The Members,**

Your Directors take pleasure in presenting 8th (Eighth) Annual Report of your Company together with the Audited Financial Statement for the year ended 31st March, 2025.

1. Financial Performance of the Company:

(Rupees in Lakhs)

Particulars	Standalone		Consolidated	
	2024-25	2023-24	2024-25	2023-24
Income	4270.27	4014.33	4270.28	4,014.33
Expenditure	4467.29	3,979.75	4466.79	3,980.36
Profit/ (Loss) Before Tax	(197.02)	34.58	(196.52)	33.97
Less: Tax expense	-	20	-	20
Less: Deferred tax	(6.80)	(4.28)	(6.79)	(4.28)
Less: Tax in respect of earlier years	12.92	(0.51)	12.92	(0.51)
Profit/ (Loss) after tax	(203.14)	19.37	(202.64)	18.76
Less: Preference Dividend	-	-	-	-
Add: Previous Year Balance B/F	724.19	118.60	723.20	118.21
Less: Capitalization of reserves	-	-	-	-
Balance carried to Balance Sheet	521.05	724.19	520.53	723.20
Less: Equity Dividend	-	-	-	-

2. Details of the Subsidiaries, Associate and Joint Ventures:

The Company does not have any Joint Venture or Associate Company as on 31st March, 2025. The statement containing salient features of the financial statements of the Company's subsidiary is given in Form AOC-1 as an ***Annexure-I*** to this Directors' Report.

The highlights of performance of subsidiaries and their contribution to the overall performance of the Company during the financial year is given under the consolidated financial statements forming part of the Annual Report.

During the year under review, none of the companies ceased to be a subsidiary of the Company.

3. State of the Company's Affairs:

The Company has earned total income of Rs. 4270.27 Lakhs [Previous Year: Rs. 4014.33 Lakhs on a standalone basis and INR 4270.28 Lakhs [Previous Year: INR 4,014.33 Lakhs] on consolidated basis. The expenses incurred during the year are INR 4467.29 Lakhs [Previous Year: INR 3,979.75 Lakhs] on standalone basis and INR 4466.79 Lakhs [Previous Year: INR 3,980.36 Lakhs] on consolidated basis. After meeting all the expenses, your Company has incurred a total loss after tax of INR 203.14 Lakhs [Previous Year: 19.37 Lakhs] on standalone basis and INR 202.64 Lakhs [Previous Year: 18.76 Lakhs] on consolidated basis.

Your Directors are expecting better business opportunities in the coming year, which may lead to expansion and diversification of the business of the company.

4. Transfer to Reserve:

During the Financial Year 2024-25, the Company has not transferred any amount to the general reserve.

5. Change in the Nature of Business, if any:

There is no change in nature of business. However, during the year, the Company has altered its Main Object and have added objects related to healthcare, chemicals, research etc. and accordingly have altered its Main Object vide Members' resolution passed in Annual General Meeting held on 30th September 2024.

6. Allotment and listing of shares:

During the financial year, the Company has not allotted any shares nor listed any shares on stock exchange.

7. Material Changes and Commitments, if any:

The Company has received a notice from the Debenture Trustee dated 30th June, 2025 and 22nd August, 2025, acting on the instructions of the Debenture Holders Ms. Bindi Mehta and Ms. Varsha Mehta, for enforcement of part of the pledged security on account of continuing default. In accordance with the provisions of the Share Pledge Agreements dated 7th May, 2024 and 24th May, 2024, read with the Debenture Transfer and Composite Amendment Agreement dated 17th December, 2024, 7,57,923 equity shares equally held by both the promoters, Mr. Paulson Paul Thazhathedath and Mr. Hans Lewis, constituting 24.12% of the total paid-up capital of the Company and pledged in favour of the Debenture Trustee, out of which pledge has been invoked on 5,21,063 equity shares, as per the instructions of the one of the NCD holders, Ms. Bindi Mehta.

8. Change in Registered Office of the Company:

During the Financial Year, the registered office of the company was shifted from 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India *to* 307, Shivai Plaza, Marol Cooperative Industrial Estate Road, Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India, within local limits of city or town.

9. Dividend:

Your Directors, during the Financial Year under review have not recommended any dividend on the Equity Shares of the Company.

10. Transfer of unclaimed shares/dividend and interest thereon to IEPF:

As required under Section 124 of the Act there are no unclaimed shares /dividend and interest thereon lying with the Company for a period of seven years liable to be transferred to the Investor Education and Protection Fund (IEPF) established by the Central Government.

11. Details of Adequacy of Internal Financial Controls:

Your Company has put in place adequate Internal Financial Controls commensurate to the scale of operations.

12. Disclosure of Accounting Treatment:

These Financial statements of the Company are prepared in accordance with the Applicable Accounting Standards (“AS”), notified under section 133 of Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information.

13. Details of Significant and Material Orders Passed by the Regulators or Courts or Tribunals Impacting the Going Concern Status and Company’s Operations in Future, if any:

No Material Orders were passed by the Regulators or Courts or Tribunals impacting the going concern status and Company’s operations in the future.

14. Significant Changes:

- a. The Company has transferred 5% stake held in CCME to Mr. Amarjeet Thakur w.e.f 1st April, 2024, thereby CCME ceased to be wholly own subsidiary of Docmode Health Technologies Limited and has become subsidiary of the company.
- b. The Company has issued and allotted 85 Senior, Unrated, Unlisted, Secured, Redeemable Non-Convertible Debentures (NCDs Tranche-I) to Aquilon Capital Emerging Sectors I and 15 NCDs to Capier Investments One, which was approved in Extra-Ordinary General Meeting dated 22nd April, 2024, against which both the Promoters i.e., Paulson Thazhathedath and Mr. Hans Lewis have pledged 1,12,500 equity shares each from their respective shareholding as collateral for the issuance of NCDs on 9th May, 2024. Additionally, charge has also been created to secure the repayment of said NCDs, as per the agreements entered by the company with the NCDs holders.
- c. The Company has issued and allotted 125 Senior, Unrated, Unlisted, Secured, Redeemable Non-Convertible Debentures (NCDs Trench-II) to Aquilon Capital Emerging Sectors I, which was approved in Extra-Ordinary General Meeting dated 22nd April, 2024, against which both the Promoters Paulson Thazhathedath and Mr. Hans Lewis have pledged 82,500 equity shares each from respective shareholding as collateral for the issuance of NCDs on 28th May, 2024. Additionally, charge has also been created to secure the repayment of NCDs, as per the agreements entered by the company with the NCDs holders.
- d. Subsequently, to meet the minimum requirement of share pledge based on market capitalization, an additional 260,967 equity shares (Tranche-I and Tranche -II) each from the respective holdings of both Promoters have been pledged as collateral for the issuance of above mentioned NCDs on 2nd August, 2024. Accordingly, charge has also been modified to secure the repayment of said NCDs, as per the agreements entered by the company with the NCDs holders.
- e. Mr. Paresh Jaysih Sampat was appointed as Managing Director of the Company with effect from 30th September, 2024 in the Annual General Meeting.
- f. The Company had altered its Main Object vide members’ resolution passed in Annual General Meeting held on 30th September, 2024.
- g. During the financial year, Capier Investments One, one of the NCD holders, holding 15 NCDs of Tranche-I, transferred these NCDs to Aquilon Capital Emerging Sectors I on 12th November 2024.

- h. During the financial year, there was a significant change in the holding pattern of the Company's Non-Convertible Debentures. Aquilon Capital Emerging Sectors I, which previously held a total of 225 Senior, Unlisted, Unrated, Secured, Redeemable Non-Convertible Debentures (comprising 100 NCDs under Tranche I and 125 NCDs under Tranche II, each having a face value of ₹1,00,000), transferred an aggregate of 150 NCDs. The transfer comprised 100 NCDs under Tranche I and 50 NCDs under Tranche II. Out of this, 25 NCDs were transferred to Ms. Bindi Mehta and another 25 NCDs to Ms. Varsha Mehta. The said transfer was duly approved by the Board of Directors at its meeting held on 11th December, 2024.

15. Number of Meeting of Board of Directors held during the year:

The Board of Directors duly met 10 (Ten) times, during the year on 10/05/2024, 27/05/2024, 30/05/2024, 22/07/2024, 08/08/2024, 27/08/2024, 09/10/2024, 14/11/2024, 11/12/2024 and 12/03/2025 in respect of which proper notices were given and the proceedings were properly recorded, signed and maintained in the Minutes book kept by the Company for the purpose.

16. Meetings of the Members:

The Last i.e. the 07th Annual General Meeting of the Company for the financial year 2023-2024 was held on 30/09/2024 at the Registered Office of the Company.

17. Particulars of the Extra-Ordinary General Meeting of the Company held during the year

An Extra Ordinary General Meeting of the members was held on 22nd April, 2024, at the registered office of the company.

18. Directors and Key Managerial Personnel:

Appointments / Re-appointments / Changes in designation:

Mr. Paresh Jaysih Sampat (DIN: 00410185), who was appointed as an Additional Director with effect from 08th August, 2024, was regularised as Director pursuant to an Ordinary Resolution passed by the shareholders at the Annual General Meeting held on 30th September, 2024

Mr. Paresh Jaysih Sampat (DIN: 00410185) was appointed as the Managing Director of the Company with effect from 30th September, 2024, pursuant to the Special Resolution passed by the shareholders at the Annual General Meeting held on the same date.

Mr. Paulson Paul Thazhathedath (DIN: 02301881) was re-designated as Whole-Time Director from the position of Managing Director with effect from 30th September, 2024, pursuant to the Special Resolution passed by the shareholders at the Annual General Meeting held on that date.

Resignations:

Mr. Krushang Rajenkumar Shah (DIN: 10048419), Independent Director, and Ms. Hiral Rushang Gandhi (DIN: 10092573), Non-Executive Director, resigned from the Board of the Company with effect from 24th April, 2024.

Ms. Reshma Susan Thomas, Company Secretary of the Company, resigned from her position with effect from 30th April, 2025.

Directors liable to retire by rotation:

During the year under review, Mr. Paulson Paul Thazhathedath, Whole-time Director, is liable to retire by rotation at the ensuing Annual General Meeting of the Company pursuant to the provisions of Section 152 of the Companies Act, 2013 read with the Companies (Appointment and Qualification of Directors) Rules, 2014 and the Articles of Association of the Company. Being eligible, he has offered himself for re-appointment, based on the recommendation of the Nomination and Remuneration Committee and the approval of the Board of Directors."

Key Managerial Personnel:

As on 31st March, 2025, the following are the Key Managerial Personnel of the Company in terms of Section 203 of the Companies Act, 2013 read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014: Mr. Paresh Jaysih Sampat, Managing Director; Mr. Hans Albert Lewis, Chief Financial Officer; Mr. Paulson Paul Thazhathedath, Whole-time Director and Ms. Reshma Susan Thomas, Company Secretary & Compliance Officer."

Independent Directors:

The Independent Directors of the Company hold office for a term of five (5) years and are not liable to retire by rotation in terms of the provisions of the Companies Act, 2013. The present Independent Directors of the Company are Mr. Nilay Shivnarayan Sharma and Mr. Sujit Nityanand Chakraborty.

Declaration of Independence from Independent Directors:

The Company has received declarations from all the Independent Directors confirming that they meet the criteria of independence as prescribed under the provisions of the Act, read with the schedules and rules issued thereunder.

Apart from the above-mentioned changes, during the Financial Year under review, no other changes took place in the constitution of the Board of Directors of the Company:

As on 31st March, 2025, the Board of Directors of the Company comprised the following: Mr. Paulson Paul Thazhathedath, Mr. Hans Albert Lewis, Mr. Nilay Shivnarayan Sharma, Mr. Sujit Nityanand Chakraborty, Mr. Paresh Jaysih Sampat and Ms. Monina Elizabeth Lewis.

19. Committees of the Board:**Audit Committee:**

Audit Committee of the Board is duly constituted in accordance with the provisions of Section 177 (8) of the Act read with Rule 6 of the Companies (Meetings of the Board and its Powers) Rules, 2014 and Regulation 18 of the Listing Regulations. The details of its composition & meetings held during the Financial Year 2024-25 etc., is as below. All recommendations made by the Audit Committee were accepted by the Board during the Financial Year 2024-25. During the year under review there are Eight (8) audit committee meetings held.

As on 31st March, 2025, the Audit Committee comprised of Mr. Sujit Nityanand Chakraborty as Chairman, Non-Executive Independent Director, Mr. Nilay Shivnarayan Sharma as Member, Non-Executive Independent Director and Ms. Monina Elizabeth Lewis as Member, Non-Executive Director.

Nomination and Remuneration Committee:

The Board of Directors has formulated a policy that provides a framework for the selection and appointment of Directors and Senior Management, and for determining the qualifications, positive attributes, and independence of Directors. The Board has also adopted a policy relating to the remuneration of Directors, Key Managerial Personnel, and Senior Management, which is available on the Company's website at <https://docmode.org/policy/>. During the year under review, five (5) meetings of the Nomination and Remuneration Committee were held.

Stakeholders Relationships Committee:

The Company has formulated and adopted Stakeholders Relationships Committee in accordance with the provisions of the Companies Act, 2013 read with the Rules made thereunder and the Listing Regulations. During the year under review Five (5) Stakeholders Relationship committee meetings was held. The details of its composition during the Financial Year 2024-25 etc., is as below.

As on 31st March, 2025, the Stakeholders Relationships Committee comprised of Mr. Sujit Nityanand Chakraborty as Chairman, Non-Executive Independent Director, Mr. Nilay Shivnarayan Sharma as Member, Non-Executive Independent Director and Ms. Monina Elizabeth Lewis as Member, Non-Executive Director.

Details of Investor Complaints

Complaints at the beginning of FY 2024-25	0
Complaints received during the year	0
Complaints resolved during the year	0
Complaints unresolved during the year	0
Complaints pending during the year	0
Complaints at the end of FY 2024-25	0

20. Independent Directors:

As on 31st March, 2025, the Board of Directors of the Company included 2 (Two) Independent Directors Mr. Sujit Nityanand Chakraborty and Mr. Nilay Shivnarayan Sharma. In Compliance with the Companies Act, 2013 and SEBI (Listing Obligations and Regulations) Requirement, 2015; the Independent Directors' Meeting of the Company was held on 26th March, 2025.

Independent Directors of the Company have been issued formal letters of appointment setting out in detail the terms of their appointment, roles, duties and responsibilities. The Company also conducts familiarization programs from time to time to keep the Independent Directors updated on their roles, rights, responsibilities, the nature of the industry in which the Company operates, and the business model of the Company.

Web link of Website for the Familiarization Policy for Independent Directors: https://d3030h7whein66.cloudfront.net/PDF/DocMode+/7.+Directors+Familiarisation+Programme_Docmode.pdf.

21. Annual Evaluation of Board's and Committee Performance:

Pursuant to the provisions of the Act, the SEBI LODR Regulations and the Guidance Note issued by SEBI, the Nomination and Remuneration Committee of the Board carried out an evaluation of performance of Independent Director, Individual Executive and Non-Executive Director and Board as whole and that of its committees.

The performance evaluation of the Chairman, the Non-Independent Directors and the Board as a whole was carried out by the Independent Directors in a separate meeting held on 26th March, 2025 after considering their overall contribution and engagement in the growth of the Company, active role in monitoring the effectiveness of Company's Corporate Governance practices and adherence to the Code of Conduct etc. The exercise of performance evaluation was carried out through a structured evaluation process covering various criteria as recommended by the Nomination and Remuneration Committee.

The Board of Directors evaluated the performance of the Nomination and Remuneration Committee based on the Committee's terms of reference. Additionally, the Committee undertook a review of the Board and other Committees. The responsibility for evaluating the Nomination and Remuneration Committee itself was placed with the Board of Directors.

Overall, the performance of the Independent Director, Individual Executive and Non-Executive Director and the Board as whole and that of its committees as a whole was quite satisfactory and up to the mark during the year under review.

22. Whistle Blower Policy:

Pursuant to the provisions of Section 177(9) of the Act, the Board of Directors of the Company has framed the Vigil Mechanism/ Whistle Blower Policy for employees and/ or volunteers of the Company. The said Policy encourages to report any action or suspected action taken within the Company that is illegal, fraudulent or in violation of any adopted policy of the Company including reporting of instances of leak or suspected leak of unpublished price sensitive information. The Policy also provides access to the Chairperson of the Audit Committee under certain circumstances. The Whistle Blower Policy is posted on the website of the Company at https://d3030h7whein66.cloudfront.net/PDF/DocMode+/1.+Whistle+Blower+Policy_Docmode.pdf.

23. Directors' Responsibility Statement:

To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statement in terms of the Provisions of the Section 134 (5) of the Companies Act, 2013 (the Act):

- a. That in the preparation of the Annual Accounts for the year ended 31st March, 2025, the applicable accounting standards have been followed along with proper explanation relating to material departures, if any;
- b. That the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31st March, 2025 and of the profit of the Company for the year ended on that date;
- c. That the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d. The Annual Accounts have been prepared on a going concern basis; and
- e. The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

24. Management Discussion and Analysis:

The Management Discussion and Analysis report as required under Regulation 34 and Schedule V of SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015 forms and integral part of this report and provides overview of the business and operations of the Company as per ***Annexure-II***

25. Code of Conduct:

The Board of Directors has adopted the Policy on Codes of Fair Disclosure and Conduct (“Fair Disclosure Code”) in accordance with the requirements of the SEBI (Prohibition of Insider Trading) Regulations, 2015. The Fair Disclosure Code of the Company lays down guidelines and procedures to be followed and disclosures to be made while dealing with shares of the Company as well as consequences of violation.

The code of practices and procedures for fair Disclosures of unpublished price sensitive information and code of conduct to regulate, monitor and report trading by Insiders is available on the website https://d3030h7whein66.cloudfront.net/PDF/DocMode+/5.+Policy+on+Code+of+Fair+Disclosure+of+UPSI_Docmode.pdf.

All Board members and Senior Management Personnel have affirmed compliance of the Code of Conduct. The Board has also adopted separate code of conduct with respect to duties of Independent Directors as per the provisions of the Companies Act, 2013 and is available on the website https://d3030h7whein66.cloudfront.net/PDF/DocMode+/11.+Policy+on+code+of+conduct+for+Indep+ent+Directors_Docmode.pdf.

26. Auditors:

In line with the Resolution passed in the Annual General Meeting of the Company held in the Calendar Year 2023, M/s. R. Sundaresan Aiyar & Co., Chartered Accountants, Mumbai (ICAI Firm Registration Number: 110564W/ Membership No. 043946) were appointed as Statutory Auditors of the Company for a period of 5 years till the conclusion of Annual General Meeting of the Company to be held in the calendar year 2028.

27. Audit Report:

- 27.1 (i) For the year under review the audit report of the Company contains adverse mark or qualification by the Statutory Auditors of the Company regarding default made in repayment of loans and borrowings and in payment of interest thereon. (ii) Further, Tax Deducted at Source (TDS) of Rs. 54.66 lakhs were not deposited with the Income Tax Department as of 31st March, 2025, and it has been pending for more than 6 months. (iii) The Company has incurred cash loss of Rs. 167 Lakhs in the financial year.

27.2 Comments of Directors on Audit Report:

With respect to the observations made by the Statutory Auditors in their report regarding the default in repayment of principal and interest on Non-Convertible Debentures (NCDs), the Board of Directors wishes to state that the Company has been facing temporary liquidity constraints arising from a slowdown in collections, increased working capital requirements, and timing mismatches in operational cash flows. These factors have resulted in delays in servicing debt obligations. Consequently, a pledge on 7,57,923 equity shares, constituting 24.12% of the total paid-up share capital of the Company and equally held by the promoters, was invoked in favour of the Debenture Trustee as per the instructions of one of the NCD holders, Ms. Bindi Mehta. The Board, along with the promoters, is actively engaged in

discussions and exploring restructuring measures to regularize these obligations and safeguard the interests of all stakeholders.

Further, the Auditors have also observed that Tax Deducted at Source (TDS) amounting to Rs. 54.66 lakhs remained unpaid for more than six months as at 31st March, 2025, and that the Company has incurred a cash loss of Rs. 167 lakhs during the financial year. These matters are also a consequence of the liquidity pressures explained above. The Company has initiated steps to clear the pending TDS liability in a phased manner along with applicable interest and is committed to ensuring strict compliance with all statutory obligations in future. Simultaneously, the management, together with the promoters, is pursuing cost optimization, operational efficiency initiatives, and exploring additional funding support to strengthen the financial position. The Board is confident that these corrective measures will enable the Company to regularize its statutory and debt obligations and restore financial stability for the benefit of all stakeholders.

28. Details of remuneration as required under Section 197(12) of the Companies Act, 2013:

The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2024-25, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year 2024-25 and the comparison of remuneration of each Key Managerial Personnel (KMP) are given in *Annexure-III*.

29. Particulars Of Employees:

Particulars of the employees as required to be disclosed in terms of Section 134 of the Companies Act, 2013 read with Rule 5 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 are given in *Annexure-IV*.

28. Secretarial Auditor:

28 Pursuant to the provisions of Section 204 of the Act read with the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors had appointed M/s. Vidhi Jobanputra & Co., Practicing Company Secretary (FCS No.: 11160 | C. P. No.: 22293) to conduct the Secretarial Audit of the Company for financial year 2024-25. The Secretarial Audit Report is annexed to this Report as *Annexure-V*. The said Report contains following qualifications / reservations or adverse remarks:

- 28.1 Regulation 242 of the SEBI (ICDR) Regulations, 2018 provides that locked-in securities held by promoters may be pledged as collateral only in favour of a scheduled commercial bank, a public financial institution, a systemically important NBFC, or a housing finance company for securing loans. However, for the purpose of securing 225 Non-Convertible Debentures (NCDs) issued to the NCDs holders as mentioned in this Directors Report, the shares were pledged in favour of Orbis Trusteeship Services Private Limited, the Debenture Trustee company.
- 28.2 The Company had approved the Financial Results and the Limited Review Report for the half-year ended 30th September, 2024, at its meeting held on 14th November, 2024. As per regulatory requirements, the outcome of the meeting along with the financial results was required to be submitted within 30 minutes of the conclusion of the meeting. However, the outcome was submitted on 16th November, 2024, and the financial results were submitted on 14th February, 2025. The delay occurred due to the expiry of the Statutory Auditor's peer review certificate, which required additional time for renewal. The Company had intimated NSE about the situation in a timely manner.
- 28.3 The Company Secretary and Compliance Officer of the Company resigned with effect from 30th April, 2025. In terms of Regulation 6 of the SEBI (LODR) Regulations, 2015, a listed entity is required to

appoint a qualified Company Secretary as Compliance Officer, and such appointment is to be made within three months from the date of vacancy. Accordingly, the due date for appointment of the new Company Secretary and Compliance Officer was 31st July, 2025. However, the appointment has not been made till date. In the interim, Mr. Paulson Paul Thazhathedath has been designated to respond to queries raised by NSE, stakeholders, and other regulatory authorities.

- 28.4 The Company has received a notice from the Debenture Trustee dated 30th June, 2025 and 22nd August, 2025, acting on the instructions of the Debenture Holder, Ms. Bindi Mehta and Ms. Varsha Mehta, for enforcement of part of the pledged security on account of continuing default on repayment of principal and interest on Rs. 1,50,00,000/- (Tranche-I and Tranche-II NCDs) raised from Ms. Bindi Mehta and Ms. Varsha Mehta by the Company. Consequently, 7,57,923 equity shares, equally held by the promoters, Mr. Paulson Paul Thazhathedath and Mr. Hans Lewis, and constituting 24.12% of the total paid-up share capital of the Company, out of which pledge has been invoked on 5,21,063 equity shares, as per the instructions of the one of the NCD holders, Ms. Bindi Mehta.
- 28.5 The Company made a delay of one (1) day in submitting the prior intimation under Regulation 29(2)/29(3) of SEBI (LODR) Regulations, 2015, in respect of the Board Meeting convened to consider the audited financial results for the half-year ended 31st May, 2025.

Comments of Directors on Secretarial Audit Report:

- a. Observation 28.1: The Board notes the deviation from the regulatory requirement and clarifies that the pledge was created solely to secure borrowings raised through NCDs in the best interest of the Company. The matter is being reviewed, and necessary corrective actions will be taken to ensure future compliance.
- b. Observation 28.2: The Board acknowledges the delay and regrets the non-compliance. It is clarified that the delay was procedural in nature and not intentional. The Company has strengthened its internal monitoring mechanism to avoid recurrence and will ensure timely submission of financial results in the future.
- c. Observation 28.3: The Board recognizes the importance of appointing a qualified Compliance Officer and confirms that continuous efforts are being made to identify and appoint a suitable candidate at the earliest. Necessary newspaper advertisements have been issued and discussions have been held with HR agencies; however, the Company has not yet been able to finalize an appropriate candidate. In the meantime, interim arrangements have been made to ensure regulatory and stakeholder communications are not disrupted.
- d. Observation 28.4: The Board regrets the financial stress that has resulted in defaults under the NCD obligations. The Board assures stakeholders that every effort is being made to protect the interests of shareholders and creditors.
- e. Observation 28.5: The Board acknowledges the lapse, which occurred due to issues faced while uploading the intimation on the stock exchange portal. Steps are being taken to strengthen compliance monitoring processes to ensure strict adherence to prescribed timelines in future.

29 Compliance with the Secretarial Standards:

The Company has complied with all the necessary provisions of “Secretarial Standards on Meetings of the Board of Directors” and “Secretarial Standards on General Meetings” issued by the Institute of Company Secretaries of India, from time to time.

30 Extract of Annual Return:

As required, in accordance with the Section 92(3) of the Act, copy of Annual Return in Form MGT-7, is available on the website of the Company www.docmode.com

31 Conservation of Energy, Technology Absorption and Foreign Exchange Earnings & Outgo:

Information in accordance with the provisions of 134(3)(m) of the Act read with the Companies (Accounts) Rules, 2014, regarding conservation of energy, technology absorption, Foreign Exchange Earnings and Outgo is given in below:

a. Conservation of Energy:

- i. **the steps taken or impact on conservation of energy:** Energy consumption is monitored and maintenance systems are improved.
- ii. **the steps taken by the Company for utilizing alternate sources of energy:** The Company is trying to make effective/ efficient use of current sources of energy.
- iii. **the capital investment on energy conservation equipments:** NIL

- b. **Technology Absorption and Research & Development:** The Company's operations do not require significant import of technology. No expenditure had been incurred on research & development activities.

c. Foreign Exchange Earning and Outgo:

(Rupees in Lakhs)

No.	Particulars	2024-25	2023-24
1.	Earning in Foreign Exchange	6.89	10.45
2.	Outgo in Foreign Exchange	99.66	29.80

32 Details relating to Deposits:

The Company has not accepted any deposits from the public/members under Section 73 of the Companies Act, 2013 (hereinafter referred to as the Act) read with Companies (Acceptance of Deposits) Rules, 2014 during the year. There are no deposits which are outstanding as on 31st March, 2025. The Company has not accepted any deposits which are not in compliance with the requirements of Chapter V of the Companies Act, 2013.

33 Particulars of Loans, Guarantees or Investments (Under Section 186 of the Act):

Loans and Investments in compliance with the provisions of the Section 186 of the Companies Act, 2013 forms part of the Notes to the financial statements of the Company.

34 Risk Management Policy:

The Company has not formulated Risk Management Policy as it is not mandatory to the Company.

35 Corporate Social Responsibility Policy:

The Company is not covered under the requirements of Section 135 of the Act read with the Companies (Corporate Social Responsibility Policy) Rules 2014.

36 Related Party Transactions:

During the year under review, no transactions were entered into by the Company with its related parties as per the provisions of Section 188 of the Companies Act, 2013. Further, there were no contracts or arrangements with any related party which were material in nature, and hence the Form AOC-2 is not applicable to the Company.

The Policy on Materiality of Related Party Transactions and dealing with Related Party Transactions as approved by the Board is put up on the Company's website and can be accessed at <https://docmode.org/policy/>.

37 Disclosure on complaints received by the Internal Complaints Committee (ICC), formed under The Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

The Company has duly constituted an Internal Complaints Committee (ICC) in accordance with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 but no complaints were received by the ICC during the year under review.

38 Disclosure relating to maintenance of cost records:

The Company is not required to conduct cost audit and maintenance of cost records is also not applicable to the company as per Section 148(1) of the Companies Act, 2013 and the rules made thereunder.

39 Details on Insolvency and Bankruptcy Code:

During the year under review, no application has been made by the Company under the Insolvency and Bankruptcy Code and accordingly the requirement of disclosing the following details is not applicable to the Company:

- i. the details of application made or any proceeding pending under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year along with their status as at the end of the financial year; and
- ii. the details of difference between amount of the valuation done at the time of onetime settlement and the valuation done while taking loan from the Banks or Financial Institutions along with the reasons thereof.

40. Corporate Governance Report:

As company is listed on SME Exchange of NSE, the compliance with the corporate governance provisions as specified in LODR under regulations 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 and clauses (b) to (i) of sub-regulation (2) of regulation 46 and Para C, D and E of Schedule V are exempted to the company. Hence, requirements of corporate governance under regulation 27 and under Para C of Schedule V of LODR have not been included in this Annual Report.

41. Details of utilization of funds & Statement of deviation(s) or variation(s):

Pursuant to Regulation 32(1) of the Listing Regulations, there was no deviation/variation in the utilization of proceeds raised in IPO by the Company. The NIL deviation reports, in respect of the IPO has been filed by the Company on a Half yearly basis, with NSE where equity shares of the Company are listed.

Further, the proceeds have been fully utilized for the purposes as disclosed in the offer document. Accordingly, no further disclosure under Regulation 32(2) is required to be given.

42. Compliance with the Maternity Benefit Act, 1961:

The Company has complied with the provisions of the Maternity Benefit Act, 1961, including all applicable amendments and rules framed thereunder. The Company is committed to ensuring a safe, inclusive, and supportive workplace for women employees. All eligible women employees are provided with maternity benefits as prescribed under the Maternity Benefit Act, 1961. The Company also ensures that no discrimination is made in recruitment or service conditions on the grounds of maternity. Necessary internal systems and HR policies are in place to uphold the spirit and letter of the legislation.

43. Acknowledgement:

The Directors express their sincere appreciation to the valued Stakeholders including Shareholders, Bankers and Clients for their support and contribution to the Company.

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
DOCMODE HEALTH TECHNOLOGIES LIMITED**

**PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLE TIME DIRECTOR
DIN: 02301881**

Place: Mumbai
Date: 29th August, 2025

Annexure to Directors' Report

1. Details of Subsidiaries in Form AOC-1 is given in **Annexure-I**
2. Management Discussion and Analysis is given in **Annexure-II**
3. Details of remuneration is given in **Annexure-III**
4. Statement containing the name and other particulars of employees is given in **Annexure-IV**
5. Secretarial Audit Report is given in **Annexure-V**

Form AOC-1

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Statement containing salient features of the financial statement of subsidiaries
Part A: Subsidiaries

(Rs. in Lakhs)

S. No.	Name of the subsidiary	Date since when subsidiary was acquired	Reporting period for the subsidiary concerned, if different from the holding company's reporting period	Reporting Currency	Exchange rate as on the last date of the Financial Year (in Rs.)	Share Capital	Reserves and Surplus	Total Assets	Total Liabilities	Investments	Turnover	Profit before taxation	Provision for taxation/deferred tax	Profit after taxation	Proposed Dividend	Extent of shareholding (%)
1	CCME World Services Private Limited*^	13/05/2020	N.A.	INR	N.A.	0.10	-0.49	6.12	6.52	-	14.31	0.51	0.01	0.5		95% [#]

*Subsidiary is yet to commence operations

^Subsidiary pursuant to Section 2(87)(ii) of the Companies Act, 2013

[#]Share Capital of the Subsidiary is held directly (94.8%) by the Holding Company and indirectly (0.02%) through its Nominees - Directors of the Company

There is no subsidiary which has been liquidated or sold during the year

Part B: Associates and Joint Ventures - Not Applicable, as there are no Joint Ventures or Associate Company

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
DOCMODE HEALTH TECHNOLOGIES LIMITED

PAULSON PAUL THAZHATHEDATH
MANAGING DIRECTOR
DIN: 02301881

HANS ALBERT LEWIS
WHOLETIME DIRECTOR
DIN: 02301853

Place: Mumbai

Date: 29th August, 2025

MANAGEMENT DISCUSSION AND ANALYSIS

1. COMPANY OVERVIEW:

DocMode Health Technologies Limited (hereinafter referred to as "the Company") was originally incorporated as "Docmode Health Technologies Private Limited" in Mumbai, Maharashtra in 2017. The Company was later converted into a public limited company in December 2022 and renamed as "Docmode Health Technologies Limited".

The Company is engaged in the business of offering integrated learning solutions through online and offline learning models to healthcare professionals and learners across the world, spanning the education value chain. The Company's offline learning model includes conferences and workshops, while the online courses are developed and presented by the in-house content development team, medical institutions, associations, subject matter experts, and key opinion leaders.

The Company's primary focus is on providing tech-driven online learning solutions that allow healthcare professionals and learners to engage in self-paced, inclusive, and individualized learning experiences. The Company's online learning model comprises notes, recorded videos, live conferences, and workshops. Additionally, the Company provides a platform for inter-professional, cross-industrial learning via panel discussions and courses, as well as leverages its performance assessment tools to enhance the clinical acumen of its users.

The Company is led by its experienced promoters, who have a collective experience of over 25 years in the fields of healthcare advertising, health IT, healthcare communications, and event management. The Company's promoters founded the Company with the vision of "Transforming Learning & Practice" in the medical fraternity, and they actively oversee the business development and strategic aspects of the Company.

The Company is supported by a team of qualified and experienced professionals who have demonstrated their ability to manage and grow the Company's operations, adapt and diversify its offerings, and leverage market opportunities. The Company is registered as ISO 27001:2013 for Information Security Management System and has also received a "ready" status from Skill India.

Contributors: The Company collaborates with international medical associations, key opinion leaders, and subject matter experts to develop certified courses for its users.

We offer the following services to Health Care Professionals:

OUR SERVICES:

a. The Company LERN:

- The Company's learning platform at DocMode.org is a learning environment and platform-as-a-service (PaaS) with a learning management system and collaborating content (CPD and CME) in partnership with leading medical institutions, subject matter experts, key opinion leaders, and top professional bodies from across the world.
- Under this program, the Company offers hybrid and blended learning programs, such as training workshops, fellowships, and observerships, along with publishing books and journals online.
- **Target Audience:** Doctors, physicians, surgeons, and allied healthcare professionals such as dietitians, physiotherapists, nurses, technicians, and paramedics.
 - i. **Certification Programs:** As of March 31, 2025, the Company has expanded its certificate program courses portfolio, having associated with leading medical associations and universities across the globe.
 - ii. **National & International Speaker Programs:** The Company organizes national and international speaker programs, inviting key opinion leaders or subject matter experts from various specializations to facilitate learning and networking initiatives.

b. The Company SURE:

- The Company SURE is a network-powered survey, studies, and research platform to further evidence-based practice in healthcare.
- It is a platform for practicing and certified healthcare professionals to participate or contribute to marketing surveys, clinical studies, and research.
- **Target Audience:** Doctors, physicians, surgeons, and allied healthcare professionals such as dietitians, physiotherapists, nurses, technicians, and paramedics.

c. The Company KNOW:

- The Company KNOW assists medico-marketing organizations through knowledge marketing services, including the review and presentation of scientific promotional literature and the customization of learning initiatives, along with CRM solutions.
- **Target Audience:** Medico-Marketing Companies and Medical Associations/Institutions.

d. The Company CARE:

- The Company offers clinical applications for healthcare providers to enhance patient care and strengthen the HCP-Patient relationship.
- **Target Audience:** Healthcare providers, including hospitals, clinics, and individual doctors.

e. The Company Clinical Research & CRO Services:

The Company has established comprehensive clinical research capabilities as a Contract Research Organization (CRO), offering end-to-end clinical trial management services.

- Services include Phase I through Phase IV clinical trials, post-marketing surveillance, regulatory submissions, and Electronic Data Capturing (EDC) systems.
- The Company's Ethics Committee has received approval from the Central Drugs Standard Control Organisation (CDSCO), enabling independent review and oversight of clinical research protocols.
- **Target Audience:** Pharmaceutical companies, biotechnology firms, medical device manufacturers, and academic research institutions globally.

f. CRAMS Services:

- The Company provides Contract Research And Manufacturing Services (CRAMS) to support pharmaceutical and biotechnology companies in their research and development activities.
- Services encompass analytical services, method development, stability studies, and regulatory support for drug development programs.
- **Target Audience:** International and domestic pharmaceutical companies, generic drug manufacturers, and specialty pharmaceutical firms.

g. The Company SHOP (previously called STORE):

- The Company's online store for healthcare professionals offers books, journals, articles, event passes, memberships, and other clinical products.
- Since its launch in 2022, the platform has significantly expanded its product portfolio and customer base.
- **Target Audience:** Doctors, physicians, surgeons, and allied healthcare professionals such as dietitians, physiotherapists, nurses, technicians, and paramedics.

2. ENVIRONMENT AND STATE OF THE INDUSTRY:

Global-Economy:

The global healthcare industry continues to demonstrate remarkable resilience and growth momentum in 2025-2026, driven by several key factors including the rising prevalence of chronic diseases, aging demographics, breakthrough advancements in medical technology, and substantial government and private sector investments. According to recent global economic assessments, while overall economic growth patterns remain cautiously optimistic, the healthcare sector continues to outperform traditional economic indicators.

The healthcare industry has consistently shown its ability to weather economic uncertainties while maintaining steady growth trajectories. The sustained demand for quality healthcare services, innovative medical devices, and pharmaceutical products continues to drive market expansion, particularly in emerging and developing economies (EMDEs) where expanding middle-class populations, increased disposable incomes, and rapidly improving healthcare infrastructure are creating robust market opportunities.

The healthcare sector's resilience can be attributed to fundamental demographic shifts, including the growing prevalence of lifestyle-related diseases, an aging global population, and an increased focus on preventive healthcare and wellness solutions. Additionally, the accelerated adoption of digital health technologies, artificial intelligence in healthcare, telemedicine platforms, and the expansion of healthcare insurance coverage have further strengthened the industry's growth prospects.

Key growth drivers for 2025-2026 include:

- Accelerated digital transformation in healthcare delivery
- Increased investment in clinical research and drug development
- Expansion of contract research services and manufacturing
- Growing emphasis on evidence-based medicine and clinical studies
- Rising demand for regulatory compliance and quality assurance in pharmaceutical research

Indian Economic Review:

India continues to position itself as a leading force in the global healthcare landscape, with economic indicators pointing towards sustained growth and expansion. The Indian economy's robust performance, supported by strong domestic consumption, strategic infrastructure investments, and favorable policy frameworks, creates an excellent foundation for healthcare sector growth.

India's healthcare sector benefits from several unique advantages including a large and growing population, increasing healthcare awareness, rising disposable incomes, and a strong base of skilled healthcare professionals. The government's continued focus on healthcare infrastructure development, digital health initiatives, and medical education reforms provides substantial support for companies operating in this space.

Key factors supporting India's healthcare sector growth in 2025-2026:

- Strong domestic demand for healthcare services and clinical research
- Government initiatives promoting pharmaceutical research and development
- Expanding healthcare infrastructure across urban and rural areas
- Increased focus on regulatory compliance and quality standards in clinical research
- Growing international recognition of Indian clinical research capabilities
- Favorable investment climate for pharmaceutical and biotechnology companies

The implementation of regulatory compliance frameworks creates opportunities for companies that maintain professional development programs, and compliant pharmaceutical research solutions.

3. COMPANY’S PERFORMANCE:

The Company’s consolidated Operating Revenue for the year ended March 31, 2025, went up by 4.41% from Rs. 4000.73 Lakhs in FY 2023-24 to Rs. 4,177.29 Lakhs. The Other Income rose 584.18% from Rs. 13.59 Lakhs in FY 2023-24 to Rs. 92.98 Lakhs for the year ended March 31, 2025, primarily due to an increase in interest income on bank deposits. Operating Expenses rose by 12.22% from Rs. 3,980.36 Lakhs in FY 2023-24 to Rs. 4466.79 Lakhs for FY 2024-25. Profit Before Tax went down by 678.51% from Rs. 33.97 Lakhs in FY 2023-24 to Rs. (196.52) Lakhs for FY 2024-25, while Profit After Tax also declined by 1180.17% from Rs. 18.76 Lakhs in FY 2023-24 to Rs. (202.64) Lakhs for the period FY 2024-25, mainly due to an increase in operational costs and debt repayment. The overall tax rate reduced by 59.76% from Rs. 15.21 Lakhs in FY 2023-24 to Rs. 6.12 Lakhs for FY 2024-25. The basic and diluted EPS for the year was Rs. (6.45) as against Rs. 0.6 in FY 2023-24. The Cash and Cash Equivalents amounted to Rs. 183.5 Lakhs as of March 31, 2025, against Rs. 310.28 Lakhs for the FY 2023-24.

Changes in Key Financial Ratios:

Ratios	FY 2024-25	FY 2023-24	% Change	Explanation (for > 25% variance)
Liquidity Ratio				
Current Ratio (times)	0.85	1.30	-34.62	Higher current liabilities
Solvency Ratio				
Debt Equity Ratio (times)	0.82	0.88	-6.82	Increase in Debt Repayment
Debt Service coverage ratio (times)	-0.02	0.27	-107.41	Increase in Debt Repayment
Profitability Ratio				
Net profit ratio (%)	-4.86	0.48	-1112.5	Increase in Purchase & Overheads
Return on Equity Ratio (%)	-21.68	2.79	-877.06	Increase in Number of Shares outstanding
Return on Capital employed (%)	-2.28	10.68	-121.35	Increase in Equity Share Capital
Return on Investment (%)	-1.14	7.14	-115.97	Increase in Purchase & Overheads
Utilisation Ratio				
Inventory Turnover Ratio (times)	-2	12.45	-116.06	Increase in Cost of Goods Sold
Trade Receivables turnover ratio (times)	4.03	4.05	-0.49	-
Trade payables turnover ratio (times)	2.14	10.89	-80.35	Increase in Cost of Goods Sold
Net capital turnover ratio (times)	-9.68	8.96	-208.04	-

4. Future Outlook:

The outlook for FY 2025-2026 remains exceptionally positive, with strong momentum building across all business segments. The Company's Q1 performance looks really good, demonstrating remarkable strength and setting a solid foundation for sustained growth throughout the fiscal year. This positive trajectory is supported by strategic investments in clinical research capabilities, expanded service offerings, and a strengthened market position in traditional healthcare business models.

The Company is strategically positioned to capitalize on the evolving healthcare landscape through a focused approach that emphasizes both traditional healthcare business models and innovative research solutions. The Company's commitment to increasing bottom-line performance and profit optimization, while maintaining aggressive revenue growth, forms the cornerstone of our strategic direction for the coming years.

Strategic Focus Areas:

Clinical Research and CRO Services Expansion: The Company is significantly expanding its clinical research capabilities and Contract Research Organization (CRO) services, positioning itself as a leading player in the traditional pharmaceutical research sector. With CDSCO approval for its Ethics Committee, the Company is well-positioned to capture substantial opportunities in both domestic and international clinical research markets. The focus on CRAMS (Contract Research And Manufacturing Services) provides

additional revenue streams and establishes the Company as a comprehensive research partner for pharmaceutical and biotechnology companies globally.

International CRO and CRAMS Opportunities: The Company is strategically targeting international markets for CRO and CRAMS services, leveraging its regulatory compliance capabilities and cost-effective service delivery model. This international expansion focuses on:

- Partnering with global pharmaceutical companies for clinical trial management
- Providing analytical and regulatory services to international clients
- Establishing presence in key international markets through strategic partnerships
- Developing specialized expertise in emerging therapeutic areas
- Building long-term relationships with multinational pharmaceutical companies

Enhanced Revenue Diversification: The Company is implementing a comprehensive revenue diversification strategy that leverages both existing strengths and new market opportunities in traditional healthcare business models. This approach ensures sustainable growth while reducing dependency on any single revenue stream.

Traditional Healthcare Business Expansion: The Company is significantly strengthening its focus on traditional pharmaceutical and healthcare business models, recognizing the substantial market opportunity in established clinical research and contract services. This strategic shift involves deeper engagement with pharmaceutical companies, clinical research organizations, and regulatory bodies through proven business models that deliver consistent returns.

Exclusive Reseller & Distributor Network: A key strategic initiative involves the development of an exclusive reseller and distributor network for the majority of the Company's current services and products. This marketing model will:

- Expand market reach through established healthcare networks
- Leverage local market knowledge and relationships
- Accelerate service delivery and customer support
- Create additional revenue streams through partnership models
- Enhance brand presence across diverse geographic markets

Technology-Driven Growth: Continued investment in clinical research technologies, data management systems, and regulatory compliance platforms will drive innovation across all service offerings, ensuring the Company remains at the forefront of healthcare research solutions.

Key Growth Drivers:

a. Clinical Research Leadership: The Company's enhanced clinical research capabilities, supported by CDSCO-approved Ethics Committee and advanced EDC systems, position it to capture growing opportunities in both domestic and international clinical research markets. The expansion into CRAMS services provides comprehensive research solutions to pharmaceutical companies globally.

b. International CRO Market Penetration: Strategic initiatives to expand global CRO and CRAMS services, supported by regulatory compliance and cost-effective delivery models, will drive significant growth in international pharmaceutical research markets.

c. Regulatory Compliance Advantage: The Company's proactive approach to regulatory compliance and quality standards provides a competitive advantage in securing large-scale research partnerships with multinational pharmaceutical companies.

d. Educational Platform Growth: The Company's continuing medical education platforms continue to demonstrate strong growth through institutional partnerships and technology-driven delivery models.

e. Partnership Ecosystem: The development of strategic partnerships with pharmaceutical companies, research institutions, and international CRO organizations will create synergistic growth opportunities and expand service delivery capabilities globally.

Financial Performance Outlook:

While the Company has navigated through challenging periods, the strategic initiatives implemented and the improving market conditions position the Company for strong financial performance in the coming years. The focus on increasing bottom-line profitability, combined with aggressive revenue growth strategies, will drive substantial improvements in key financial metrics.

The Company's approach to sustainable growth emphasizes:

- Operational efficiency improvements through streamlined clinical research processes
- Strategic cost management in traditional healthcare business operations
- Revenue optimization across all business units, particularly CRO and CRAMS services
- Enhanced cash flow management through diversified revenue streams
- Strategic capital allocation for maximum returns in high-growth segments

Market Position Strengthening:

The Company's comprehensive service portfolio, combined with its clinical research leadership and regulatory compliance capabilities, creates a strong competitive advantage in the pharmaceutical research sector. The Company's position as a full-service CRO and CRAMS provider in the healthcare research space provides multiple avenues for growth and market expansion.

The strategic focus on clinical research and traditional pharmaceutical business models, supported by the exclusive reseller and distributor network, will significantly enhance market penetration and revenue generation capabilities. This approach leverages proven business models while maintaining the innovation and research excellence that defines the Company's competitive advantage.

With substantial opportunities in the global CRO and CRAMS markets and a strategic focus on both domestic and international expansion, the Company is positioned for sustained growth and market leadership in the evolving pharmaceutical research landscape.

5. Accounting Policies:

The Company has selected the accounting policies described in the Notes to Accounts, which have been consistently applied, and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as on March 31, 2024, and of the Profit or Loss of the Company for the year. The significant accounting policies and practices followed by the Group are disclosed in Notes of the Consolidated Financial Statements for the year.

6. Related Party Transactions:

Related Party transactions are defined as transactions of sale / purchase of goods / services made by the Company with Promoters, Directors, Key Managerial Personnel, Subsidiaries, Associates, or other parties in which Promoters or Director are having significant interest / control directly or indirectly, which may have potential conflict of interest with the Company. There were no material transactions during the year under review that were prejudicial to the interests of the Company.

All transactions covered under related party transactions were regularly ratified and/or approved by the Board, the guiding principles being arm's length, fairness, and transparency. Please refer to Note 34 of the standalone financial statements and Note 35 of the consolidated financial statements for details of related party transactions during the year.

7. Human Resources:

The Company's Human Resource (HR) department is committed to developing and maintaining a high-performing workforce that is aligned with the Company's strategic goals. With this objective, it has implemented a number of innovative practices and invested in best-in-class processes to create an enabling environment for its employees. One of the key talent development initiatives taken by the Company in the past year was to invest in leadership and management development for a large pool of its middle management with the help of the country's leading management institute.

8. Risks, Challenges and Concerns:

The Company operates in a complex and evolving environment, facing several critical risks that could impact its business. Awareness of these risks and proactive management are central to sustaining growth and protecting stakeholder interests.

- a. **Channel Risks:** Serving healthcare professionals and learners through both online and offline platforms demands continuous enhancement of content quality, technology, and mentoring capabilities. Effective channel management-including direct marketing, referrals, and digital optimization-is essential to maintain strong engagement and retention.
- b. **Obsolescence Risk:** Rapid innovation in educational technology and shifting skill requirements necessitate agile curriculum development and content updates to stay relevant and competitive.
- c. **Execution Risk:** The Company acknowledges the potential for disruptions including delays, quality lapses, and cost inefficiencies. These risks stem from internal and external factors and could adversely affect financial outcomes and brand reputation.

The Company has Risk Management Policy covering the above mitigation approaches to manage all probable and possible risks to the Company.

9. Internal Controls and Their Adequacies:

The Company maintains a robust internal control system to ensure operational efficiency, regulatory compliance, asset protection, accurate reporting, and effective risk management. Key elements include clear roles and responsibilities, documented policies, an authority matrix, active management review, regular internal and statutory audits, reliable audit trails, and oversight by the Board. The framework is periodically reviewed and updated to address evolving business needs.

10. Cautionary Statement:

Statements in this management discussion and analysis describing the Company's views about the industry, objectives, estimates, and expectations may be "forward-looking statements" within the meaning of applicable laws and regulations. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Actual results, performances, or achievements could differ materially from those expressed or implied in such statements. Readers are cautioned as not to place undue reliance.

Details pertaining to remuneration as required under Section 197(12) of the Companies Act, 2013 read with Rules 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.

(i) The percentage increase in remuneration of each Director, Chief Financial Officer and Company Secretary during the financial year 2024-25, ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the financial year 2024-25 and the comparison of remuneration of each Key Managerial Personnel (KMP) against the performance are as under:

No	Name of Director / KMP and designation	Remuneration for the FY 2024-25 ('In Lakhs)	% increase in Remuneration in the FY 2023-24	Ratio of remuneration to median employees' remuneration	Comparison of remuneration of the KMP against the performance of the Company
1	Paulson Paul Thazhathedath, Whole Time Director	39	NIL	8.21	NA
2	Hans Albert Lewis, Whole Time Director	39	NIL	8.21	NA
3.	Reshma Susan Thomas	2.85	NIL	13.68	NA

Consolidated Net Profit before exceptional item and tax for the year ended 31st March, 2025 has decreased by 678.51%.

- (ii) The median remuneration of employees of the Company during financial year was Rs. 4,74,750/-
- (iii) In the financial year there was no increase in percentage of the median remuneration of employees.
- (iv) There were 58 permanent employees on the rolls as on 31st March 2025.
- (v) Average percentage increase made in the salaries of employees other than the managerial personnel (i.e. Managing Director & CFO and Whole Time Director) in the FY 2024-25: 95.99% from FY 2023-24.
- (vi) The percentage increase in the managerial remuneration in the FY 2024-25: NIL
- (vii) It is affirmed that the remuneration paid is as per the Remuneration Policy.

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
DOCMODE HEALTH TECHNOLOGIES LIMITED

PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLE TIME DIRECTOR
DIN: 02301881

Place: Mumbai
Date: 29th August, 2025

Statement containing the name and other particulars of employees

[Pursuant to Section 197 (12) of the Companies Act, 2013 read with rule 5 (2) and Rule 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

- (a) Name of the top ten employees in terms of the remuneration drawn, including name of employees employed throughout the financial year 2024-25 who were in receipt of remuneration equal or greater than Rs. 1,02,00,000/- per annum: **Nil**
- (b) Name of Employees, employed for part of the financial year 2024-25 who were in receipt of remuneration equal or greater than Rs. 8,50,000/- per month: **Nil**
- (c) No employee was in receipt of remuneration for the year under review in the aggregate or at a rate which in the aggregate, was in excess of that drawn by the managing director or whole-time director or manager and holds by himself or along with his spouse and dependent children, not less than two percent of the equity shares of the company.

**FOR AND ON BEHALF OF THE BOARD OF DIRECTORS
DOCMODE HEALTH TECHNOLOGIES LIMITED**

**PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLE TIME DIRECTOR
DIN: 02301881**

Place: Mumbai

Date: 29th August, 2025

SECRETARIAL AUDIT REPORT
FORM NO. MR-3
FOR THE FINANCIAL YEAR ENDED 31ST MARCH, 2025
[Pursuant to section 204(1) of the Companies Act, 2013 and rule No. 9 of the Companies
(Appointment and Remuneration Personnel) Rules, 2014]

To,
The Members,
Docmode Health Technologies Limited
307, Shivai Plaza, Marol Cooperative Industrial Estate Road,
Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India

I have conducted the secretarial audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by **Docmode Health Technologies Limited** having CIN: L74999MH2017PLC297413 (Hereinafter called ‘the Company’). Secretarial Audit was conducted for the financial year 2024-25, in a manner that provided a reasonable basis for evaluating the corporate conducts/statutory compliances of the Company and for expressing our opinion thereon.

Based on our verification of the Company’s books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, the explanations and clarifications given to me and representations made by the Management, during the audit period covering the financial year ended on 31st March, 2025 (“Audit Period”), the Company has complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and legal compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

1. I have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2025 and I report that the Company has complied with the provisions of the following list of laws and regulations, including amendments thereof:
 - (i) The Companies Act, 2013 (the Act) and the rules made there under;
 - (ii) The Securities Contracts (Regulation) Act, 1956 (‘SCRA’) and the rules made there under;
 - (iii) The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
 - (iv) Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; **[Not applicable during the Audit Period]**.
 - (v) The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 (‘SEBI Act’):
 - a) SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015;
 - b) SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018;
 - c) SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - d) SEBI (Buyback of Securities) Regulations, 2018; **[Not applicable during the Audit Period]**.
 - e) SEBI (Share Based Employee Benefits and Sweat Equity) Regulations 2021; **[Not applicable during the Audit Period]**.
 - f) SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021; **[Not applicable during the Audit Period]**.
 - g) SEBI (Prohibition of Insider Trading) Regulations, 2015;
 - h) SEBI (Depositories and Participants) Regulations, 2018;
 - i) SEBI (Registrars to an Issue and Share Transfer Agents) Regulations, 1993
 - j) SEBI (Delisting of Equity Shares) Regulations, 2021 **[Not applicable during the Audit Period]**
 - (vi) We have relied on the representations made by the Company and its officers for systems and mechanism formed by the Company for compliances of other specific applicable Acts, Laws and Regulations to the Company. As informed by the management, apart from the Information Technology Act, 2000, there are no other laws specifically applicable to the Company.

2. We have not examined compliance by the company with respect to:
 - (i) Applicable financial laws, like direct and indirect tax laws, maintenance of financial records, etc., since the same have been subject to review by statutory (financial) auditors, tax auditors and other designated professionals.
 - (ii) As informed by the company the Industry specific laws/general laws as applicable to the company has been complied with. The management has also represented and confirmed that all the laws, rules, regulations, orders, standards and guidelines as are specifically applicable to the Company relating to Industry/Labour etc., have been complied with.
3. I have also examined compliance with the applicable clauses of the following:
 - (i) Secretarial Standards with regard to Meeting of Board of Directors (SS-1) and General Meetings (SS-2) issued by The Institute of Company Secretaries of India (effective from 01st July, 2015); under the provisions of Companies Act, 2013;
 - (ii) SME Listing Agreement entered into by the Company with NSE (SME Platform)
4. On the basis of our examination and representation made by the Company, we report that during the period under review the Company has generally complied with the provisions of the Act, Rules, Regulations, Guidelines etc. mentioned above and there are no material non-compliances that have come to our knowledge subject to the following observations:
 - (i) Regulation 242 of the SEBI (ICDR) Regulations, 2018 provides that locked-in securities held by promoters may be pledged as collateral only in favour of a scheduled commercial bank, a public financial institution, a systemically important NBFC, or a housing finance company for securing loans. However, for the purpose of securing 225 Non-Convertible Debentures (NCDs) issued to the NCDs holders as mentioned in this Directors Report, the shares were pledged in favour of Orbis Trusteeship Services Private Limited, the Debenture Trustee company.
 - (ii) The Company had approved the Financial Results and the Limited Review Report for the half-year ended 30th September, 2024, at its meeting held on 14th November, 2024. As per regulatory requirements, the outcome of the meeting along with the financial results was required to be submitted within 30 minutes of the conclusion of the meeting. However, the outcome was submitted on 16th November, 2024, and the financial results were submitted on 14th February, 2025. The delay occurred due to the expiry of the Statutory Auditor's peer review certificate, which required additional time for renewal. The Company had intimated NSE about the situation in a timely manner.
 - (iii) The Company Secretary and Compliance Officer of the Company resigned with effect from 30th April, 2025. In terms of Regulation 6 of the SEBI (LODR) Regulations, 2015, a listed entity is required to appoint a qualified Company Secretary as Compliance Officer, and such appointment is to be made within three months from the date of vacancy. Accordingly, the due date for appointment of the new Company Secretary and Compliance Officer was 31st July, 2025. However, the appointment has not been made till date. In the interim, Mr. Paulson Paul Thazhathedath has been designated to respond to queries raised by NSE, stakeholders, and other regulatory authorities.
 - (iv) The Company has received a notice from the Debenture Trustee dated 30th June, 2025 and 22nd August, 2025, acting on the instructions of the Debenture Holder, Ms. Bindi Mehta and Ms. Varsha Mehta, for enforcement of part of the pledged security on account of continuing default on repayment of principal and interest on Rs. 1,50,00,000/- (Tranche-I and Tranche-II NCDs) raised from Ms. Bindi Mehta and Ms. Varsha Mehta by the Company. Consequently, 7,57,923 equity shares, equally held by the promoters, Mr. Paulson Paul Thazhathedath and Mr. Hans Lewis, and constituting 24.12% of the total paid-up share capital of the Company, out of which pledge has been invoked on 5,21,063 equity shares, as per the instructions of the one of the NCD holders, Ms. Bindi Mehta.
 - (v) The Company made a delay of one (1) day in submitting the prior intimation under Regulation 29(2)/29(3) of SEBI (LODR) Regulations, 2015, in respect of the Board Meeting convened to consider the audited financial results for the half-year ended 31st May, 2025.
5. I further report that during the audit period: -
 - (i) The Company has issued and allotted 85 Senior, Unrated, Unlisted, Secured, Redeemable Non-Convertible Debentures (NCDs Tranche-I) to Aquilon Capital Emerging Sectors I and 15 NCDs to Capier Investments

One, which was approved in Extra-Ordinary General Meeting dated 22nd April, 2024, against which both the Promoters i.e., Paulson Thazhathedath and Mr. Hans Lewis have pledged 1,12,500 equity shares each from their respective shareholding as collateral for the issuance of NCDs on 9th May, 2024. Additionally, charge has also been created to secure the repayment of said NCDs, as per the agreements entered by the company with the NCDs holders.

- (ii) The Company has issued and allotted 125 Senior, Unrated, Unlisted, Secured, Redeemable Non-Convertible Debentures (NCDs Trench-II) to Aquilon Capital Emerging Sectors I, which was approved in Extra-Ordinary General Meeting dated 22nd April, 2024, against which both the Promoters Paulson Thazhathedath and Mr. Hans Lewis have pledged 82,500 equity shares each from respective shareholding as collateral for the issuance of NCDs on 28th May, 2024. Additionally, charge has also been created to secure the repayment of NCDs, as per the agreements entered by the company with the NCDs holders.
- (iii) Subsequently, to meet the minimum requirement of share pledge based on market capitalization, an additional 260,967 equity shares (Tranche-I and Tranche-II) each from the respective holdings of both Promoters have been pledged as collateral for the issuance of above mentioned NCDs on 2nd August, 2024. Accordingly, charge has also been modified to secure the repayment of said NCDs, as per the agreements entered by the company with the NCDs holders.
- (iv) Mr. Krushang Rajenkumar Shah (DIN: 10048419), Independent Director and Ms. Hiral Rushang Gandhi (DIN: 10092573), Non-Executive Director, resigned w.e.f. 24th April, 2024.
- (v) Mr. Paulson Paul Thazhathedath (DIN: 02301881) was designated as Whole Time Director from the position of Managing Director w.e.f. 30th September, 2024.
- (vi) The Company had appointed Mr. Paresh Jaysih Sampat (DIN: 00410185) as Additional Director w.e.f. 08th August, 2024. Further, his designation was changed to Managing Director w.e.f. 30th September, 2024.
- (vii) The Company changed its Main Objects vide Members' Special Resolution passed in Extra-Ordinary General Meeting dated 30th September, 2024.
- (viii) During the financial year, Capier Investments One, one of the NCD holders, holding 15 NCDs of Tranche-I, transferred these NCDs to Aquilon Capital Emerging Sectors I on 12th November 2024.
- (ix) During the financial year, there was a significant change in the holding pattern of the Company's Non-Convertible Debentures. Aquilon Capital Emerging Sectors I, which previously held a total of 225 Senior, Unlisted, Unrated, Secured, Redeemable Non-Convertible Debentures (comprising 100 NCDs under Tranche I and 125 NCDs under Tranche II, each having a face value of ₹1,00,000), transferred an aggregate of 150 NCDs. The transfer comprised 100 NCDs under Tranche I and 50 NCDs under Tranche II. Out of this, 25 NCDs were transferred to Ms. Bindi Mehta and another 25 NCDs to Ms. Varsha Mehta. The said transfer was duly approved by the Board of Directors at its meeting held on 11th December, 2024.

6. I further report that:

- (i) The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.
- (ii) That the company has filed all forms in time with/without any additional fees to the Registrar of Companies/ Regional Director or Central Government under various sections of The Companies Act, 2013.
- (iii) Adequate notice is given to all directors to schedule the committee and Board Meetings, agenda and detailed notes on agenda are sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meetings.
- (iv) All the decisions at the Board Meetings and the Committee Meetings were carried out unanimously as recorded in the minutes of the Board of Directors and minutes of the Committee Meetings as the case may be.
- (v) There are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

7. I further report that:

- (i) There are adequate systems and processes in the Company commensurate with the size and operations of the company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.
- (ii) I further report that during the audit period there were no specific events/actions having a major bearing on the Company's affairs in pursuance of the above referred laws, rules, guidelines and standards.

**FOR M/s. VIDHI JOBANPUTRA & CO.
PRACTICING COMPANY SECRETARY**

**VIDHI JOBANPUTRA
PROPRIETOR
FCS NO.: 11160 | C. P. No.: 22293
UDIN: F011160G001057348**

Date: 22nd August, 2025
Place: Mumbai

*This report is to be read with my letter of even date which is annexed as 'Enclosure-I' and forms an integral part of this report.

To,
The Members,
Docmode Health Technologies Limited
307, Shivai Plaza, Marol Cooperative Industrial Estate Road,
Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India

My Secretarial Audit Report for the financial Year ended March 31, 2025 of even date is to be read along with this letter.

1. Maintenance of Secretarial records is the responsibility of the management of the Company. My responsibility is to express an opinion on these Secretarial records based on my audit.
2. I have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the processes and practices | followed provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Wherever required, I have obtained Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations and standards is the responsibility of the management. My examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**FOR M/s. VIDHI JOBANPUTRA & CO.
PRACTICING COMPANY SECRETARY**

**VIDHI JOBANPUTRA
PROPRIETOR
FCS NO.: 11160 | C. P. No.: 22293
UDIN:F011160G001057348**

Date: 22nd August, 2025
Place: Mumbai

Independent Auditor's Report on Standalone Financial Statements

To the Members of DocMode Health Technologies Limited (Formerly known as DocMode Health Technologies Private Limited)

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the standalone financial statements of DocMode Health Technologies Limited (Formerly known as DocMode Health Technologies Private Limited) ("The Company"), which comprise the standalone Balance Sheet as at 31st March 2025, and standalone Statement of Profit and Loss and standalone Statement of Cash flows for the year then ended, and notes to the standalone financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2025, its Loss and its Cash Flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the standalone Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the standalone financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on standalone financial statements.

Information other than the standalone financial statements and auditors' report thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the financial statements and our auditor's report thereon. The company's annual report is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the standalone Financial Statements of the current period. These matters were addressed in the context of our audit of the standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no Key Audit matters to be communicated in our report.

Responsibilities of Management and Those Charged with Governance for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records,

relevant to the preparation and presentation of the standalone financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the standalone financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these standalone financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the standalone financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management and Board of Directors.
- Conclude on the appropriateness of management and Board of Directors use of the going concern basis of accounting in preparation of standalone financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the standalone financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the standalone financial statements, including the disclosures, and whether the standalone financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A', a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.
2. As required by Section 143 (3) of the Act, we report that:
 - a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
 - b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
 - c) The standalone Balance Sheet, the standalone Statement of Profit and Loss and the standalone Cash Flow Statement dealt with by this Report are in agreement with the books of account.
 - d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - e) On the basis of the written representations received from the Directors as on 31st March, 2025 taken on record by the Board of Directors, none of the Directors is disqualified as on 31st March, 2025 from being appointed as a director in terms of Section 164 (2) of the Act.
 - f) With respect to the adequacy of the internal financial controls with reference to standalone financial statements of the Company and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.
 - g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company does not have any pending litigations which would impact its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
 - iv. (a) The Management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share Premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:
 - directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company ("Ultimate Beneficiaries") or
 - provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.(b) The Management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any person(s) or entity(ies), including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the Company shall:
 - directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or
 - provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.
 - v. Based on the audit procedures performed that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the

representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (a) and (b) above, contain any material misstatement.

- vi. The company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.
- vii. Based on our examination which included test checks the Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility except that audit trail was not enabled at the database level to log any direct changes for the accounting software used for maintaining the books of account. For accounting software for which audit trail feature is enabled, the audit trail facility has been operating throughout the year for all relevant transactions recorded in the software and we did not come across any instance of audit trail feature being tampered with during the course of our audit.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Company to its directors during the year is in accordance with the provisions of section 197 read with Schedule V to the Act.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: May 30, 2025
UDIN: 25043946BBIQXA7435

Annexure-A to Independent Auditors' Report on the Standalone Financial Statements for the year ended 31st March 2025

(Referred to in paragraph 1 under “Report on Other Legal and Regulatory Requirements’ section of our report of even date)

- i) (a) (A) The Company has maintained proper records showing full particulars, including quantitative details and the situation of Property, plant, and equipment.

(B) The Company has maintained proper records showing full particulars of intangible assets.

(b) According to the information and explanation given to us and on the basis of our examination of the records of the Company, Property, plant and equipment have been physically verified by the management at reasonable intervals. No material discrepancies were noticed on such verification.

(c) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the title deeds of immovable properties (other than immovable properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) disclosed in the standalone financial statements are held in the name of the Company.

(d) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not revalued its Property, plant and equipment (including Right-of-use assets) or Intangible assets or both during the year

(e) According to the information and explanations given to us and on the basis of our examination of the records of the Company, there are no proceedings initiated or pending against the Company for holding any benami property under the Prohibition of Benami Property Transactions Act, 1988 and rules made thereunder.

- ii) (a) The inventory has been physically verified by the management during the year. In our opinion, the frequency of such verification is reasonable and procedures and coverage as followed by management were appropriate. No discrepancies were noticed on verification between the physical stocks and the book records that were 10% or more in the aggregate for each class of inventory.

(b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been sanctioned working capital limits in excess of ₹ 5 crore, in aggregate, at any points of time during the year, from banks or financial institutions on the basis of security of current assets and hence reporting under clause 3(ii)(b) of the Order is not applicable.

- iii) According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not made any investments in, provided guarantee or security, granted any loans or advances in the nature of loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties during the year. Consequently, the provisions of clauses iii (a), (b) and (c) of the order are not applicable to the Company.
- iv) According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, or provided any guarantee or security as specified under Section 185 of the Companies Act, 2013 and the Company has not provided any guarantee or security as specified under Section 186 of the Companies Act, 2013.
- v) In our opinion and according to the information and explanation given to us, the Company has not accepted any deposits or amounts which are deemed to be deposits from the public. Accordingly, clause 3(v) of the Order is not applicable.
- vi) As per information & explanation given to us, the Central Government has not prescribed the maintenance of cost records under section 148 (1) of the Companies Act, 2013 for the products manufactured and/or services rendered by the Company. Accordingly, clause 3(vi) of the Order is not applicable.
- vii) (a) The Company does not have any liability in respect of Sales tax, Service Tax, Duty of Excise and Value Added Tax during the year since effective July 1, 2017, these statutory dues have been subsumed into GST.

The company is regular in depositing undisputed statutory dues, including Goods and Service Tax (GST), Provident Fund, Employees' State Insurance, Income-tax, Duty of Customs, Cess and other material statutory dues with the appropriate authorities, where applicable. According to the information and explanations given to us, no undisputed amounts payable in respect of GST, Provident fund, Employees' State Insurance, Income-tax, Duty of Customs, Cess and other material statutory dues were in arrears as at 31 March 2025 for a period of more than six months from the date they became payable except the payment of Tax Deducted at Source of Rs.54.66 Lacs.

(b) According to the information and explanations given to us, there are no dues of GST, Provident Fund, Employees' State Insurance, Income-tax, Sales Tax, Service Tax, Duty of Customs, Value Added tax, Cess or other statutory dues which have not been deposited on account of any disputes.

- viii) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not surrendered or disclosed any transactions, previously unrecorded as income in the books of account, in the tax assessments under the Income-tax Act, 1961 as income during the year.
- ix) (a) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has defaulted in repayment of loans and borrowings or in the payment of any interest thereon to any lender.

Nature of borrowing including debt securities	Name of lender*	Amount not paid on due date	Whether principal or interest	Period of Default	Remarks, if any
Non Convertible Debentures (NCD Tranche – I)	Aquilon Capital Emerging Sector Fund I	25,00,000	Principal	17 Days	
Non Convertible Debentures (NCD Tranche – I)	Bindi Mehta	25,00,000	Principal	31 Days	
Non Convertible Debentures (NCD Tranche – I)	Bindi Mehta	69,041	Interest	104 Days	

Non Convertible Debentures (NCD Tranche – I)	Bindi Mehta	1,52,877	Interest	90 Days	
Non Convertible Debentures (NCD Tranche – I)	Bindi Mehta	1,38,082	Interest	59 Days	
Non Convertible Debentures (NCD Tranche – II)	Bindi Mehta	17,740	Interest	104 Days	
Non Convertible Debentures (NCD Tranche – II)	Varsha Mehta	17,740	Interest	104 Days	
Non Convertible Debentures (NCD Tranche – II)	Bindi Mehta	39,281	Interest	90 Days	
Non Convertible Debentures (NCD Tranche – II)	Varsha Mehta	39,281	Interest	90 Days	
Non Convertible Debentures (NCD Tranche – II)	Bindi Mehta	35,479	Interest	59 Days	
Non Convertible Debentures (NCD Tranche – II)	Varsha Mehta	35,479	Interest	59 Days	

b) According to the information and explanations given to us and on the basis of our examination of the records of the Company, the Company has not been declared a wilful defaulter by any bank or financial institution or government or government authority.

(c) In our opinion and according to the information and explanations given to us by the management, term loans were applied for the purpose for which the loans were obtained.

(d) According to the information and explanations given to us and on an overall examination of the balance sheet of the Company, we report that no funds raised on short-term basis have been used for long-term purposes by the Company.

(e) According to the information and explanations given to us and on an overall examination of the financial statements of the Company, we report that the Company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries as defined under the Companies Act, 2013.Accordingly, clause 3(ix)(e) of the Order is not applicable.

(f) According to the information and explanations given to us and procedures performed by us, we report that the Company has not raised loans during the year on the pledge of securities held in its subsidiaries as defined under the Companies Act, 2013. Accordingly, clause 3(ix)(f) of the Order is not applicable.

- x) (a) In February 2024, the company has raised funds by way of Initial Public Offer (IPO) by issuing 8,49,600 equity shares of Rs.10/- each, at a premium of Rs.69/- per share. The funds as raised were not fully utilised till 31st March, 2024. However, the entire amount raised has been fully utilised till 31st March 2025 as follows;

Sr. No	Original Object	Modified Object	Original Allocation (Rs. in Lacs)	Funds Utilized till March 31,2025 (Rs. In Lacs)
1	Purchase of IT infrastructure and operating system	NA	303.08	303.08
2	Meeting incremental working capital requirements	NA	200.00	200.00
3	General corporate purposes	NA	103.10	103.10

(b) During the year, the company has raised funds through private placement by issuing 225 Non-Convertible Debentures having Face Value of Rs.1,00,000/- each at par and the funds as raised have been fully applied for the purposes for which they were raised.

xi) (a) Based on examination of the books and records of the Company and according to the information and explanations given to us, considering the principles of materiality outlined in Standards on Auditing, we report that no fraud by the Company or on the Company has been noticed or reported during the course of the audit.

(b) No report under sub-section (12) of section 143 of the Companies Act has been filed in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year and upto the date of this report.

(c) According to the information and explanations given to us, no whistle-blower complaints were received during the year by the Company.

xii) According to the information and explanations given to us, the company is not a Nidhi Company. Accordingly, clause (xii) of the order is not applicable to the company.

xiii) According to the information and explanations given to us, all transactions with the related parties are in compliance with sections 177 and 188 of Companies Act, 2013 where applicable and the details have been disclosed in the Financial Statements etc. as required by the applicable accounting standards.

xiv) (a) Based on information and explanations provided to us and our audit procedures, in our opinion, the Company has an internal audit system commensurate with the size and nature of its business.

(b) We have considered the internal audit reports of the Company issued till date for the period under audit.

xv) According to the information and explanations given to us, in our opinion during the year the company has not entered into any non-cash transactions with its directors or persons connected to its directors and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the company.

xvi) (a) The Company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, clause 3(xvi)(a) of the Order is not applicable.

(b) The Company has not conducted any Non-Banking Financial or Housing Finance activities during the year and hence, the company is not required to obtain certificate of registration from the Reserve Bank of India as per the Reserve Bank of India Act, 1934. Accordingly, reporting under clause 3(xvi)(b) of the order is not applicable.

(c) The Company is not a Core Investment Company (CIC) as defined in the regulations made by the Reserve Bank of India. Accordingly, clause 3(xvi)(c) of the Order is not applicable.

(d) According to the information and explanations provided to us during the course of audit, the Group does not have any CIC. Accordingly, the requirements of clause 3(xvi)(d) are not applicable.

xvii) The company has incurred cash loss of Rs.167 Lacs in the financial year. The company has not incurred cash loss in the immediately preceding financial year.

xviii) No auditor has resigned from the post of the statutory auditors during the period under review.

xix) According to the information and explanations given to us and on the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements, our knowledge of the Board of Directors and management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report that company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the company as and when they fall due.

xx) In our opinion and according to the information and explanations given to us, the Company is not covered under the provisions of section 135 (5) of the Companies Act, 2013. Accordingly, clause (xx) of the order is not applicable.

xxi) The requirement of clause 3(xxi) is not applicable in respect of Standalone Financial Statements.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: May 30, 2025
UDIN: 25043946BMIQXA7435

Annexure - B to the Independent Auditor's Report for the year ended 31st March 2025

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

(Referred to in Paragraph 1(f) under 'Report on Other Legal and Regulatory Requirements section of our report of even date)

Opinion

We have audited the internal financial controls with reference to the financial statements of DocMode Health Technologies Limited (Formerly known as DocMode Health Technologies Private Limited) ("The Company") as of March 31, 2025, in conjunction with our audit of the standalone financial statements of the Company as at and for the year ended on that date.

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting, and such internal financial controls over financial reporting were operating effectively as at March 31, 2025, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

Management's Responsibility for Internal Financial Controls

The Company's management is responsible for establishing and maintaining internal financial controls based on "the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India". These responsibilities include the design, implementation, and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditors' Responsibility

Our responsibility is to express an opinion on the Company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting were established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness.

Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

Meaning of Internal Financial Controls Over Financial Reporting

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

for **R. Sundaresan Aiyar & Co**
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: May 30, 2025
UDIN: 25043946BMIQXA7435

DocMode Health Technologies Limited (Formerly known as Docmode Health Technologies Private Limited) CIN : L74999MH2017PLC297413 Balance Sheet as at March 31,2025				Indian Rupee in Lacs
Particulars		Note	March 31,2025	March 31,2024
I.	EQUITY AND LIABILITIES			
1	Shareholder's funds			
(a)	Share capital	3	314.28	314.28
(b)	Reserves and surplus	4	521.05	724.19
(c)	Money received against share warrants		-	-
2	Share application money pending allotment		-	-
3	Non-current liabilities			
(a)	Long Term Borrowings	5	112.45	438.20
(b)	Deferred Tax Liabilities (Net)		-	-
(c)	Other Long Term Liabilities		-	-
(d)	Long Term Provisions	6	69.71	66.28
4	Current liabilities			
(a)	Short Term Borrowings	7	569.91	479.82
(b)	Trade Payables	8	533.54	275.59
(c)	Other Current Liabilities	9	1,451.63	356.00
(d)	Short Term Provisions	10	358.55	363.35
TOTAL			3,931.11	3,017.71
II.	ASSETS			
1	Non-current assets			
(a)	Property, Plant and Equipment and Intangible Assets	11		
(i)	Property, Plant and Equipment		120.74	95.21
(ii)	Intangible Assets		0.84	1.61
(iii)	Capital Work-In-Progress		-	-
(iv)	Intangible Assets under Development		1,159.76	849.92
(b)	Non Current Investments	12	120.61	110.10
(c)	Deferred Tax Assets (net)	13	25.51	18.71
(d)	Long-term Loans and Advances	14	8.70	7.58
(e)	Other Non Current Assets	15	12.91	13.13
2	Current assets			
(a)	Current Investments	16	8.69	16.24
(b)	Inventories	17	1,116.93	251.39
(c)	Trade Receivables	18	923.94	1,146.89
(d)	Cash and Cash Equivalents	19	178.81	308.76
(e)	Short Term Loans and Advances	20	246.85	198.17
(f)	Other Current Assets	21	6.81	-
TOTAL			3,931.11	3,017.71
	Significant Accounting Policies	2		
	The notes are integral parts of the financial statements			
As per our report of even date for R Sundaresan Aiyar & Co Chartered Accountants Firm Registration No.: 110564W				for DocMode Health Technologies Limited
CA R Sunderesan Aiyar Partner M. No.:043946 Place : Mumbai Date : May 30, 2025 UDIN :		Paulson Paul Thazhathedath Wholetime Director DIN 02301881 Place : Mumbai Date : May 30, 2025		Hans Albert Lewis Wholetime Director & CFO DIN: 02301853 PAN: ACOPL6883G Place : Mumbai Date : May 30, 2025
		Paresh Jaysih Sampat Managing Director DIN: 00410185 Place : Mumbai Date : May 30, 2025		

<p style="text-align: center;">DocMode Health Technologies Limited <i>(Formerly known as Docmode Health Technologies Private Limited)</i> CIN : L74999MH2017PLC297413 Statement of Profit & Loss for the year ended March 31,2025</p>				
Indian Rupee in Lacs				
Particulars		Note	March 31,2025	March 31,2024
I.	Revenue from Operations	22	4,177.29	4,000.73
II.	Other Income	23	92.97	13.59
III.	Total Income (I + II)		4,270.27	4,014.33
IV.	Expenses:			
	Purchases/Consumption of Goods & Services	24	4,478.42	3,136.75
	Changes in Inventories	25	(865.55)	1.58
	Employee benefits Expense	26	376.30	495.21
	Finance Costs	27	191.21	165.22
	Depreciation and Amortization Expense	11	29.92	2.44
	Other Expenses	28	256.99	178.55
	Total expenses		4,467.29	3,979.75
V	Profit before exceptional and extraordinary items and tax (III- IV)		(197.02)	34.58
VI	Exceptional Items		-	-
VII	Profit before extraordinary items and tax (V - VI)		(197.02)	34.58
VIII	Extraordinary items		-	-
IX	Profit before tax (VII- VIII)		(197.02)	34.58
X	Tax expense:			
	(1) Current tax		-	20.00
	Less : MAT Credit Entitlement		-	-
			-	20.00
	(2) Deferred tax Liability/(Asset)		(6.80)	(4.28)
	(3) Tax in respect of earlier years		12.92	(0.51)
	(4) Profit / (Loss) of Prior Period Depreciation		-	-
			6.12	15.21
XI	Profit (Loss) for the period from continuing operations (IX-X)		(203.14)	19.37
XII	Profit/(loss) from discontinuing operations		-	-
XIII	Tax expense of discontinuing operations		-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		-	-
XV	Profit (Loss) for the period (XI + XIV)		(203.14)	19.37
XVI	Earnings per equity share of Rs. 10 each			
	Basic		(6.46)	0.62
	Diluted		(6.46)	0.62
	Significant Accounting Policies	2		
	The notes are integral parts of the financial statements			
<div> <div> As per our report of even date for R Sundaresan Aiyar & Co Chartered Accountants Firm Registration No.: 110564W CA R Sunderesan Aiyar Partner M. No.:043946 Place : Mumbai Date : May 30, 2025 UDIN : </div> <div> for DocMode Health Technologies Limited <div> Paulson Paul Thazhathedath Wholetime Director DIN 02301881 Place : Mumbai Date : May 30, 2025 </div> <div> Hans Albert Lewis Wholetime Director & CFO DIN: 02301853 PAN: ACOPL6883G Place : Mumbai Date : May 30, 2025 </div> </div> <div> Paresh Jaysih Sampat Managing Director DIN: 00410185 Place : Mumbai Date : May 30, 2025 </div> </div>				

Statement of Cash Flows for the year ended March 31,2025

Indian Rupee in Lacs

(A)	CASH FLOW FROM OPERATING ACTIVITIES	March 31,2025	March 31,2024
	Net Profit before Tax and Extraordinary Items	(197.02)	34.58
	Adjusted for		
	Depreciation	29.92	2.44
	Profit on Sale of Fixed Assets	-	-
	Provision for Gratuity	3.43	17.43
	Interest Expenses	191.21	165.22
	Operating Profit before Working Capital changes	27.54	219.66
	Adjutments for changes in working capital		
	(Increase)/Decrease in Inventories	(865.55)	1.58
	(Increase)/Decrease in Trade and Other Receivables	222.95	(317.44)
	(Increase)/Decrease in Short Loans & Advances	(48.68)	13.44
	(Increase)/Decrease in Long term Loans & Advances	(1.13)	(7.46)
	(Increase)/Decrease in Other Current Assets	(6.81)	-
	Increase/(Decrease) in Trade Payables	257.94	(25.36)
	Increase/(Decrease) in Other Non Current liabilities	-	-
	Increase/(Decrease) in Current liabilities	1,095.64	355.59
	Increase/(Decrease) in Short Term Provisions	(4.81)	208.32
	Cash generated from operations	677.11	448.34
	Direct Taxes Paid	(12.92)	0.51
	NET CASH FLOW FROM OPERATING ACTIVITIES	664.19	448.85
(B)	CASH FLOW FROM INVESTING ACTIVITIES		
	Sale/ (Purchase) of Fixed Assets	(364.53)	(741.73)
	Sale/ (Purchase) of Investments	(2.96)	(6.41)
	Rent Deposit paid to landlord for office premises	0.22	(6.67)
	NET CASH USED IN INVESING ACTIVITIES	(367.27)	(754.81)
(C)	CASH FLOW FROM FINANCING ACTIVITIES		
	Proceeds/(Repayment) from long term borrowings	(325.75)	(3.29)
	Proceeds from Short Term Borrowings	90.08	73.37
	Proceeds from issue of Shares	-	671.18
	Interest paid	(191.21)	(165.22)
	NET CASH FROM FINANCING ACTIVITIES	(426.88)	576.04
	NET INCREASE IN CASH AND CASH EQUIVALANTS (A+B+C)	(129.96)	270.09
	OPENING BALANCE OF CASH AND CASH EQUIVALANTS	308.76	38.68
	CLOSING BALANCE OF CASH AND CASH EQUIVALANTS	178.81	308.76

for DocMode Health Technologies Limited

Paulson Paul Thazhathedath
Wholetime Director
DIN 02301881

Hans Albert Lewis
 Wholetime Director & CFO
 DIN: 02301853
 PAN: ACOPL6883G

Paresh Jaysih Sampat
Managing Director
DIN: 00410185

AUDITORS' REPORT ON CASH FLOW STATEMENT

We have examined the above Cash Flow Statement of Docmode Health Technologies Ltd. derived from audited financial statements and the books and records maintained by the company for the period ended March 31, 2025 and found the same in agreement therewith.

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

Place : Mumbai
Date : May 30, 2025
UDIN :

CA R Sunderesan Aiyar
Partner
M. No.:043946

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes to the financial statements
for the period ended March 31, 2025
Indian Rupee in Lacs

1. Background of the Company

Docmode Health Technologies Limited ("the Company") was incorporated on July 17, 2017. The Company is a public limited company incorporated and domiciled in India. The registered office of the Company is located at 307, Shivai Plaza, Marol Co-op Industrial Estate Road, Sagbag, Marol, Andheri (East), Mumbai 400059. The Company is engaged in the business of providing comprehensive & interactive learning programs for healthcare professionals through e-Learning measures and providing online CME (continuous medical education) Certification Courses and designing & conducting surveys, quizzes, questionnaires, etc. for collecting data insights related to the healthcare industry for the healthcare stakeholders. The Company also conducts offline/ online events/ sessions/ seminars for knowledge enhancement and sharing for the healthcare stakeholders.

The Board of Directors approved the standalone financial statements for the year ended March 31, 2025

2. Significant accounting policies

2.1 Basis of preparation & presentation

The financial statements have been prepared to comply in all material respects with the Accounting Standards issued as per the provisions of Section 133 of the Companies Act, 2013 read with rule 7 of Companies (Accounts) Rules 2014. The financial statements are prepared on going concern basis under the historical cost convention on the accrual basis except in case of assets for which provision for impairment is made and revaluation is carried out. The accounting policies have been consistently applied by the Company.

2.2 Functional and Presentation Currency

These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are mentioned in lakhs and rounded off to 2 decimals unless, otherwise stated.

2.3 Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires judgements, estimates and assumptions to be made that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Difference between the actual results and estimates are recognized in the year in which the results are known / materialized.

2.4 Property, Plant & Equipment

Tangible assets

Tangible assets are stated at cost net of recoverable taxes, trade discounts and rebates and include amounts added on revaluation, less accumulated depreciation and impairment loss, if any. The cost of tangible assets comprises its purchase price, borrowing cost and any cost directly attributable to bring the asset to its working condition for its intended use, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to assets.

Subsequent expenditures related to an item of Tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

Projects under which assets are not ready for its intended use are disclosed under capital work in progress.

Intangible assets

Intangible assets are stated at cost of acquisition net of recoverable taxes less accumulated amortization / depletion and impairment loss, if any. The cost comprises purchase price, borrowing cost and any cost directly attributable to bring the asset to its working condition for its intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to intangible assets.

2.5 Leases

Leases of assets, where the company assumes substantially all the risk and benefits of ownership are classified as finance leases. Finance leases are capitalized at the lower of fair value of the leased assets at inception and the present value of minimum lease payments. Lease payments are apportioned between the finance charge and the outstanding liability. The finance charge is allocated periods during the lease term at a constant periodic rate of interest on the remaining balance of the liability.

Leases where the lessor effectively retains substantially all the risk and benefits of ownership are classified, as operating leases. Lease rentals in respect of assets taken under operating leases are charged to statement of profit & loss on a straight line basis over the lease term.

2.6 Depreciation

Depreciation is provided on a pro-rata basis under the Written Down Value method over the useful life of the assets as prescribed under part C of Schedule II of the Companies Act, 2013.

Fixed assets individually costing Rupees Five Thousand or less are depreciated at 100% over a period of one year.

Assets under finance lease are amortized over their estimated useful life or the lease term whichever is lower.

2.7 Impairment

As asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. An impairment loss is charged to the Profit & Loss Statement in the year in which asset is treated as impaired. The impairment loss recognized in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

2.8 Foreign Currency Transactions

i. Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of transaction or that approximates the actual rate at the date of transaction.

ii. Monetary items denominated in foreign currencies at the year-end are restated at year end rates. In case of items which are covered by forward exchange contracts, the difference between the year-end rate and the rate on the date of contract is recognized as exchange difference and the premium paid on forward contracts is recognized over the life of contract.

iii. Non-monetary foreign currency assets are carried at cost.

iv. Any income or expense on account of exchange differences either on settlement or on translation is recognized in the Profit & Loss Statement, except in the case of long term liabilities, where they relate to acquisition of fixed assets, in which case they are adjusted to the carrying cost of such assets.

2.9 Investments

Current investments are carried at lower of cost and quoted / fair value, computed category-wise. Non-current investments are stated at cost. Provision for diminution in the value of Non-Current Investments is made only if such a decline is other than temporary.

2.10 Cash and Cash equivalents

Cash and cash equivalents comprise cash and cash on deposit with banks. The company considers all highly liquid investments with a remaining maturity at the date of purchase of three months or less and that are readily convertible to known amounts of cash to be cash equivalents.

2.11 Revenue recognition

i. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

ii. Revenue from sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer. Revenue from sale of goods is net of sales tax, trade discounts, rebates etc.

iii. Revenue from services is recognized as and when the services are rendered in accordance with the terms of the specific contracts, net of all contractual deductions. Revenue from Services is recognized net of all taxes and levies..

iv. Income from interest on deposits is recognized on a time proportion basis.

v. Dividend income is recognized when the right to receive payment is established.

2.12 Employee benefits

(i) Short term employment benefits

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by the employees are recognized as expense during the period when the employee render the services. These benefits include performance incentive and compensated absences.

(ii) Post-employment benefits

a) Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which the Company pays specified contributions to a separate entity. The Company makes specified monthly contribution towards Provident Fund and pension scheme. The Company's contribution is recognized as an expense in the Profit and Loss Statement during the period in which the employee renders the related service.

b) Defined benefit plans

Gratuity

Benefits payable to eligible employees of the Company with respect to gratuity, a defined benefit plan is accounted for on the basis of an actuarial valuation as at the balance sheet date. In accordance with the Payment of Gratuity Act, 1972, the plan provides for lump sum payments to vested employees upon retirement, death while in service or upon termination of employment in an amount equivalent to 15 days salary for each completed year of service. Vesting occurs upon completion of five years of service. The company contributes premium towards gratuity liability arrived by actuarial valuation performed by an independent actuary.

Actuarial Valuation

The actuarial valuation method used for measuring the liability either Gratuity or Compensated absence is the Projected Unit Credit method. The estimate of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors. The expected rate of return on plan assets is the Company's expectation of the average long term rate of return expected on investments of the fund during the estimated term of the obligations. Actuarial gain/losses are recognized in the Statement of Profit and Loss in the year they are determined.

2.13 Borrowing costs

Borrowing costs include exchange difference arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs that are attributable to the acquisition or construction of a qualifying asset are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred. Capitalisation of borrowing costs is suspended during the extended period in which active development is interrupted. Capitalisation of borrowing costs is ceased when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete. Other borrowing costs are charged to statement of profit and loss as and when incurred.

2.14 Provisions, contingent liabilities and contingent assets

Provision is recognized in the accounts when there is present obligation as a result of a past event(s) and it is probable that an outflow of resources will be required and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date.

Contingent liabilities are disclosed unless the possibility of outflow of resources is remote.

Contingent assets are neither recognized nor disclosed in the financial statements.

2.15 Income Taxes

Tax expense comprises of current tax and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities, using the applicable tax rates.

Deferred income tax reflect the current period timing difference between taxable income and accounting income for the year and reversal of timing difference of earlier years/period. Deferred tax assets are recognized only to the extent there is reasonable certainty that the sufficient future income will be available except that deferred tax assets, in case there are unabsorbed depreciation or losses, are recognized only if there is virtual certainty that sufficient future taxable income will be available to realize the same.

Deferred tax assets and liabilities are measured using the tax rates and tax law that have been enacted or substantively enacted by the Balance Sheet date.

2.16 Earnings per share

Basic earnings per share are computed by dividing the net profit for the year attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the net profit attributable to the equity shareholders for the year by the weighted average number of equity and dilutive equity equivalent shares outstanding during the year, except where the results would be anti-dilutive.

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
Indian Rupee in Lacs
Note 3
Share Capital

	March 31,2025	March 31,2024
Authorised Share Capital		
40,00,000 (P.Y 40,00,000) Equity Shares of Rs. 10 each	400.00	400.00
50,000(P.Y 50,000) Preference Shares of Rs 10 each	5.00	5.00
Total	405.00	405.00
Issued, Subscribed & Paid up		
31,42,800 (P.Y 31,42,800) Equity Shares of Rs. 10 each fully paid	314.28	314.28
Total	314.28	314.28

The Company has only one class of equity shares having a par value of Rs. 10 per share. Each Shareholder is eligible for one vote per share. In the event of liquidation, the equity shareholders are eligilble to receive the remaining assets of the Company, after distribution of all preferential amounts, In proportion of their shareholding.

Reconciliation of no. of shares outstanding at the beginning and at the end of the year

Particulars	March 31,2025 Equity Shares		March 31,2024 Equity Shares	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	3,142,800	31,428,000	2,293,200.00	22,932,000.00
Shares Issued during the year	-	-	849,600.00	8,496,000.00
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	3,142,800	31,428,000	3,142,800.00	31,428,000.00

Details of Shares held by shareholders holding more than 5% in the Company:

Name of Shareholder	March 31,2025		March 31,2024	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Paulson Paul Thazhathedath	745,290	23.71%	745,290.00	0.24
Hans Albert Lewis	745,290	23.71%	745,290.00	0.24
Anil Khanna	401,310	12.77%	401,310.00	0.13
Aalok Pathak	400,164	12.73%	400,164.00	0.13
	2,292,054	72.93%	2,292,054.00	0.73

Details of Shares held by Promoters at the end of the year

Name of Promoter	March 31,2025		March 31,2024		% Change During the year
	No. of Shares held	% of Holding	No. of Shares held	% of Holding	
Paulson Paul Thazhathedath	745,290	24%	745,290	0.24	-
Kenneth Paul Lewis	382	0.01%	382	0.0	-
Hans Albert Lewis	745,290	24%	745,290	0.24	-
	1,490,962	47%	1,490,962	0.47	-

Note 4

Reserves and Surplus

	March 31,2025	March 31,2024
Surplus/Deficit in the Statement of Profit and Loss		
Opening Balance	724.19	118.60
(-) Capitalisation of reserves	-	-
(+) Securities Premium	-	586.22
(+) Net Profit/(Net Loss) For the current year	(203.14)	19.37
Closing Balance	521.05	724.19
Total	521.05	724.19

Note 5
Long Term Borrowings

	March 31,2025	March 31,2024
Secured Loans		
Unsecured Loans		
a) Bonds / Debentures	-	-
b) Term Loans	-	-
A) From Banks	3.49	74.60
B) From Other Parties	108.96	359.60
e) Loans & Advances from Related Parties	-	4.00
Total	112.45	438.20

Note 6
Long Term Provisions

	March 31,2025	March 31,2024
a) Provision for Employee Benefits	69.71	66.28
Total	69.71	66.28

Note 7
Short Term Borrowings

	March 31,2025	March 31,2024
Secured Loans		
a) Bonds / Debentures	175.00	-
(Secured by way of pledge of shares & other assets)		
d) Bank Overdraft Account	111.12	109.99
(Secured by way of lien on Fixed Deposit with Bank)		
Unsecured Loans		
Current Maturities of Long Term Borrowings	283.78	369.84
Total	569.91	479.82

Note 8
Trade Payables

	March 31,2025	March 31,2024
Total outstanding dues of Creditors of Micro & Small Enterprises	184.02	28.24
Total outstanding dues of Creditors other than Micro & Small Enterprises	349.52	247.36
	-	-
Total	533.54	275.59

Trade Payables Ageing Schedule as at March 31,2025

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	172.68	11.34	-	-	184.02
Others	333.99	11.38	-	4.14	349.52
Dispute dues-MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total					533.54

Trade Payables Ageing Schedule as at March 31,2024

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	18.52	9.72	-	-	28.24
Others	145.14	119.03	2.54	-	266.71
Dispute dues-MSME	-	-	-	-	-
Disputed dues - Others	-	-	-	-	-
Total					294.95

Note 9
Other Current Liabilities

	March 31,2025	March 31,2024
a) Interest Accrued and due on Debentures	1.54	-
b)Income Received in Advance	1,381.33	356.00
c) Unpaid matured debentures and interest accrued thereon	55.45	-
d) Other Payables	13.32	-
Total	1,451.63	356.00

Note 10
Short Term Provisions

	March 31,2025	March 31,2024
a) Provision for Employee Benefits	139.98	129.32
b) GST Payable	21.29	18.87
c) TDS Payable	191.27	209.17
d) Audit Fees Payable	6.00	6.00
Total	358.55	363.35

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Note 11 - Property, Plant and Equipment
Indian Rupee in Lacs

Particulars/Assets	Tangible Assets				Intangible			Gross Total
	Computers	Machinery	Office Equipments	Total	Software	Assets Under Development	Total	
Gross Block								
At 1st April 2023	10.77	0.45	1.55	12.77	5.41	202.80	208.21	220.98
Additions	8.07	86.54		94.61	-	647.12	647.12	741.73
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 1st April 2024	18.84	86.99	1.55	107.38	5.41	849.92	855.33	962.71
Additions	0.09	54.60		54.69	-	309.84	309.84	364.53
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 31st March 2025	18.93	141.59	1.55	162.07	5.41	1,159.76	1,165.17	1,327.24
Depreciation								
At 1st April 2023	10.09	0.15	0.95	11.20	2.34	-	2.34	13.53
Additions	0.63	0.06	0.28	0.97	1.47	-	1.47	2.44
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 1st April 2024	10.73	0.21	1.23	12.17	3.80	-	3.80	15.97
Additions	4.85	24.18	0.13	29.16	0.76	-	0.76	29.92
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 31st March 2025	15.57	24.39	1.36	41.32	4.57	-	4.57	45.89
Net Block								
At 31st March 2024	8.11	86.77	0.32	95.21	1.61	849.92	851.53	946.74
At 31st March 2025	3.36	117.19	0.19	120.74	0.84	1,159.76	1,160.60	1,281.35

If Assets Purchase During the Year the Dep formula = Life used in Purchasing Year x Depreciable Amount over whole Life x Rate of Depreciation
If Opening Assets Depreciation Formula = IF(AND(Remaining Life<1,Remaining Life>0),(Opening WDV-Salvage Value),(Opening WDV*Rate of Depreciation))

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
Indian Rupee in Lacs
Note 12
Non Current Investments

	March 31,2025	March 31,2024
(Unquoted, fully paid up, at cost)		
Investment in Equity Instruments	0.10	0.10
Investment in Fixed Deposits	120.52	110.00
Total	120.61	110.10

NOTE 13
Deferred Tax Assets (Net)

	March 31,2025	March 31,2024
Deferred Tax Assets	25.51	18.71
Total	25.51	18.71

Note 14
Long Term Loans and Advances

	March 31,2025	March 31,2024
a) Capital Advances	-	-
b) Loans and Advances to related Parties	-	-
Unsecured, Considered good	6.05	4.93
c) Other Loans and Advances		
Unsecured, Considered good	2.65	2.65
Total	8.70	7.58

NOTE 15
Other Non Current Assets

	March 31,2025	March 31,2024
i) Security Deposits		
Central Depository Services	0.10	0.10
Rent Security Deposits	6.10	6.32
National Stock Exchange	6.71	6.71
Total	12.91	13.13

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
Indian Rupee in Lacs
Note16
Current Investments

	March 31,2025	March 31,2024
Investment in Fixed Deposit	8.69	16.24
	8.69	16.24

Note 17
Inventories

	March 31,2025	March 31,2024
a) Inventory of Digital Course Content	250.16	251.39
b) Service Work in Progress	866.77	-
	1,116.93	251.39

Note 18
Trade Receivables

	March 31,2025	March 31,2024
Trade Receivable		
Unsecured, considered good	923.94	1,146.89
Less: Provision for doubtful debts	-	-
Total	923.94	1,146.89

Trade Receivables Ageing Schedule as at March 31,2025

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables- Considered Good	150.05	29.62	77.95	666.32	-	923.94
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	150.05	29.62	77.95	666.32	-	923.94

Trade Receivables Ageing Schedule as at March 31,2024

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables- Considered Good	227.51	238.77	525.32	155.29	-	1,146.89
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	227.51	238.77	525.32	155.29	-	1,146.89

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
Indian Rupee in Lacs
Note19
Cash and Cash Equivalents

	March 31,2025	March 31,2024
Cash & Cash Equivalents		
a) Balance with Bank	176.12	305.08
b) Cheques, Drafts on Hand	-	-
c) Cash on Hand	2.68	3.68
Total	178.81	308.76

Note 20
Short Term Loans and Advances

	March 31,2025	March 31,2024
Loans & Advances to related Parties		
Others		
Balances with revenue authorities	25.37	-
Advance Tax & TDS (Net of Provision for Tax)	160.89	132.56
TDS Revcoverable from NBFC	18.10	13.12
Other Loans & Advances	42.49	52.49
Total	246.85	198.17

NOTE 21
Other Current Assets

	March 31,2025	March 31,2024
Excess Interest Paid Recoverable	6.81	-
Total	6.81	-

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
Indian Rupee in Lacs
Note 22
Revenue from Operations

Particulars	March 31,2025	March 31,2024
Sale of products		
Sale of Goods	682.39	683.54
Sale of Services		
Sale of Services	3,494.90	3,317.20
Other Operating Revenue	-	-
Total	4,177.29	4,000.73

Note 23
Other Income

Particulars	March 31,2025	March 31,2024
Interest Income	13.02	13.44
Miscellaneous Income	2.27	0.15
Sundry Balances written off	77.64	-
Discount Received	0.04	0.01
Total	92.97	13.59

Note 24
Purchases/Consumption of Goods & Services

Particulars	March 31,2025	March 31,2024
CME Course Content	22.40	8.41
Purchase of Books	14.83	104.40
Printed Literature	200.63	174.56
Travelling Expenses	208.31	83.07
Event Consumables	976.51	632.53
Professional Fees	2,607.41	1,610.18
Contractee Fees	415.74	510.23
Webinar Expenses	15.03	3.83
Transcription Charges	4.93	6.14
Service Charges	2.52	0.25
Content Expenses	10.11	3.16
Total	4,478.42	3,136.75

Note 25
Changes in inventories

Particulars	March 31,2025	March 31,2024
Opening Stock		
Finished Goods	-	-
Service Work in Progress	-	-
CME Course Content & Books	251.39	252.96
Total (A)	251.39	252.96
Closing Stock		
CME Course Content & Books	250.16	251.39
Service Work in Progress	866.77	-
Others	-	-
Total (B)	1,116.93	251.39
Total (A-B)	(865.55)	1.58

Note 26
Employee Benefits Expenses

Particulars	March 31,2025	March 31,2024
Salaries & Wages	337.55	437.60
Contribution to Providend Fund and Other Fund	26.74	29.81
Contribution to Recognised Gratuity Fund	5.61	17.89
Staff Welfare	6.40	9.92
Employee Insurance Premium	-	-
Total	376.30	495.21

Note 27
Finance Costs

Particulars	March 31,2025	March 31,2024
a) Interest Expenses		
On Borrowings	157.47	133.79
On Deferred/Delayed Payment of Taxes	29.54	14.72
b) Other Borrowing Cost	1.26	16.02
c) translation	2.93	0.68
Total	191.21	165.22

Note 28
Other Expenses

Particulars	March 31,2025	March 31,2024
Event Expenses	0.52	-
Advertising & Marketing Expenses	8.27	9.15
Cloud Services	4.16	1.69
Service Charges	11.18	11.45
Software Charges	7.20	4.10
Webinar Expenses	3.72	-
Electricity Expenses	1.63	1.91
Rent	41.61	41.02
Recruitment Charges	3.49	1.44
Commission & Brokerage	0.56	7.95
Telephone Expenses	0.56	0.48
Insurance Charges	0.64	0.87
Repairs & Maintenance	0.79	1.03
Sponsorship Service	-	4.30
Office Expenses	4.96	4.83
Professional Fees	115.68	24.57
IT Consultancy & Support Service	1.73	3.49
Profession Tax	0.08	0.03
Travelling Expenses	9.51	5.03
GST Expensed out	5.61	7.86
Printing, Postage & Courier	2.03	3.02
Rates & Taxes	1.84	-
Director Sitting Fees	-	1.50
Other Expenses	20.91	6.97
Business Promotion	-	2.10
IPO Expenses	-	21.24
Donation	-	5.50
Prior Period Expenses	4.31	1.01
Payment to Auditors		
Auditor Remuneration	6.00	6.00
Total	256.99	178.55

Note 29 - Contingent liabilities & Commitments in respect

Particulars	March 31,2025	March 31,2024
A. Contingent Liabilities		
a Claims against the company not acknowledge as debts	Nil	Nil
b. Guarantees	Nil	Nil
c.Other money for which the company is contingently liable.	Nil	Nil
Total	-	-

B. Commitments

There are no commitments as at 31st March, 2025

Note 30 - Deferred Tax Asset (Liability)

Particulars	March 31,2025	March 31,2024
Permanent Difference		
Items disallowed under Income Tax Act, 1961	-	-
Timing Difference		
Difference in Gratuity Provision	(71.57)	(68.07)
Difference in Fixed Assets	(4.40)	0.83
Total	(75.97)	(67.25)
Deferred Tax Asset on Timing Difference	(21.00)	(19.00)

Note 31 - Auditor's Remuneration

Particulars	March 31,2025	March 31,2024
Statutory Audit Fees	6.00	6.00
Total	6.00	6.00

Note 32 - Expenditure / Income in foreign currency (on accrual basis):

Particulars	March 31,2025	March 31,2024
Import	99.66	29.80
Export	6.89	10.45
Total	106.55	40.25

Note 33 - Earning Per Share

Particulars	March 31,2025	March 31,2024
Net Profit after tax	(203.14)	19.37
Weighted Average number of equity shares	31.43	31.43
EPS (Basic) (Rs.)	(6.46)	0.62
EPS (Diluted) (Rs.)	(6.46)	0.62
Face Value per equity share (Rs.)	10.00	10.00

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes To The Financial Statements
Indian Rupee in Lacs
Note 34 - Related Party Transactions

(a) Names of Related Parties & Nature of Relationship		
Paulson Paul Thazhathedath	Director	
Hans Albert Lewis	Director	
Paresh Sampat	Director	
Monina Elizabeth Lewis	Director	
CCME World Services Pvt Ltd	Subsidiary Company	
Docmode Endeavors LLP	Director having substantial Interest	
Augmentors Healthcare Limited	Director having substantial Interest	
Aumen Healthcare Pvt Ltd	Director having substantial Interest	
Kenneth Paul Lewis	Relative of Director	
(b) Director Remuneration	March 31,2025	March 31,2024
Paulson Paul Thazhathedath	39.00	39.00
Hans Albert Lewis	39.00	39.00
Total	78.00	78.00
(c) Loan given to Related Party	March 31,2025	March 31,2024
Paulson Paul Thazhathedath	-	-
Hans Albert Lewis	-	-
CCME World Services Pvt Ltd	6.00	4.90
Total	6.00	4.90
(d) Loan given by Related Party	March 31,2025	March 31,2024
Paulson Paul Thazhathedath	-	4.00
Hans Albert Lewis	-	-
Total	-	4.00
(e) Income Received in Advance from Related Party	March 31,2025	March 31,2024
Augmentors Healthcare Limited	17.93	-
Total	17.93	-
(f) Capital Expenditure	March 31,2025	March 31,2024
Augmentors Healthcare Limited	-	143.06
Aumen Healthcare Pvt Ltd	-	214.08
Total	-	357.14

Note 35 - Leases		
Particulars	March 31,2025	March 31,2024
Operating Lease		
Lease rentals charged to revenue for lease agreements for the right to use the following assets		
Office Equipments	20.37	16.23
Office Premises	21.25	24.78
Total	41.61	41.02
The Lease agreements are executed for a reasonable period with a renewal clause and also provide for termination at will by either party by giving prior notice.		

Note 36 - Disclosure pursuant to Accounting Standard 15 (Employee benefits)		
<i>a) Defined Contribution Plans to Provident fund (defined contribution)</i> The Company makes contributions to Provident Fund which is defined contribution plans for qualifying employees. Under the scheme, the Company is required to contribute a specified percentage of the payroll cost to fund the benefits. The Company recognized Rs 13.18/- Lacs (March,2024: Rs.14.72/- Lacs) for provident fund contributions in the Statement of Profit and Loss. The contributions payable to the plan by the Company are at the rates specified in the rules of the scheme.		
<i>a) Gratuity (defined benefit)</i> Every employee is entitled to the benefit equivalent to 15 days of total gross salary last drawn for each completed year of service. Gratuity is payable to all eligible employees of the Company on retirement or separation or death or permanent disablement in terms of the provisions of the Payment of Gratuity Act. The Company recognized Rs.5.61/- Lacs (March, 2024: Rs.17.88/- Lacs) in the Statement of Profit and Loss.		

	March,2025	March, 2024
Method	Projected Unit Credit Method	Projected Unit Credit Method
Assumptions		
Discount Rate	6.83%	7.22%
Expected Return on Plan Assets	Funded	Funded
Expected Return on Plan Assets	Funded	Funded
Mortality Table	Indian Assured Lives Mortality (2012-14) Urban	Indian Assured Lives Mortality (2012-14) Urban
Future Salary increases	10%	0.10
Disability	Nil	Nil
Attrition	5%	0.05
Retirement	60, 65 & 70 years	60 years

Note 37 - Funding Arrangement
No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to any other person(s) or entity(ies), including foreign entities (“Intermediaries”) with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company (“Ultimate Beneficiaries”) or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Note 38 - Segment Information
The Company is engaged in the business of providing vocational training. DocMode is a platform that provides authoritative, comprehensive and interactive learning programs for Health Professionals - Doctors, Nurses, Allied and Medical Students - across the world. The company is comeup with new segments during the year namely publishing of Medical books, trading of medical books and journals, conducting customised and inhouse events. The company operates in 13 geographical segments within India namely Maharashtra, Karnataka, Himachal Pradesh, Uttarakhand, West Bengal, Kerala, Tamilnadu, Telangana, Andhra Pradesh, Uttar Pradesh, Goa, Delhi, Haryana.

Note 39 - Other Additional Information
Information with regard to the other additional information and other disclosures to be disclosed by way of notes to statement of profit and loss as specified in the Schedule III of the Companies Act, 2013 is either ‘nil’ or ‘not applicable’ to the Company for the year.

Note 40 - Others
Previous year figures have been regrouped / reclassified wherever necessary to correspond with the current year classification / disclosure.

<div>DocMode Health Technologies Limited</div> <div>(Formerly known as Docmode Health Technologies Private Limited)</div> <div>CIN : L74999MH2017PLC297413</div>					
<div>Notes To The Financial Statements</div> <div>Additional Regulatory Information (Continued)</div>					
X) RATIO ANALYSIS					
Sr.No	Ratios	Numerator	Denominator	March 31,2025	March 31,2024
Liquidity Ratio					
1	Current Ratio (times)	Current Assets	Current Liabilities	0.85	1.30
Solvency Ratio					
2	Debt Equity Ratio (times)	Total Debt	Shareholder's Equity (Total Equity)	0.82	0.88
3	Debt Service coverage ratio (times)	Earnings Available for Debt Service	Debt Service (Interest + Principal)	(0.02)	0.27
Profitability Ratio					
4	Net profit ratio (%)	Profit or (Loss) For the Year	Revenue From Operations	(4.86)	0.48
5	Return on Equity Ratio (%)	Net Profit After Tax	Average Shareholder's Equity	(21.68)	2.79
6	Return on Capital employed (%)	Earnings Before Interest & Tax	Capital Employed (Average Total Equity + Debt)	(2.28)	10.68
7	Return on Investment (%)	Earnings Before Interest and Tax	Average Total Assets	(1.14)	7.14
Utilisation Ratio					
8	Inventory Turnover Ratio (times)	Cost of Goods Sold	Average Inventory	(2.00)	12.45
9	Trade Receivables turnover ratio (times)	Revenue From Operations	Average Trade Receivables	4.03	4.05
10	Trade payables turnover ratio (times)	Cost of Goods Sold	Average Trade Payables	2.14	10.89
11	Net capital turnover ratio (times)	Revenue From Operations	Working Capital	(9.68)	8.96
As per our report of even date					
for R Sundaresan Aiyar & Co			for Docmode Health Technologies Limited		
Chartered Accountants					
Firm Registration No.: 110564W					
CA R Sunderesan Aiyar			Paulson Paul Thazhathedath		
Partner			Wholetime Director		
M. No.:043946			DIN 02301881		
Place : Mumbai			Place : Mumbai		
Date : May 30, 2025			Date : May 30, 2025		
UDIN :			Hans Albert Lewis		
			Wholetime Director & CFO		
			DIN: 02301853		
			PAN: ACOPL6883G		
			Place : Mumbai		
			Date : May 30, 2025		
			Paresh Jaysih Sampat		
			Managing Director		
			DIN: 00410185		
			Place : Mumbai		
			Date : May 30, 2025		

Independent Auditor's Report on Consolidated Financial Statements

To the Members of DocMode Health Technologies Limited (Formerly known as DocMode Health Technologies Private Limited)

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the consolidated financial statements of DocMode Health Technologies Limited (Formerly known as DocMode Health Technologies Private Limited) ("The Holding Company"), and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") which comprises the Consolidated Balance Sheet as at 31st March 2025, and the Consolidated Statement of Profit and Loss and Consolidated Statement of Cash Flows for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies and other explanatory information(hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors on separate financial statements of such subsidiaries as were audited by the other auditors, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the consolidated state of affairs of the Group as at 31st March 2025, its consolidated loss and consolidated cash flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on consolidated financial statements.

Information other than the consolidated financial statements and auditors' report thereon

The Holding Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexures to Board's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the consolidated Financial Statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the Consolidated Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the consolidated Financial Statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated Financial Statements of the current year. These matters were addressed in the context of our audit of the Consolidated Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

We have determined that there are no Key Audit matters to be communicated in our report.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Consolidated Financial Statements that give a true and fair view of the financial position, financial performance and cash flows of the Group in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and

detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Consolidated Financial Statements, the respective Management and Board of Directors of the Companies are responsible for assessing the ability of each company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the company or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Companies are also responsible for overseeing the financial reporting process of each company.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Holding Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Holding Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance the with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Consolidated Financial Statements of the current year and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be

communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

We did not audit the financial statements of a subsidiary, whose financial statements reflect total assets of Rs.6.13 Lacs as at March 31, 2025 and total revenue Rs.14.38 Lacs for the year ended on that date, as considered in the consolidated financial statements. These financial statements have been audited by other auditors whose reports have been furnished to us by the Management and our opinion on the consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and our report in terms of sub-section (3) of section 143 of the Act, in so far as it relates to the aforesaid subsidiary is based solely on the audit reports of the other auditors.

Our opinion on the consolidated financial statements, and our report on Other Legal and Regulatory Requirements below, is not modified in respect of the above matters.

Report on Other Legal and Regulatory Requirements

3. As required by the Companies (Auditors' Report) Order, 2020 ("the Order") issued by the Central Government of India in terms of Section 143(11) of the Act, we give in the "Annexure A" a statement on the matters specified in paragraph 3 and 4 of the Order, to the extent applicable.
4. As required by Section 143 (3) of the Act based on our audit and on the consideration of reports of the other auditors on separate financial statements of such as were audited by other auditor, as noted in the 'Other Matters' paragraph, we report, to the extent applicable that:
 - i) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.
 - j) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditor.
 - k) The Consolidated Balance Sheet, the Consolidated Statement of Profit & Loss and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.
 - l) In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
 - m) On the basis of the written representations received from the Directors as on 01st April 2024 taken on record by the Board of Directors, none of the Directors is disqualified as on 31st March 2025 from being appointed as a Director in terms of Section 164 (2) of the Act.
 - n) With respect to the adequacy of the internal financial controls with reference to financial statements of the Group and the operating effectiveness of such controls, refer to our separate Report in 'Annexure B'.
 - o) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- viii. The Group does not have any pending litigations which would impact its financial position.
- ix. The Group did not have any material foreseeable losses on long-term contracts including derivative contracts during the year ended 31st March, 2025.
- x. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company and its subsidiary company.
- xi. (a) The Management has represented that, to the best of their knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share Premium or any other sources or kind of funds) by the Holding Company or its subsidiary company to or in any other

person(s) or entity(ies), including foreign entities (“Intermediaries”), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:

- directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Group (“Ultimate Beneficiaries”) or
- provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

(b) The Management has represented, that, to the best of its knowledge and belief, no funds have been received by the Holding Company or its subsidiary from any person(s) or entity(ies), including foreign entities (“Funding Parties”), with the understanding, whether recorded in writing or otherwise, that the Group shall:

- directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party (“Ultimate Beneficiaries”) or
- provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

- xii. Based on the audit procedures that have been considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under sub-clause (i) and (ii) of Rule 11(e), as provided under (iv) and (v) above, contain any material misstatement.
- xiii. The Holding Company has not declared or paid any dividend during the year in contravention of the provisions of section 123 of the Companies Act, 2013.
- xiv. Based on our examination which included test checks the Holding Company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility except that audit trail was not enabled at the database level to log any direct changes for the accounting software used for maintaining the books of account. For accounting software for which audit trail feature is enabled, the audit trail facility has been operating throughout the year for all relevant transactions recorded in the software and we did not come across any instance of audit trail feature being tampered with during the course of our audit.
- p) With respect to the other matters to be included in the Auditor’s Report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, the remuneration paid by the Holding Company to its directors during the year is in accordance with the provisions of section 197 read with Schedule V to the Act.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: May 30, 2025
UDIN: 25043946BMIQXB7502

Annexure-A to Independent Auditors' Report on the Consolidated Financial Statements for the year ended 31st March 2025

(Referred to in paragraph 1 under “Report on Other Legal and Regulatory Requirements’ section of our report of even date)

xxi) In our opinion and according to the information and explanations given to us, the Companies (Auditor’s Report) Order, 2020 of the Holding Company did not include any unfavourable answers or qualifications or adverse remarks.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: May 30, 2025
UDIN: 25043946BMIQXB7502

Annexure B to the Independent Auditor's Report of Consolidated Financial Statements for the year ended 31st March 2025

Report on the Internal Financial Controls over financial reporting with reference to consolidated financial statements under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 ("the Act")

(Referred to in Paragraph 2(f) under 'Report on Other Legal and Regulatory Requirements section of our report of even date)

Opinion

We have audited the internal financial controls with reference to the consolidated financial statements of DocMode Health Technologies Limited ("the Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") as of March 31, 2025, in conjunction with our audit of the consolidated financial statements of the Holding Company as at and for the year ended on that date.

In our opinion, the Holding Company and its subsidiary have, in all material respects, an adequate internal financial controls system over financial reporting with reference to consolidated financial statements, and such internal financial controls over financial reporting were operating effectively as at March 31, 2025, based on the internal control over financial reporting with reference to consolidated financial statements criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India".

Management's Responsibility for Internal Financial Controls

The respective Company's Management and Board of Directors of the Holding Company and its subsidiaries, which are companies incorporated in India are responsible for establishing and maintaining internal financial controls based on the internal financial controls with reference to consolidated financial statements criteria established by the respective company considering the essential components of internal control stated in the Guidance Note. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and Completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditors' Responsibility

Our responsibility is to express an opinion on the Holding Company and its subsidiaries, which are companies incorporated in India, internal financial controls over financial reporting with reference to consolidated financial statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls with reference to consolidated financial statements. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls with reference to consolidated financial statements were established and maintained and whether such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting with reference to the consolidated financial statements and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting with reference to the consolidated financial statements,

assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's judgement, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on internal financial controls over financial reporting with reference to consolidated financial statements.

Meaning of Internal Financial Controls Over Financial Reporting with reference to the consolidated financial statements

A Holding company's internal financial control over financial reporting with reference to the consolidated financial statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Holding company's internal financial control over financial reporting with reference to the consolidated financial statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Holding company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Holding company are being made only in accordance with authorisations of management and directors of the Holding company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Holding company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls Over Financial Reporting with reference to the consolidated financial statements

Because of the inherent limitations of internal financial controls over financial reporting with reference to the consolidated financial statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these consolidated financial statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these consolidated financial statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

for R. Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

CA R Sundaresan Aiyar
Partner
Membership No.: 043946
Place: Mumbai
Date: May 30, 2025

DocMode Health Technologies Limited (Formerly known as Docmode Health Technologies Private Limited) CIN : L74999MH2017PLC297413 Consolidated Balance Sheet as at March 31,2025			
Indian Rupees in Lacs			
Particulars	Note	March 31,2025	March 31,2024
I. EQUITY AND LIABILITIES			
1 Shareholder's funds			
(a) Share capital	3	314.28	314.28
(b) Reserves and surplus	4	520.53	723.20
(c) Money received against share warrants		-	-
Minority Interest	5	0.03	-
2 Share application money pending allotment		-	-
3 Non-current liabilities			
(a) Long Term Borrowings	6	112.45	438.20
(b) Deferred Tax Liabilities (Net)		-	-
(c) Other Long Term Liabilities		-	-
(d) Long Term Provisions	7	69.71	66.28
4 Current liabilities			
(a) Short Term Borrowings	8	569.91	479.82
(b) Trade Payables	9	534.06	273.30
(c) Other Current Liabilities	10	1,451.63	356.00
(d) Short Term Provisions	11	358.55	363.35
TOTAL		3,931.14	3,014.43
II. ASSETS			
1 Non-current assets			
(a) Property, Plant and Equipment and Intangible Assets	12		
(i) Property, Plant and Equipment		120.74	95.21
(ii) Intangible Assets		0.84	1.61
(iii) Capital Work-In-Progress		-	-
(iv) Intangible Assets under Development		1,159.76	849.92
(b) Non Current Investments	13	120.52	110.00
(c) Deferred Tax Assets (net)	14	25.51	18.71
(d) Long-term Loans and Advances	15	2.78	0.03
(e) Other Non Current Assets	16	12.91	13.13
2 Current assets			
(a) Current Investments	17	8.69	16.24
(b) Inventories	18	1,116.93	251.39
(c) Trade Receivables	19	923.94	1,146.89
(d) Cash and Cash Equivalents	20	183.50	310.28
(e) Short Term Loans and Advances	21	248.20	201.02
(f) Other Current Assets	22	6.81	-
TOTAL		3,931.14	3,014.43
Significant Accounting Policies	2		
The notes are integral parts of the financial statements			
As per our report of even date for R Sundaresan Aiyar & Co Chartered Accountants Firm Registration No.: 110564W			
for DocMode Health Technologies Limited			
CA R Sunderesan Aiyar Partner M. No.:043946 Place : Mumbai Date : May 30, 2025 UDIN :	Paulson Paul Thazhathedath Wholtime Director DIN 02301881 Place : Mumbai Date : May 30, 2025	Hans Albert Lewis Whole Time Director & CFO DIN 02301853 PAN: ACOPL6883G Place : Mumbai Date : May 30, 2025	
	Paresh Jaysih Sampat Managing Director DIN: 00410185 Place : Mumbai Date : May 30, 2025		

DocMode Health Technologies Limited <i>(Formerly known as Docmode Health Technologies Private Limited)</i> CIN : L74999MH2017PLC297413 Consolidated Statement of Profit & Loss for the year ended March 31,2025				
Indian Rupees in Lacs				
Particulars		Note	March 31,2025	March 31,2024
I.	Revenue from Operations	23	4,177.29	4,000.73
II.	Other Income	24	92.98	13.59
III.	Total Income (I + II)		4,270.28	4,014.33
IV.	Expenses:			
	Purchases/Consumption of Goods & Services	25	4,476.94	3,136.56
	Changes in inventories	26	(865.55)	1.58
	Employee benefits Expense	27	376.30	495.11
	Finance Costs	28	191.89	165.72
	Depreciation and Amortization Expense	12	29.92	2.44
	Other Expenses	29	257.29	178.95
	Total expenses		4,466.79	3,980.36
V	Profit before exceptional and extraordinary items and tax (III- IV)		(196.52)	33.97
VI	Exceptional Items		-	-
VII	Profit before extraordinary items and tax (V - VI)		(196.52)	33.97
VIII	Extraordinary items		-	-
IX	Profit before tax (VII- VIII)		(196.52)	33.97
X	Tax expense:			
	(1) Current tax		0.08	20.00
	Less : MAT Credit Entitlement		0.08	-
	(2) Deferred tax Liability/(Asset)		-	20.00
	(3) Tax in respect of earlier years		(6.79)	(4.28)
	(4) Profit / (Loss) of Prior Period Depreciation		12.92	(0.51)
			-	-
			6.12	15.21
XI	Profit (Loss) for the period from continuing operations (IX-X)		(202.64)	18.76
XII	Profit/(loss) from discontinuing operations		-	-
XIII	Tax expense of discontinuing operations		-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		-	-
XV	Profit (Loss) for the period (XI + XIV)		(202.64)	18.76
XVI	Earnings per equity share of Rs. 10 each			
	Basic		(6.45)	0.60
	Diluted		(6.45)	0.60
	Significant Accounting Policies	2		
	The notes are integral parts of the financial statements			
As per our report of even date for R Sundaresan Aiyar & Co Chartered Accountants Firm Registration No.: 110564W CA R Sunderesan Aiyar Partner M. No.:043946 Place : Mumbai Date : May 30, 2025 UDIN :				
for DocMode Health Technologies Limited Paulson Paul Thazhathedath Wholetime Director DIN 02301881 Place : Mumbai Date : May 30, 2025 Hans Albert Lewis Whole Time Director & CFO DIN 02301853 PAN: ACOPL6883G Place : Mumbai Date : May 30, 2025 Paresh Jaysih Sampat Managing Director DIN: 00410185 Place : Mumbai Date : May 30, 2025				

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Consolidated Statement of Cash Flows for the period ended March 31,2025

Indian Rupees in Lacs

(A) CASH FLOW FROM OPERATING ACTIVITIES	March 31,2025	March 31,2024
Net Profit before Tax and Extraordinary Items	(196.52)	33.97
Adjusted for		
Depreciation	29.92	2.44
Profit on Sale of Fixed Assets	-	-
Provision for Gratuity	3.43	17.43
Interest Expenses	191.89	165.72
Operating Profit before Working Capital changes	28.72	219.56
Adjustments for changes in working capital		
(Increase)/Decrease in Inventories	(865.55)	1.58
(Increase)/Decrease in Trade and Other Receivables	222.95	(317.44)
(Increase)/Decrease in Short Loans & Advances	(47.26)	10.60
(Increase)/Decrease in Long term Loans & Advances	(2.75)	(0.03)
(Increase)/Decrease in Other Current Assets	(6.81)	-
Increase/(Decrease) in Trade Payables	260.75	(27.81)
Increase/(Decrease) in Other Non Current liabilities	-	-
Increase/(Decrease) in Current liabilities	1,095.64	355.59
Increase/(Decrease) in Short Term Provisions	(4.81)	208.32
Cash generated from operations	680.89	450.36
Direct Taxes Paid	(12.84)	0.51
NET CASH FLOW FROM OPERATING ACTIVITIES	668.05	450.87
(B) CASH FLOW FROM INVESTING ACTIVITIES		
Sale/ (Purchase) of Fixed Assets	(364.53)	(741.73)
Sale/ (Purchase) of Investments	(2.96)	(6.41)
Rent Deposit paid to landlord for office premises	0.22	(6.67)
NET CASH USED IN INVESING ACTIVITIES	(367.27)	(754.81)
(C) CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds/(Repayment) from long term borrowings	(325.75)	(3.29)
Proceeds from Short Term Borrowings	90.08	73.37
Proceeds from issue of Shares	-	671.18
Interest paid	(191.89)	(165.72)
NET CASH FROM FINANCING ACTIVITIES	(427.56)	575.54
NET INCREASE IN CASH AND CASH EQUIVALANTS (A+B+C)	(126.78)	271.60
OPENING BALANCE OF CASH AND CASH EQUIVALANTS	310.28	38.68
CLOSING BALANCE OF CASH AND CASH EQUIVALANTS	183.50	310.28

for DocMode Health Technologies Limited

Paresh Jaysih Sampat
Managing Director
DIN: 00410185

Paulson Paul Thazhathedath
Wholetime Director
DIN 02301881

Hans Albert Lewis
Whole Time Director & CFO
DIN 02301853
PAN: ACOPL6883G

AUDITORS' REPORT ON CASH FLOW STATEMENT

We have examined the above Consolidated Cash Flow Statement of Docmode Health Technologies Ltd. derived from audited financial statements and the books and records maintained by the company for the period ended March 31, 2025 and found the same in agreement therewith.

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

Place : Mumbai
Date : May 30, 2025
UDIN :

CA R Sunderesan Aiyar
Partner
M. No.:043946

DocMode Health Technologies Limited (Formerly known as Docmode Health Technologies Private Limited) CIN : L74999MH2017PLC297413 Consolidated Statement of Financial Results for the Half year ended March 31,2025						
Particulars		For half year ended			Indian Rupees in Lacs	
		March 31,2025	September 30,2024	March 31,2024	For year ended	
		Audited	Unaudited	Audited	March 31,2025	March 31,2024
					Audited	Audited
I.	Revenue from Operations	2,135.48	2,041.81	1,640.31	4,177.29	4,000.73
II.	Other Income	8.88	84.10	7.31	92.98	13.59
III.	Total Income (I + II)	2,144.36	2,125.91	1,647.62	4,270.28	4,014.33
IV.	Expenses:					
	Purchases/Consumption of Goods & Services	4,341.06	135.88	81.65	4,476.94	3,136.56
	Changes in inventories	(756.57)	(108.97)	1.19	(865.55)	1.58
	Employee benefits Expense	197.49	178.80	202.74	376.30	495.11
	Finance Costs	82.63	109.26	81.94	191.89	165.72
	Depreciation and Amortization Expense	15.78	14.14	0.91	29.92	2.44
	Other Expenses	(1,591.03)	1,848.31	1,437.62	257.29	178.95
	Total expenses	2,289.37	2,177.43	1,806.05	4,466.79	3,980.36
V	Profit before exceptional and extraordinary items and tax (III- IV)	(145.00)	(51.52)	(158.42)	(196.52)	33.97
VI	Exceptional Items		-	-	-	-
VII	Profit before extraordinary items and tax (V - VI)	(145.00)	(51.52)	(158.42)	(196.52)	33.97
VIII	Extraordinary items		-	-	-	-
IX	Profit before tax (VII- VIII)	(145.00)	(51.52)	(158.42)	(196.52)	33.97
X	Tax expense:				0.08	
	(1) Current tax	(0.08)	-	(38.00)	(0.08)	20.00
	Less : MAT Credit Entitlement		-	-	-	-
		(0.08)	-	(38.00)	-	20.00
	(2) Deferred tax Liability/(Asset)	(7.41)	0.62	(3.43)	(6.79)	(4.28)
	(3) Tax in respect of earlier years	-	-	0.26	12.92	(0.51)
	(4) Profit / (Loss) of Prior Period Depreciation		-	-	-	-
		(7.49)	0.62	(41.17)	6.12	15.21
XI	Profit (Loss) for the period from continuing operations (IX-X)	(137.51)	(52.13)	(117.25)	(202.64)	18.76
XII	Profit/(loss) from discontinuing operations		-	-	-	-
XIII	Tax expense of discontinuing operations		-	-	-	-
XIV	Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)		-	-	-	-
XV	Profit (Loss) for the period (XI + XIV)	(150.51)	(52.13)	(117.25)	(202.64)	18.76
XVI	Earnings per equity share of Rs. 10 each					
	Basic	(0.00)	(1.66)	(3.73)	(6.45)	0.60
	Diluted	(0.00)	(1.66)	(3.73)	(6.45)	0.60
Significant Accounting Policies						
The notes are integral parts of the financial statements						
1 The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ("the listing Regulations") have been approved by the Board of Directors at their respective meeting held on May 30, 2025. The Statutory Auditors of the company have carried out the audit of the aforesaid results for the half year and year ended 31st March 2025. The Financial Results have been prepared in accordance with the Accounting Standards as prescribed under section 133 of the Companies Act, 2013 read with rules 7 of Companies (Account) Rules 2014 by the Ministry of Corporate Affairs and Amendments thereof.						
2 As per Ministry of Corporate Affairs Notification dated February 16,2015, Companies whose Securities are listed on SME Exchange as referred in Chapter XB of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 are exempted from the compulsory requirement of adoption of Ind AS.						
3 The above Consolidated Financial Results have been reviewed by the Audit Committee and Approved by the Board of Directors at their respective meeting held on May 30, 2025. and have been audited by the Statutory Auditors of the Company						
4 The Primary reporting of the company has been performed on the basis of business segment. The management of the company has evaluated the company's overall performance as one segment which is "Transforming Learning and Practice" and operates in a single business segment based on the nature of business, the risk and returns, the organisation structure and the internal control Financial systems. Accordingly, the figures appearing in these financial statements relate to the company's single business segment. The company has significant operations based in India, hence there are no reportable geographical segments in Consolidated Financial Statements.						
5 The Figures for half year ended on 31st March 2025 are the balancing figures between the audited figures in respect of the financial year and the reviewed year to date figures for the half year ended on 30th September 2024.						
6 The balance appearing under the trade payables, Loans & Advances, Other Current Liabilities are subject to confirmation and reconciliation and consequent adjustments, if any, will be accounted for in the year of confirmation and / or reconciliation.						
7 The company has issued and allotted 8,49,600 equity shares of Rs. 10/- Each at premium of Rs.69/- Per Equity Share through Initial Public Offer Aggregating to Rs. 671.18 Lakhs. The details of utilization of the net IPO proceeds is mentioned below:						
Particulars		As per Prospectus	Funds Utilised			
Purchase of IT infrastructure and operating system		303.08	303.08			
Meeting incremental working capital requirements		200.00	200.00			
General corporate purposes		103.10	103.10			
8 During the year, the company has raised funds through private placement by issuing 225 Non-Convertible Debentures having Face Value of Rs.1,00,000/- each at par and the funds as raised have been fully applied for the purposes for which they were raised.						
9 Previous period figures have been regrouped/reclassified and restated wherever considered necessary to make them comparable.						
for DocMode Health Technologies Limited						
Paulson Paul Thazhathedath Wholetime Director DIN 02301881 Place : Mumbai Date : May 30, 2025		Hans Albert Lewis Whole Time Director & CFO DIN 02301853 PAN: ACOPL6883G Place : Mumbai Date : May 30, 2025		Paresh Jaysih Sampat Managing Director DIN: 00410185 Place : Mumbai Date : May 30, 2025		

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes to the financial statements
for the period ended March 31, 2025
(Currency: Indian rupee)

1. Background of the Company

Docmode Health Technologies Limited ("the Company") was incorporated on July 17, 2017. The Company is a public limited company incorporated and domiciled in India. The registered office of the Company is located at 307, Shivai Plaza, Marol Co-op Industrial Estate Road, Sagbag, Marol, Andheri (East), Mumbai 400059. The Company is engaged in the business of providing comprehensive & interactive learning programs for healthcare professionals through e-Learning measures and providing online CME (continuous medical education) Certification Courses and designing & conducting surveys, quizzes, questionnaires, etc. for collecting data insights related to the healthcare industry for the healthcare stakeholders. The Company also conducts offline/online events/ sessions/ seminars for knowledge enhancement and sharing for the healthcare stakeholders.

The Board of Directors approved the standalone financial statements for the year ended March 31, 2025

2. Significant accounting policies

2.1 Basis of preparation & presentation

The financial statements have been prepared to comply in all material respects with the Accounting Standards issued as per the provisions of Section 133 of the Companies Act, 2013 read with rule 7 of Companies (Accounts) Rules 2014. The financial statements are prepared on going concern basis under the historical cost convention on the accrual basis except in case of assets for which provision for impairment is made and revaluation is carried out. The accounting policies have been consistently applied by the Company.

2.2 Functional and Presentation Currency

These financial statements are presented in Indian Rupees (INR), which is also the Company's functional currency. All amounts are mentioned in lakhs and rounded off to 2 decimals unless, otherwise stated.

2.3 Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires judgements, estimates and assumptions to be made that affect the reported amounts of assets and liabilities, disclosure of contingent liabilities on the date of the financial statements and the reported amount of revenue and expenses during the reporting period. Difference between the actual results and estimates are recognized in the year in which the results are known / materialized.

2.4 Property, Plant & Equipment

Tangible assets

Tangible assets are stated at cost net of recoverable taxes, trade discounts and rebates and include amounts added on revaluation, less accumulated depreciation and impairment loss, if any. The cost of tangible assets comprises its purchase price, borrowing cost and any cost directly attributable to bring the asset to its working condition for its intended use, net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to assets.

Subsequent expenditures related to an item of Tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance.

Projects under which assets are not ready for its intended use are disclosed under capital work in progress.

Intangible assets

Intangible assets are stated at cost of acquisition net of recoverable taxes less accumulated amortization / depletion and impairment loss, if any. The cost comprises purchase price, borrowing cost and any cost directly attributable to bring the asset to its working condition for its intended use and net charges on foreign exchange contracts and adjustments arising from exchange rate variations attributable to intangible assets.

2.5 Leases

Leases of assets, where the company assumes substantially all the risk and benefits of ownership are classified as finance leases. Finance leases are capitalized at the lower of fair value of the leased assets at inception and the present value of minimum lease payments. Lease payments are apportioned between the finance charge and the outstanding liability. The finance charge is allocated periods during the lease term at a constant periodic rate of interest on the remaining balance of the liability.

Leases where the lessor effectively retains substantially all the risk and benefits of ownership are classified, as operating leases. Lease rentals in respect of assets taken under operating leases are charged to statement of profit & loss on a straight line basis over the lease term.

2.6 Depreciation

Depreciation is provided on a pro-rata basis under the Written Down Value method over the useful life of the assets as prescribed under part C of Schedule II of the Companies Act, 2013.

Fixed assets individually costing Rupees Five Thousand or less are depreciated at 100% over a period of one year.

Assets under finance lease are amortized over their estimated useful life or the lease term whichever is lower.

2.7 Impairment

As asset is treated as impaired when the carrying cost of asset exceeds its recoverable value. An impairment loss is charged to the Profit & Loss Statement in the year in which asset is treated as impaired. The impairment loss recognized in prior accounting period is reversed if there has been a change in the estimate of recoverable amount.

2.8 Foreign Currency Transactions

i. Transactions denominated in foreign currencies are recorded at the exchange rate prevailing on the date of transaction or that approximates the actual rate at the date of transaction.

ii. Monetary items denominated in foreign currencies at the year-end are restated at year end rates. In case of items which are covered by forward exchange contracts, the difference between the year-end rate and the rate on the date of contract is recognized as exchange difference and the premium paid on forward contracts is recognized over the life of contract.

iii. Non-monetary foreign currency assets are carried at cost.

iv. Any income or expense on account of exchange differences either on settlement or on translation is recognized in the Profit & Loss Statement, except in the case of long term liabilities, where they relate to acquisition of fixed assets, in which case they are adjusted to the carrying cost of such assets.

2.9 Investments

Current investments are carried at lower of cost and quoted / fair value, computed category-wise. Non-current investments are stated at cost. Provision for diminution in the value of Non-Current Investments is made only if such a decline is other than temporary.

2.10 Cash and Cash equivalents

Cash and cash equivalents comprise cash and cash on deposit with banks. The company considers all highly liquid investments with a remaining maturity at the date of purchase of three months or less and that are readily convertible to known amounts of cash to be cash equivalents.

2.11 Revenue recognition

i. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured.

ii. Revenue from sale of goods is recognized when the significant risks and rewards of ownership have been transferred to the buyer. Revenue from sale of goods is net of sales tax, trade discounts, rebates etc.

iii. Revenue from services is recognized as and when the services are rendered in accordance with the terms of the specific contracts, net of all contractual deductions. Revenue from Services is recognized net of all taxes and levies..

iv. Income from interest on deposits is recognized on a time proportion basis.

v. Dividend income is recognized when the right to receive payment is established.

2.12 Employee benefits

(i) Short term employment benefits

The undiscounted amount of short term employee benefits expected to be paid in exchange for the services rendered by the employees are recognized as expense during the period when the employee render the services. These benefits include performance incentive and compensated absences.

(ii) Post-employment benefits

a) Defined contribution plans

A defined contribution plan is a post-employment benefit plan under which the Company pays specified contributions to a separate entity. The Company makes specified monthly contribution towards Provident Fund and pension scheme. The Company's contribution is recognized as an expense in the Profit and Loss Statement during the period in which the employee renders the related service.

b) Defined benefit plans

Gratuity

Benefits payable to eligible employees of the Company with respect to gratuity, a defined benefit plan is accounted for on the basis of an actuarial valuation as at the balance sheet date. In accordance with the Payment of Gratuity Act, 1972, the plan provides for lump sum payments to vested employees upon retirement, death while in service or upon termination of employment in an amount equivalent to 15 days salary for each completed year of service. Vesting occurs upon completion of five years of service. The company contributes premium towards gratuity liability arrived by actuarial valuation performed by an independent actuary.

Actuarial Valuation

The actuarial valuation method used for measuring the liability either Gratuity or Compensated absence is the Projected Unit Credit method. The estimate of future salary increases considered takes into account the inflation, seniority, promotion and other relevant factors. The expected rate of return on plan assets is the Company's expectation of the average long term rate of return expected on investments of the fund during the estimated term of the obligations. Actuarial gain/losses are recognized in the Statement of Profit and Loss in the year they are determined.

2.13 Borrowing costs

Borrowing costs include exchange difference arising from foreign currency borrowings to the extent they are regarded as an adjustment to the interest cost. Borrowing costs that are attributable to the acquisition or construction of a qualifying asset are capitalized as part of the cost of such assets. A qualifying asset is one that necessarily takes substantial period of time to get ready for intended use. All other borrowing costs are recognised as an expense in the period in which they are incurred. Capitalisation of borrowing costs is suspended during the extended period in which active development is interrupted. Capitalisation of borrowing costs is ceased when substantially all the activities necessary to prepare the qualifying asset for its intended use or sale are complete. Other borrowing costs are charged to statement of profit and loss as and when incurred.

2.14 Provisions, contingent liabilities and contingent assets

Provision is recognized in the accounts when there is present obligation as a result of a past event(s) and it is probable that an outflow of resources will be required and a reliable estimate can be made. Provisions are not discounted to their present value and are determined based on the best estimate required to settle the obligation at the reporting date.

Contingent liabilities are disclosed unless the possibility of outflow of resources is remote.

Contingent assets are neither recognized nor disclosed in the financial statements.

2.15 Income Taxes

Tax expense comprises of current tax and deferred tax. Current tax is measured at the amount expected to be paid to the tax authorities, using the applicable tax rates.

Deferred income tax reflect the current period timing difference between taxable income and accounting income for the year and reversal of timing difference of earlier years/period. Deferred tax assets are recognized only to the extent there is reasonable certainty that the sufficient future income will be available except that deferred tax assets, in case there are unabsorbed depreciation or losses, are recognized only if there is virtual certainty that sufficient future taxable income will be available to realize the same.

Deferred tax assets and liabilities are measured using the tax rates and tax law that have been enacted or substantively enacted by the Balance Sheet date.

2.16 Earnings per share

Basic earnings per share are computed by dividing the net profit for the year attributable to the equity shareholders by the weighted average number of equity shares outstanding during the year. Diluted earnings per share is computed by dividing the net profit attributable to the equity shareholders for the year by the weighted average number of equity and dilutive equity equivalent shares outstanding during the year, except where the results would be anti-dilutive.

Note 3
Share Capital

	March 31,2025	March 31,2024
Authorised Share Capital		
40,00,000 (P.Y 40,00,000) Equity Shares of Rs. 10 each	400.00	400.00
50,000(P.Y 50,000) Preference Shares of Rs 10 each	5.00	5.00
Total	405.00	405.00
Issued, Subscribed & Paid up		
31,42,800 (P.Y 31,42,800) Equity Shares of Rs. 10 each fully paid	314.28	314.28
Total	314.28	314.28

The Company has only one class of equity shares having a par value of Rs. 10 per share. Each Shareholder is eligible for one vote per share. In the event of liquidation, the equity shareholders are eligilble to receive the remaining assets of the Company, after distribution of all preferential amounts, In proportion of their shareholding.

Reconciliation of no. of shares outstanding at the beginning and at the end of the year

Particulars	March 31,2025 Equity Shares		March 31,2024 Equity Shares	
	Number	Amount	Number	Amount
Shares outstanding at the beginning of the year	3,142,800.00	31,428,000.00	2,293,200.00	22,932,000.00
Shares Issued during the year	-	-	849,600.00	8,496,000.00
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	3,142,800.00	31,428,000.00	3,142,800.00	31,428,000.00

Details of Shares held by shareholders holding more than 5% in the Company:

Name of Shareholder	March 31,2025		March 31,2024	
	No. of Shares held	% of Holding	No. of Shares held	% of Holding
Paulson Paul Thazhathedath	745,290.00	24%	745,290.00	24%
Hans Albert Lewis	745,290.00	24%	745,290.00	24%
Anil Khanna	401,310.00	13%	401,310.00	13%
Aalok Pathak	400,164.00	13%	400,164.00	13%
	2,292,054.00	73%	2,292,054.00	73%

Details of Shares held by Promoters at the end of the year

Name of Promoter	March 31,2025		March 31,2024		% Change During the year
	No. of Shares held	% of Holding	No. of Shares held	% of Holding	
Paulson Paul Thazhathedath	745,290.00	24%	745,290.00	0.24	-
Hans Albert Lewis	745,290.00	24%	745,290.00	0.24	-
Kenneth Paul Lewis	382.00	0%	382.00	0.00	-
	1,490,580.00	47%	1,490,580.00	0.47	-

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes to the Consolidated financial statements
(Currency: Indian rupee in Lacs)
Note 4
Reserves and Surplus

	March 31,2025	March 31,2024
Surplus/Deficit in the Statement of Profit and Loss		
Opening Balance	723.20	118.21
(-) Capitalisation of reserves	-	-
(+) Securities Premium	-	586.22
(+) Net Profit/(Net Loss) For the current year	(202.67)	18.76
Closing Balance	520.53	723.20
Total	520.53	723.20

Note 5
Minority Interest

	-	-
Equity Share Capital	0.01	-
Add: Profit attributable to minority shareholders	0.03	-
Total	0.03	-

Note 6
Long Term Borrowings

	March 31,2025	March 31,2024
Secured Loans		
Unsecured Loans		
a) Bonds / Debentures	-	-
b) Term Loans	-	-
A) From Banks	3.49	74.60
B) From Other Parties	108.96	359.60
e) Loans & Advances from Related Parties	-	4.00
Total	112.45	438.20

Note 7
Long Term Provisions

	March 31,2025	March 31,2024
a) Provision for Employee Benefits	69.71	66.28
Total	69.71	66.28

Note 8
Short Term Borrowings

	March 31,2025	March 31,2024
Secured Loans		
a) Bonds / Debentures (Secured by way of pledge of shares & other assets)	175.00	-
b) Loans and Advances from Related Parties	-	-
c) Deposits	-	-
d) Other Loans & Advances (Specify Nature)	-	-
d) Bank Overdraft Account (Secured by way of lien on Fixed Deposit with Bank)	111.12	109.99
Unsecured Loans		
B) From Other Parties	-	-
Current Maturities of Long Term Borrowings	283.78	369.84
Total	569.91	479.82

Note 9
Trade Payables

	March 31,2025	March 31,2024
Total outstanding dues of Creditors of Micro & Small Enterprises	184.52	18.55
Total outstanding dues of Creditors other than Micro & Small Enterprises	349.54	254.76
	-	-
Total	534.06	273.30

Trade Payables Ageing Schedule as at March 31,2025

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	172.93	11.59	-	-	184.52
Others	333.99	11.38	-	4.16	349.54
Dispute dues-MSME					-
Dispute dues-Others					-
Total					534.06

Trade Payables Ageing Schedule as at March 31,2024

Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	13.78	4.76	-	-	18.55
Dispute dues-Others	172.82	0.40	79.00	2.54	254.76
Dispute dues-MSME	-	-	-	-	-
Others	-	-	-	-	-
Total					273.30

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes to the Consolidated financial statements
(Currency: Indian rupee in Lacs)

Note 10
Other Current Liabilities

	March 31,2025	March 31,2024
a) Interest Accrued and due on Debentures	1.54	-
b)Income Received in Advance	1,381.33	356.00
c) Unpaid matured debentures and interest accrued thereon	55.45	-
d) Other Payables	13.32	-
Total	1,451.63	356.00

Note 11
Short Term Provisions

	March 31,2025	March 31,2024
a) Provision for Employee Benefits	139.98	129.32
b) GST Payable	21.29	18.87
c) TDS Payable	191.27	209.17
d) Audit Fees Payable	6.00	6.00
Total	358.55	363.35

DocMode Health Technologies Limited (Formerly known as Docmode Health Technologies Private Limited) Note 12 - Property, Plant and Equipment (Currency: Indian rupee in Lacs)								
Particulars/Assets	Tangible Assets				Intangible			Gross Total
	Computers	Machinery	Office Equipments	Total	Software	Assets Under Development	Total	
Gross Block								
At 1st April 2023	10.77	0.45	1.55	12.77	5.41	202.80	208.21	220.98
Additions	8.07	86.54	-	94.61	-	647.12	647.12	741.73
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 1st April 2024	18.84	86.99	1.55	107.38	5.41	849.92	855.33	962.71
Additions	0.09	54.60	-	54.69	-	309.84	309.84	364.53
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 31st March 2025	18.93	141.59	1.55	162.07	5.41	1,159.76	1,165.17	1,327.24
Depreciation								
At 1st April 2023	10.09	0.15	0.95	11.20	2.34	-	2.34	13.53
Additions	0.63	0.06	0.28	0.97	1.47	-	1.47	2.44
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 1st April 2024	10.73	0.21	1.23	12.17	3.80	-	3.80	15.97
Additions	4.85	24.18	0.13	29.16	0.76	-	0.76	29.92
Deductions/Adjustments	-	-	-	-	-	-	-	-
At 31st March 2025	15.57	24.39	1.36	41.32	4.57	-	4.57	45.89
Net Block								
At 31st March 2024	8.11	86.77	0.32	95.21	1.61	849.92	851.53	946.74
At 31st March 2025	3.36	117.19	0.19	120.74	0.84	1,159.76	1,160.60	1,281.35
If Assets Purchase During the Year the Dep formula = Life used in Purchasing Year x Depreciable Amount over whole Life x Rate of Depreciation If Opening Assets Depreciation Formula = IF(AND(Remaining Life<1,Remaining Life>0),(Opening WDV-Salvage Value),(Opening WDV*Rate of Depreciation))								

Note 13
Non Current Investments

	March 31,2025	March 31,2024
(Unquoted, fully paid up, at cost)		
Investment in Equity Instruments	0.00	0.00
Investment in Fixed Deposits	120.52	110.00
Total	120.52	110.00

NOTE 14
Deferred Tax Assets (Net)

	March 31,2025	March 31,2024
Deferred Tax Assets	25.51	18.71
Total	25.51	18.71

Note 15
Long Term Loans and Advances

	March 31,2025	March 31,2024
a) Capital Advances	-	-
b) Loans and Advances to related Parties	-	-
Unsecured, Considered good	0.05	0.03
c) Other Loans and Advances		
MAT Credit Entitlement	0.08	-
Unsecured, Considered good	2.65	-
Total	2.78	0.03

NOTE 16
Other Non Current Assets

	March 31,2025	March 31,2024
i) Security Deposits		
Central Depository Services	0.10	6.15
Rent Security Deposits	6.10	0.27
National Stock Exchange	6.71	6.71
Total	12.91	13.13

Note17
Current Investments

	March 31,2025	March 31,2024
Investment in Fixed Deposit	8.69	16.24
	8.69	16.24

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes to the Consolidated financial statements
(Currency: Indian rupee in Lacs)
Note 18
Inventories

	March 31,2025	March 31,2024
a) Inventory of Digital Course Content	250.16	251.39
b) Service Work in Progress	866.77	-
	1,116.93	251.39

Note 19
Trade Receivables

	March 31,2025	March 31,2024
Trade Receivable		
Secured, considered good	-	-
Unsecured, considered good	923.94	1,146.89
Unsecured, considered doubtful	-	-
Less: Provision for doubtful debts	-	-
Total	923.94	1,146.89

Trade Receivables Ageing Schedule as at March 31,2025

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables- Considered Good	150.05	29.62	77.95	666.32	-	923.94
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	150.05	29.62	77.95	666.32	-	923.94

Trade Receivables Ageing Schedule as at March 31,2024

Particulars	Outstanding for following periods from due date of payment					
	Less than 6 Months	6 Months - 1Year	1-2 Years	2-3 Years	More than 3 Years	Total
Undisputed Trade Receivables- Considered Good	227.51	238.77	525.32	155.29	-	1,146.89
Undisputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables- Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables- Considered Doubtful	-	-	-	-	-	-
Others	227.51	238.77	525.32	155.29	-	1,146.89

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes to the Consolidated financial statements
(Currency: Indian rupee in Lacs)
Note20
Cash and Cash Equivalents

	March 31,2025	March 31,2024
Cash & Cash Equivalents		
a) Balance with Bank	180.82	306.60
b) Cheques, Drafts on Hand	-	-
c) Cash on Hand	2.68	3.68
Total	183.50	310.28

Note 21
Short Term Loans and Advances

	March 31,2025	March 31,2024
Loans & Advances to related Parties		
Others		
Balances with revenue authorities	25.37	-
Advance Tax & TDS (Net of Provision for Tax)	162.24	132.75
TDS Revcoverable from NBFC	18.10	13.12
Other Loans & Advances	42.49	55.14
Total	248.20	201.02

NOTE 22
Other Current Assets

	March 31,2025	March 31,2024
Excess Interest Paid Recoverable	6.81	-
Total	6.81	-

DocMode Health Technologies Limited
(Formerly known as Docmode Health Technologies Private Limited)
CIN : L74999MH2017PLC297413
Notes to the Consolidated financial statements
(Currency: Indian rupee in Lacs)
Note 23
Revenue from Operations

	March 31,2025	March 31,2024
Sale of products		
Sale of Goods	682.39	683.54
Sale of Services		
Sale of Services	3,494.90	3,317.20
Other Operating Revenue	-	-
Total	4,177.29	4,000.73

Note 24

Other Income

	March 31,2025	March 31,2024
Interest Income	13.02	13.44
Miscellaneous Income	2.27	0.15
Sundry Balances written off	77.64	-
Discount Received	0.04	0.01
Total	92.98	13.59

Note 25

Purchases/Consumption of Goods & Services

	March 31,2025	March 31,2024
CME Course Content	22.40	8.41
Purchase of Books	14.83	105.17
Printed Literature	200.63	174.56
Travelling Expenses	208.31	83.07
Event Consumables	976.51	632.53
Professional Fees	2,620.24	1,611.97
Contractee Fees	415.74	510.23
Webinar Expenses	0.72	1.08
Transcription Charges	4.93	6.14
Service Charges	2.52	0.25
Content Expenses	10.11	3.16
Total	4,476.94	3,136.56

Note 26

Changes in inventories

	March 31,2025	March 31,2024
Opening Stock		
Finished Goods	-	-
Service Work in Progress	-	-
CME Course Content & Books	251.39	252.96
Total (A)	251.39	252.96
Closing Stock		
CME Course Content & Books	250.16	248.54
Service Work in Progress	866.77	-
Others	-	2.85
Total (B)	1,116.93	251.39
Total (A-B)	(865.55)	1.58

Note 27

Employee Benefits Expenses

	March 31,2025	March 31,2024
Salaries & Wages	337.55	437.50
Contribution to Providend Fund and Other Fund	26.74	29.81
Contribution to Recognised Gratuity Fund	5.61	17.89
Staff Welfare	6.40	9.92
Employee Insurance Premium	-	-
Total	376.30	495.11

Note 28

Finance Costs

	March 31,2025	March 31,2024
a) <u>Interest Expenses</u>		
On Borrowings	157.47	133.79
On Deferred/Delayed Payment of Taxes	29.54	14.72
b) Other Borrowing Cost	2.00	16.49
c) translation	2.87	0.72
Total	191.89	165.72

Note 29

Other Expenses

	March 31,2025	March 31,2024
Event Expenses	0.52	-
Advertising & Marketing Expenses	8.27	9.15
Cloud Services	4.16	1.69
Service Charges	11.18	11.45
Software Charges	7.20	4.10
Webinar Expenses	3.72	-
Electricity Expenses	1.63	1.91
Rent	41.61	41.02
Recruitment Charges	3.49	1.44
Commission & Brokerage	0.56	7.95
Telephone Expenses	0.56	0.48
Insurance Charges	0.64	0.87
Repairs & Maintenance	0.79	1.03
Sponsorship Service	-	4.30
Office Expenses	4.97	4.83
Professional Fees	115.68	24.60
IT Consultancy & Support Service	1.73	3.49
Profession Tax	0.10	0.15
Travelling Expenses	9.51	5.03
GST Expensed out	5.61	7.86
Printing, Postage & Courier	2.03	3.02
Rates & Taxes	1.84	-
Director Sitting Fees	-	1.50
Other Expenses	20.92	6.97
Business Promotion	-	2.10
IPO Expenses	-	21.24
Donation	-	5.50
Prior Period Expenses	4.31	1.01
<u>Payment to Auditors</u>		
Auditor Remuneration	6.25	6.25
Total	257.29	178.95

Note 30 - Contingent liabilities & Commitments in respect

Particulars	March 31,2025	March 31,2024
A. Contingent Liabilities		
a Claims against the company not acknowledge as debts	Nil	Nil
b. Guarantees	Nil	Nil
c.Other money for which the company is contingently liable.	Nil	Nil
Total	-	-

B. Commitments

There are no commitments as at 31st March, 2025

Note 31 - Deferred Tax Asset (Liability)

Particulars	March 31,2025	March 31,2024
<u>Permanent Difference</u>		
Items disallowed under Income Tax Act, 1961	-	-
<u>Timing Difference</u>		
Difference in Gratuity Provision	68.07	22.97
Difference in Fixed Assets	(0.83)	1.98
Total	67.25	24.94
Deferred Tax Asset on Timing Difference	19.00	7.00

Note 32 - Auditor's Remuneration

Particulars	March 31,2025	March 31,2024
Statutory Audit Fees	6.00	6.00
Total	6.00	6.00

Note 33 - Expenditure / Income in foreign currency (on accrual basis):

Particulars	March 31,2025	March 31,2024
Import	99.66	29.80
Export	6.89	10.45
Total	106.55	40.25

Note 34 - Earning Per Share

Particulars	March 31,2025	March 31,2024
Net Profit after tax	(202.64)	18.76
Weighted Average number of equity shares	31.43	31.43
EPS (Basic) (Rs.)	(6.45)	0.60
EPS (Diluted) (Rs.)	(6.45)	0.60
Face Value per equity share (Rs.)	10.00	10.00

Note 35 - Related Party Transactions

(a) Names of Related Parties & Nature of Relationship		
Paulson Paul Thazhathedath	Director	
Hans Albert Lewis	Director	
Paresh Sampat	Director	
Monina Elizabeth Lewis	Director	
Docmode Endeavors LLP	Director having substantial Interest	
Augmentors Healthcare Limited	Director having substantial Interest	
Aumen Healthcare Pvt Ltd	Director having substantial Interest	
Kenneth Paul Lewis	Relative of Director	
(b) Director Remuneration		
	March 31,2025	March 31,2024
Paulson Paul Thazhathedath	39.00	39.00
Hans Albert Lewis	39.00	39.00
Total	78.00	78.00
(d) Loan given by Related Party		
	March 31,2025	March 31,2024
Paulson Paul Thazhathedath	-	4.00
Total	-	4.00
(e) Income Received in Advance from Related Party		
	March 31,2025	March 31,2024
Augmentors Healthcare Limited	17.93	-
Total	17.93	-
(d) Loan given by Related Party		
	March 31,2025	March 31,2024
Augmentors Healthcare Limited	-	143.06
Aumen Healthcare Pvt Ltd	-	214.08
Total	-	357.14

Note 36 - Leases

Particulars	March 31,2025	March 31,2024
Operating Lease		
Lease rentals charged to revenue for lease agreements for the right to use the following assets are		
Office Equipments	20.37	16.23
Office Premises	21.25	24.78
Total	41.61	41.02
The Lease agreements are executed for a reasonable period with a renewal clause and also provide for termination at will by either party by giving prior notice.		

Note 37 - Disclosure pursuant to Accounting Standard 15 (Employee benefits)

a) Defined Contribution Plans to Provident fund (defined contribution)

The Company makes contributions to Provident Fund which is defined contribution plans for qualifying employees. Under the scheme, the Company is required to contribute a specified percentage of the payroll cost to fund the benefits. The Company recognized Rs 13.18/- Lacs (March, 2024: Rs.14.72/- Lacs) for provident fund contributions in the Statement of Profit and Loss. The contributions payable to the plan by the Company are at the rates specified in the rules of the scheme.

a) Gratuity (defined benefit)

Every employee is entitled to the benefit equivalent to 15 days of total gross salary last drawn for each completed year of service. Gratuity is payable to all eligible employees of the Company on retirement or separation or death or permanent disablement in terms of the provisions of the Payment of Gratuity Act. The Company recognized Rs.5.61/- Lacs (March, 2024: Rs.17.88/- Lacs) in the Statement of Profit and Loss.

	March, 2025	March, 2024
Method	Projected Unit Credit Method	Projected Unit Credit Method
Assumptions		
Discount Rate	6.83%	7.22%
Expected Return on Plan Assets	Funded	Funded
Expected Return on Plan Assets	Funded	Funded
Mortality Table	Indian Assured Lives Mortality (2012-14) Urban	Indian Assured Lives Mortality (2012-14) Urban
Future Salary increases	10%	0.10
Disability	Nil	Nil
Attrition	5%	0.05
Retirement	60, 65 & 70 years	60 years

Note 38 - Funding Arrangement

No funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other person(s) or entity(ies), including foreign entities ("Intermediaries") with the understanding, whether recorded in writing or otherwise, that the Intermediary shall lend or invest in party identified by or on behalf of the Company (Ultimate Beneficiaries). The Company has not received any fund from any party(s) (Funding Party) with the understanding that the Company shall whether, directly or indirectly lend or invest in other persons or entities identified by or on behalf of the Company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries.

Note 39 - Segment Information

The Company is engaged in the business of providing vocational training. DocMode is a platform that provides authoritative, comprehensive and interactive learning programs for Health Professionals - Doctors, Nurses, Allied and Medical Students - across the world. The company is comeup with new segments during the year namely publishing of Medical books, trading of medical books and journals, conducting customised and inhouse events. The company operates in 13 geographical segments within India namely Maharashtra, Karnataka, Himachal Pradesh, Uttarakhand, West Bengal, Kerala, Tamilnadu, Telangana, Andhra Pradesh, Uttar Pradesh, Goa, Delhi, Haryana.

Note 40 - Other Additional Information

Information with regard to the other additional information and other disclosures to be disclosed by way of notes to statement of profit and loss as specified in the Schedule III of the Companies Act, 2013 is either 'nil' or 'not applicable' to the Company for the year.

Note 41 - Others

Previous year figures have been regrouped / reclassified wherever necessary to correspond with the current year classification / disclosure.

As per our report of even date
for R Sundaresan Aiyar & Co
Chartered Accountants
Firm Registration No.: 110564W

for DocMode Health Technologies Limited

CA R Sunderesan Aiyar
Partner

Paulson Paul Thazhathedath
Wholtime Director

Hans Albert Lewis
Whole Time Director & CFO

M. No.:043946
Place : Mumbai
Date : May 30, 2025
UDIN :

DIN 02301881
Place : Mumbai
Date : May 30, 2025

DIN 02301853
Place : Mumbai
Date : May 30, 2025

Paresh Jaysih Sampat
Managing Director
DIN: 00410185
Place : Mumbai
Date : May 30, 2025

NOTICE OF THE 8TH ANNUAL GENERAL MEETING OF THE COMPANY

NOTICE is hereby given that the Annual General Meeting of the members of Docmode Health Technologies Limited (“the Company”), shall be held on 30th September, 2025, Tuesday, at 2 p.m., at the corporate office of the Company situated at 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India, to transact the following business:

ORDINARY BUSINESS:

ITEM NO. 1:

TO RECEIVE, CONSIDER AND ADOPT THE STANDALONE AUDITED BALANCE SHEET FOR THE PERIOD ENDED 31ST MARCH, 2025, THE PROFIT & LOSS ACCOUNTS AS ON THAT DATE TOGETHER WITH REPORTS OF DIRECTORS AND AUDITORS THEREON:

To consider and, if thought fit, to pass, the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the Provisions of Section 129, 134 and other applicable Provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force) read with Companies (Accounts) Rules, 2014, the Standalone Balance Sheet as at 31st March, 2025, the Standalone Profit and Loss Account and Standalone Cash Flow Statement for the financial year ended 31st March, 2025, along with the Schedules & Notes attached thereto and the Directors’ Report and the Standalone Auditors’ Report, as laid before the Shareholders, be and are hereby approved and adopted.”

“RESOLVED FURTHER THAT pursuant to the Provisions of Section 92 and Section 137 of the Companies Act, 2013 any Director of the Company, be and is hereby authorized to file the adopted annual accounts, annual return and other returns, with the statutory authorities in connection with the said Annual General Meeting for the Financial Year ended 31st March, 2025 and to do all such acts, deeds, things and matters.”

“RESOLVED FURTHER THAT copy of this resolution signed by any of the Director, be submitted to the concerned authorities and they be hereby requested to act upon the same.”

ITEM NO. 2:

TO RECEIVE, CONSIDER AND ADOPT THE CONSOLIDATED AUDITED BALANCE SHEET FOR THE PERIOD ENDED 31ST MARCH, 2025, THE PROFIT & LOSS ACCOUNTS AS ON THAT DATE TOGETHER WITH REPORTS OF DIRECTORS AND AUDITORS THEREON:

To consider and, if thought fit, to pass, the following resolution as an Ordinary Resolution:

“RESOLVED THAT pursuant to the Provisions of Section 129, 134 and other applicable Provisions, if any, of the Companies Act, 2013 (including any statutory modifications or re-enactment thereof for the time being in force) read with Companies (Accounts) Rules, 2014, the Consolidated Balance Sheet as at 31st March, 2025, the Consolidated Profit and Loss Account and Consolidated Cash Flow Statement for the financial year ended 31st March, 2025, along with the Schedules & Notes attached thereto and the Consolidated Auditors’ Report, as laid before the Shareholders, be and are hereby approved and adopted.”

“RESOLVED FURTHER THAT pursuant to the Provisions of Section 92 and Section 137 of the Companies Act, 2013 any Director of the Company, be and is hereby authorized to file the adopted annual accounts, annual return and other returns, with the statutory authorities in connection with the said Annual General Meeting for the Financial Year ended 31st March, 2025 and to do all such acts, deeds, things and matters.”

“RESOLVED FURTHER THAT copy of this resolution signed by any of the Director, be submitted to the concerned authorities and they be hereby requested to act upon the same.”

ITEM NO. 3:

TO APPROVE AND RECOMMEND THE REAPPOINTMENT OF MR. PAULSON PAUL THAZHATHEDATH (DIN: 02301881), WHOLE TIME DIRECTOR, LIABLE TO RETIRE BY ROTATION AT THE 8TH ANNUAL GENERAL MEETING OF THE COMPANY:

To consider and, if thought fit, to pass, the following resolution as an Ordinary Resolution:

“RESOLVED THAT Mr. Paulson Paul Thazhathedath (DIN: 02301881), Whole time Director of the Company who retires by rotation and is eligible for reappointment, be and is hereby reappointed as Whole time Director of the Company.”

“RESOLVED FURTHER THAT any one Director of the Company be and is hereby authorised to make the necessary filings with the Registrar of the Company and to do all such acts, deeds, things and matter as may deem necessary to give effect to this resolution.”

“RESOLVED FURTHER THAT the copy of this resolution certified by any Director or authorised signatory of the Company, be submitted to the concerned authorities and they may be requested to act upon the same.”

SPECIAL BUSINESS:

ITEM NO. 4:

APPROVAL OF RELATED PARTY TRANSACTION:

To consider and, if thought fit to pass, with or without modification(s), the following resolutions as Special Resolution:

“RESOLVED THAT pursuant to the provisions of Section 188 and other applicable provisions of the Companies Act, 2013 read with the Rules made there under (including any statutory modification(s) or reenactment thereof for the time being in force), the Company’ Policy on “Materiality of Related Party Transactions and also on dealing with Related Party Transactions” and all other applicable laws and regulations, as amended, supplemented or re-enacted from time to time, and as per the recommendation and approval of the Audit Committee and Board of Directors of the Company, as amended from time to time, the consent of the Members of the Company be and is hereby accorded to the Board of Directors of the Company (“Board”), for entering into and / or carrying out and / or continuing with existing contracts / arrangements/ transactions or modification(s) of earlier/ arrangements/transactions or as fresh and independent transaction(s) or otherwise (whether individually or series of transaction(s) taken together or otherwise), with the related parties of the Company, as per the details set out in the explanatory statement annexed to this notice, notwithstanding the fact that the aggregate value of all these transaction(s), whether undertaken directly by the Company or along with its subsidiary(ies), may exceed the prescribed thresholds as per provisions of companies Act, 2013 as applicable from time to time, provided, however, that the said contract(s)/ arrangement(s)/ transaction(s) shall be carried out at an arm’s length basis and in the ordinary course of business of the Company for the financial year 2025-26”.

“RESOLVED FURTHER THAT any Director of the Company be and is hereby authorised, on behalf of the Company, to do all such acts, deeds, matters and things as may be necessary, proper or desirable and to sign and execute all necessary documents, agreements, applications and returns for the purpose of giving effect to the aforesaid resolution along with filing of necessary E-form with the Registrar of Companies.”

“RESOLVED FURTHER THAT copy of this resolution certified by any of the Director, be submitted to the concerned authorities and they be hereby requested to act upon the same.”

ITEM NO. 5:

TO CONSIDER THE PAYMENT OF REMUNERATION TO MR. HANS ALBERT LEWIS, (DIN: 02301853) WHOLE TIME DIRECTOR OF THE COMPANY:

To consider and, if thought fit, to pass, with or without modification(s), the following resolution as a Special Resolution:

“RESOLVED THAT pursuant to the provisions under Section 196, 197, 198, Schedule V as applicable and other applicable provisions, if any, of the Companies Act, 2013, recommendation of remuneration and Nomination committee, (hereinafter referred to as “the Act”) including any statutory amendments, modifications or re-enactment thereof and subject to such other requisite approvals, as may be required in this regard, the consent of the members be and is hereby accorded to the payment of remuneration to Mr. Hans Albert Lewis (DIN:02301853), Whole-time Director, for the remaining two (2) years of his tenure with effect from 2nd January, 2026 till 11th December, 2027, on the same remuneration and on the terms and conditions as approved by the members of the Company in its meeting held on 06th January, 2023, and as set out in the explanatory statement forming part of this resolution, notwithstanding that such remuneration may exceed the limits prescribed under Sections 197 and 198 of the Act, but shall remain within the limits specified in Schedule V of the Act in the event of no profits or inadequate profits in any financial year.”

“RESOLVED FURTHER THAT the remuneration as set out in the explanatory statement forming part of this resolution payable to Mr. Hans Albert Lewis, Whole Time Director for 2 (Two) years w.e.f. 2nd January, 2026 is subject to the condition that:

- a. the total remuneration payable in any financial year by way of salary, perquisites, commission and other allowances shall not exceed the overall limit of five percent (5%) of the net profits of the Company as applicable to each of the Managing/Whole time Directors of the Company and/ or ten percent (10%) of the net profits of the Company for all Managing/Whole-time Directors in accordance with the provisions of Section 197, 198 and other applicable provisions, if any, of the Companies Act, 2013 read with Schedule V including any statutory amendments, modifications or re-enactments thereof, as may be made thereto and for the time being in force; or
- b. if the remuneration exceeds the limits as prescribed in the provisions of Section 197, 198 of the Companies Act, 2013, the remuneration payable shall be as specified under Section II of Part II of Schedule V to the Companies Act, 2013 without obtaining the approval of the Central Government in case of no profits/ inadequate profits.”

“RESOLVED FURTHER THAT notwithstanding anything contained in Section 197, 198 and Schedule V of the Companies Act, 2013 or any amendment/re-enactment thereof or any revised/new schedule thereof, in the event of absence of profits or inadequate profits in any financial year, the salary, perquisites and statutory benefits, as may be fixed by the Board shall be paid as minimum remuneration to Mr. Hans Albert Lewis, Whole Time Director of the company.”

“RESOLVED FURTHER THAT the Board of Directors of the Company (which includes a Committee, constituted for the time being in force) be and is hereby authorized to do all such acts, deeds and things, to enter into such agreement(s), deed(s) of amendment(s) or any such document(s), as the Board may, in its absolute discretion, consider necessary, expedient or desirable including power to sub-delegate, in order to give effect to this resolution or as otherwise considered by the Board to be in the best interest of the Company, as it may deem fit.”

FOR DOCMODE HEALTH TECHNOLOGIES LIMITED

PAULSON PAUL THAZHATHEDATH
CHAIRMAN AND WHOLETIME DIRECTOR
DIN: 02301881

Date: 29.08.2025
Place: Mumbai

Enclosure(s):

- 1. Explanatory Statement - *Enclosure – I*
- 2. Attendance Slip - *Enclosure – II*
- 3. Proxy Form - *Enclosure – III*
- 4. Route Map – *Enclosure -IV*

NOTES:

- (a) A member entitled to attend and vote at the meeting is entitled to appoint a proxy to attend and vote instead of himself and the proxy need not be a member. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than ten percent of the total share capital of the Company carrying voting rights. A member holding more than ten percent of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
- (b) In order for the proxies to be effective, the proxy forms duly completed and stamped should reach or must be deposited at the registered office of the Company not later than 48 hours before the time of the meeting.
- (c) An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 relating to the special business to be transacted at the meeting is annexed hereto.
- (d) Relevant documents referred to in the Notice and the accompanying Statement are open for inspection by the members at the Registered Office of the Company on all working days, during business hours up to the date of the Meeting. Additionally, copies of the relevant documents are available for inspection at the registered office of the Company and will also be made available at the Meeting.
- (e) In accordance with the applicable MCA Circulars, SEBI Circulars, provisions of the Companies Act, 2013 ('the Act') and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), the AGM of the Company is being held through Physical meeting and no e-voting facility would be provided for voting at the meeting. The venue for the AGM shall be the place as mentioned in the notice of AGM.
- (f) Members are requested to update their Bank Mandate / NECS / Direct Credit details / Name / Address / Power of Attorney and update their Core Banking Solutions enabled account number with the Depository Participants with whom they maintain their demat accounts.
- (g) Non-resident Indian Members are requested to immediately inform their Depository Participants about:
 - the change in the residential status on return to India for permanent settlement;
 - the particulars of the NRE account with a Bank in India, if not furnished earlier
- (h) The Securities and Exchange Board of India has mandated the submission of the PAN by every participant in the securities market. Members holding shares in electronic form are, therefore, requested to submit their PAN to their Depository Participant(s).
- (i) In compliance with the aforesaid MCA General Circulars and SEBI Circular dated 12th May, 2020, 15th January, 2021, 13th May, 2022 and 05th January, 2023, Notice of the AGM along with the Annual Report 2024-25 is being sent only through electronic mode to those Members whose email addresses are registered with the Company/ Depositories. A weblink containing exact path where details of Annual Report is available for those shareholders whose email id is not registered with the Company.
- (j) The Members are requested to register their e-mail address, in respect of demat holdings with the respective Depository Participant by following the procedure prescribed by the Depository Participant.
- (k) Members may note that the Notice and Annual Report 2024-25 will also be available on the Company's website www.docmode.org, website of National Stock Exchange of India Limited at www.nseindia.com.
- (l) Institutional/Corporate Shareholders (i.e. other than individuals/HUF, NRI etc.) are required to send a scanned copy (PDF/JPG Format) of its board or governing body Resolution/Authorization etc, authorizing its representative to attend the physical AGM on its behalf or to vote at AGM. The said Resolution/Authorization shall be sent to the Scrutinizer by email through registered email address to csvjobanputra@gmail.com with a copy marked to the Company at legal@docmode.com.
- (m) The Register of Directors and Key Managerial Personnel and their shareholding maintained under section 170 of the Act and Register of Contracts or arrangements in which directors are interested maintained under section 189 of the Act, and any other relevant documents referred to in this Notice of AGM and explanatory statement and also referred in other reports attached with this notice, will be available physically for inspection by the members without any fee during AGM. Members seeking to inspect such documents, can send an email to legal@docmode.com
- (n) In case of joint holders, the Member whose name appears as the first holder in the order of names as per the Register of Members of the Company will be entitled to vote at the AGM.

- (o) Members who would like to express their views or ask questions during the AGM may register themselves till Tuesday, September 23, 2025, by sending request mentioning their name, demat account / folio number, email id, mobile number through their registered email to the Company at legal@docmode.com. Members holding shares as on the cut-off date shall be entitled to register and participate at the AGM. Members who are registered in advance will only be allowed to express their views or ask questions at AGM. The Company reserves the right to restrict the number of questions and number of speakers, depending upon availability of time as appropriate for smooth conduct of the AGM.
- (p) The facility for voting through Ballot Paper shall be made available at the AGM and the members attending the AGM, who are otherwise not barred from attending the meeting, shall be able to exercise their right to vote at the AGM through Ballot Paper.
- (q) The Members, whose names appear in the Register of Members / list of Beneficial Owners as on 23rd September, 2025, being the cut-off date, are entitled to vote on the resolutions set forth in this notice. A person who is not a member as on the cut-off date should treat this Notice for information purposes only. Once the vote on a resolution(s) is cast by the Member, the Member shall not be allowed to change it subsequently.
- (r) The relevant details, pursuant to Regulations 26(4) and 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ("SEBI Listing Regulations") and Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India, in respect of Directors seeking re-appointment at this AGM is annexed as **Annexure -1**.
- (s) Details of Scrutinizer and result of e-voting:
- a. The Company has appointed M/s. Vidhi Jobanputra & Co., Practicing Company Secretary (FCS No.: 11160 | C. P. No.: 22293) to act as the Scrutinizer, to scrutinize the entire e-voting in a fair and transparent manner.
 - b. The Scrutinizer shall submit his report to the Chairman of the meeting or any person authorized by him within two working days of the conclusion of the AGM. The results declared along with the report of Scrutinizer shall be placed on the website of the Company www.docmode.org and on website of NSDL immediately after declaration of results by the Chairman or person authorized by him in this behalf. The Company shall simultaneously forward the results to National Stock Exchange of India Limited where the shares of the Company are listed.
 - c. The resolution(s) will be deemed to be passed on the AGM date subject to receipt of the requisite number of votes in favour of the resolution(s). The Results declared along with the Scrutinizer's Report(s) will be available on the website of the Company at <https://docmode.org/> and the communication will be sent to the National Stock Exchange of India Limited.

EXTRACT OF EXPLANATORY STATEMENT APPROVED IN MINUTES IN RESPECT OF THE SPECIAL BUSINESS PASSED PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013, READ WITH REGULATION 36 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

The following statement set out all material facts and details relating to Item No. 4 & 5 mentioned in the accompanying Notice.

ITEM NO. 4:

The Members are hereby informed that the provisions of the Regulation 23 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, does not apply to the company as being SME. However, the provisions of Section 188(1) of the Companies Act, 2013 governs the Related Party Transactions for entering into any contract, transactions or arrangement with the related party(ies), the Company obtain the approval of Shareholders by way of a resolution as prescribed in Rule 15 of the Companies (Meeting of Board and its Power) Rules, 2014. The Company proposes to enter into certain related party transaction(s) as mentioned below, on mutually agreed terms and conditions, and the aggregate of such transaction(s), may cross the applicable materiality thresholds as prescribed in rule 15 of the Companies (Meeting of Board and its Power) Rules, 2014.

Accordingly, the prior approval of the members is being sought for all such arrangements/ transactions proposed to be undertaken by the Company. All the said transactions shall be in the ordinary course of business of the Company and on an arm’s length basis. The Audit Committee has, on the basis of relevant details provided by the management, as required by the law, at its meeting held on 30th May, 2025, reviewed and approved the said transaction(s), subject to approval of the Members, while noting that such transaction shall be on arms’ length basis and in the ordinary course of business of the Company.

The Board of Directors in the meeting held on 30th May, 2025, and the Audit Committee has, in the meeting held on 30th May, 2025, under Section 177, provided Omnibus Approval for certain Transactions with companies who are related parties of the company in the following matters under Section 188 (1) of Companies Act, 2013 which are repetitive in nature, at arm’s length and in ordinary course of business for the financial year 2025-26:

Name of the related party and its relationship with the listed entity or its subsidiary, including nature of its concern or interest (financial or otherwise)	Aumen Healthcare Private Limited Paresh Jaysih Sampat, who has been appointed as Managing Director is Common Director	Augmentors Healthcare Limited Paresh Jaysih Sampat, who has been appointed as Managing Director is Common Director	Chemolec Enterprises LLP Paresh Jaysih Sampat, who has been appointed as Managing Director is Common Director
Type, tenure, material terms and particulars	Material terms and conditions are based on the contracts which inter alia include the rates based on prevailing/ extant market conditions and commercial terms as on the date of entering into the contract(s). Approval of the shareholders is being sought for entering into an transactions mentioned under “Nature of Transactions” during FY 2025-26	Material terms and conditions are based on the contracts which inter alia include the rates based on prevailing/ extant market conditions and commercial terms as on the date of entering into the contract(s). Approval of the shareholders is being sought for entering into an transactions mentioned under “Nature of Transactions” during FY 2025-26	Material terms and conditions are based on the contracts which inter alia include the rates based on prevailing/ extant market conditions and commercial terms as on the date of entering into the contract(s). Approval of the shareholders is being sought for entering into an transactions mentioned under “Nature of Transactions” during FY 2025-26

Nature of transaction as per Section 188 of the Companies Act, 2013	Transactions / Contracts / Purchases / Sales / of Goods / Services and availing or rendering of any services	Transactions / Contracts / Purchases / Sales / of Goods / Services and availing or rendering of any services	Transactions / Contracts / Purchases / Sales / of Goods / Services and availing or rendering of any services
Value of Proposed Transactions (in Rs.)	10,00,00,000	10,00,00,000	10,00,00,000
The percentage of the listed entity's annual consolidated turnover, for the immediately preceding financial year, that is represented by the value of the proposed transaction (and for a RPT involving a subsidiary, such percentage calculated on the basis of the subsidiary's annual turnover on a standalone basis shall be additionally provided)	Regulation 23 of LODR is not applicable to the company. However, as per provisions of section 188 of the companies Act, 2013, "nature of Transactions" mentioned above may exceed 10% of the turnover of the company.	Regulation 23 of LODR is not applicable to the company. However, as per provisions of section 188 of the companies Act, 2013, "nature of Transactions" mentioned above may exceed 10% of the turnover of the company.	Regulation 23 of LODR is not applicable to the company. However, as per provisions of section 188 of the companies Act, 2013, "nature of Transactions" mentioned above may exceed 10% of the turnover of the company.
If the transaction relates to any loans, inter-corporate deposits, advances or investments made or given by the listed entity or its subsidiary:			
i) details of the source of funds in connection with the proposed transaction;	NA	NA	NA
ii) where any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments, • nature of indebtedness; • cost of funds; and • tenure;	NA	NA	NA
iii) applicable terms, including covenants, tenure, interest rate and repayment schedule, whether secured or unsecured; if secured, the nature of security; and	NA	NA	NA
(iv) the purpose for which the funds will be utilised by the ultimate beneficiary of such funds pursuant to the RPT	NA	NA	NA
Justification as to why the RPT is in the interest of the listed entity	Mr. Paresh Sampat, Managing Director of the company is common director in above mentioned related party companies	Mr. Paresh Sampat, Managing Director of the company is common director in above mentioned related party companies	Mr. Paresh Sampat, Managing Director of the company is common director in above mentioned related party companies
Any valuation or other external report relied upon by the listed entity in relation to the transactions	NA	NA	NA
Any other information that may be relevant	All important information forms part of the statement setting	All important information forms part of the statement setting	All important information forms part of the statement setting out material facts, pursuant to Section 102(1)

	out material facts, pursuant to Section 102(1) of the Companies Act, 2013 forming part of this Notice	out material facts, pursuant to Section 102(1) of the Companies Act, 2013 forming part of this Notice	of the Companies Act, 2013 forming part of this Notice
Material terms of the contract or arrangement including the value, if any	As per agreed terms	As per agreed terms	As per agreed terms
Advance paid or received for the contract or arrangement, if any	Nil	Nil	Nil
Manner of determining the pricing and other commercial terms, both included as part of contract and not considered as part of the contract	As per the Market Price	As per the Market Price	As per the Market Price
Whether all factors relevant to the contract have been considered, if not, the details of factors not considered with the rationale for not considering those factors	Yes	Yes	Yes
Any other information relevant or important for the Board to take a decision on the proposed transaction	Nil	Nil	Nil

Accordingly, the members are requested to review the above-mentioned related party transactions under Section 188 (1) of Companies Act, 2013 which the Company may enter in the financial year 2025-26. Since the aforesaid Sections requires approval of the Shareholders of the Company by way of passing resolution, your Directors recommend the resolution set out in Item no. 4 for your approval.

Except Mr. Paresh Jaysih Sampat and his relatives, none of the Directors, Key Managerial Persons (KMPs) of the Company or any relatives of such Director or KMPs, shall be considered to be concerned or interested in the proposed resolutions, except to the extent of their shareholding.

ITEM NO. 5:

To consider the Payment of Remuneration to Mr. Hans Albert Lewis, Whole Time Director of the Company:

The Members are hereby informed that Mr. Hans Albert Lewis was appointed as a Whole-Time Director of the Company for a period of 5 (Five) years with effect from 12th December, 2022, by the Board of Directors in its meeting held on the same day.

At the time of his appointment, the Company was a private limited company and, therefore, the provisions of Section 197 of the Companies Act, 2013 were not applicable. However, the Company was converted into a public limited company w.e.f. 2nd January, 2023, and consequently various provisions of the Companies Act, including Section 197, Section 198 and Schedule V, became applicable to the Company from that date.

In view of this, the Board of Directors, at its meeting held on 6th January, 2023, approved the payment of remuneration to Mr. Hans Albert Lewis for a period of 3 (Three) years commencing from 2nd January, 2023, subject to the approval of the Members, which was subsequently obtained in the Extra-Ordinary General Meeting of the Company held on 6th January, 2023.

Now, for the balance period of 2 (Two) years of his existing tenure, i.e., from 2nd January, 2026 to 11th December, 2027, the Company proposes to continue payment of remuneration to Mr. Hans Albert Lewis on the same terms and conditions which were earlier approved by the Members and in compliance with the provisions of the Companies Act, 2013 and Schedule V thereto.

As a private limited company, he was obtaining following remuneration from the company and same remuneration shall be paid to him as Whole Time Director of the public listed company:

A) Salary and Perquisites:
Salary 3,25,000/- (Rupees Three Lakhs Twenty-Five Thousand only) per month
Perquisites: As may be decided by the Board.

B) The Whole Time Director shall also be eligible to the following perquisites which are not included in the computation of ceiling remuneration specified in the said Part II Section IV of Schedule V of the Companies Act, 2013:

- 1. Contribution to Provident Fund, Superannuation Fund or Annuity Fund to the extent these either singly or put together are not taxable under the Income Tax Act, 1961.
- 2. Gratuity payable at a rate not exceeding half a month’s salary for each completed year of service.
- 3. Encashment of the leave at the end of the tenure.

Apart from the company, from no other places he is not obtaining remuneration.

C) Other terms:

- 1. He shall be entitled to re-imbursement of actual out of pocket expenses incurred in connection with the business of the Company.
- 2. He shall be entitled to re-imbursement of entertainment expenses incurred for the business of the Company.
- 3. As long as he functions as Whole Time Director, he shall not be paid any sitting fees to attend any meeting of the Board and/or Committee thereof.
- 4. In the event of inadequacy or absence of profits in any financial year, he will be entitled to the payment of salary and perquisites, as may be decided by the Board, as minimum remuneration, subject to necessary approvals, if required notwithstanding the fact that it may exceed the limits prescribed under Section 196, 197 of the Companies Act, 2013, along with the perquisites stated under point (B) above which are not included in the computation of limits for the remuneration or perquisites aforesaid.
- 5. He shall be entitled to earned/privileged leave as per the Rules of the Company.
- 6. He shall be entitled for telephone facility as per Company’s policy.

Further, pursuant to the provisions of Section 117(3), 197, Schedule V as applicable and other applicable provisions, if any, of the Companies Act, 2013, the said terms & conditions of remuneration shall be placed for the approval of the members in the Annual General Meeting.

Accordingly, the Board recommends the resolution as set out at Item No. 05 of the Notice in relation to the remuneration to Mr. Hans Albert Lewis as Whole Time Director, for the approval by the members of the Company, by way of a Special resolution.

Except Mr. Hans Albert Lewis, himself, no other Director or Key Managerial Personnel of the Company and their relatives is concerned or interested, financial or otherwise, in the resolution set out at Item No. 05 of the notice.

The necessary information/disclosure in compliance with Schedule V of the Companies Act, 2013 relating to Mr. Hans Albert Lewis has been provided below:

I. General Information:

No.	Particulars/Subject	Information
1.	Nature of Industry	IT enabled services. It provides IT Platform for Outcome based Learning in Healthcare
2.	Date or expected date of commencement of commercial Production	17 th July, 2017
3.	In case of new companies, expected date of commencement of activities as per project approved by financial institutions appearing in the prospectus	N.A.

4.	Financial performance based on given indicators	In the Financial Year 2024-25, the Company made a total turnover of Rs. 4270.27 Lakhs (including other income) and Loss of Rs. 203.14 Lakhs after tax.
5.	Export performance and net foreign exchange collections	During the Financial Year 2024-25, Export of services of Rs. 6.89 Lakhs (Previous Year Rs. 10.45 Lakhs).
6.	Foreign Investments or collaborators, if any.	N.A.

II. Information about the Appointee:

No.	Particulars/Subject	Information
1.	Background Details	Hans Albert Lewis has completed his graduation in Mass Media, Advertising from Wilson College, Mumbai in the year 2004 and Master Degree in Philosophy in 2015. He has more than 16 years of experience in the field of Mass Media and Advertisement. He has worked in the field of Healthcare Advertising as a Copywriter and followed up as a Sponsorship Head in Medical Events.
2.	Past Renumeration	Same as mentioned under Point A above of the explanatory statement
3.	Recognition or Awards	Nil
4.	Job Profile and his Suitability	As the Whole Time Director of the Company, he is responsible for the marketing strategy, online advertising and Social Media Marketing and day to day management of the Company. In view of his enriched experience, appreciable contribution and enlarged leadership, the Board proposes for the payment of remuneration to Mr. Hans Albert Lewis, Whole Time Director, for a further period of 2 (Two) Years w.e.f. 02nd January, 2026, as per the details stated in explanatory statement of Item No. 05 of the Notice.
5.	Remuneration proposed	Salary, other perquisites and other terms as fully set out in the explanatory statement of Item No. 05 of the Notice. The remuneration proposed is as per Section II of Part II of Schedule V of the Companies Act, 2013.
6.	Comparative remuneration profile with respect to industry, size of the company, profile of the position and person	The remuneration proposed is as per Section II of Part II of Schedule V of the Companies Act, 2013 which is comparable with the Companies of the same size and profitability.
7.	Pecuniary relationship directly or indirectly with the company personnel, if any	Apart from the remuneration and perquisites paid to them as Whole-time Directors as stated above and their respective shareholding held directly in the Company, he do not have any pecuniary relationship directly or indirectly with the Company and its managerial personnel.

III. OTHER INFORMATION

No.	Particulars/Subject	Information
1.	Reason of loss or inadequate profits	Company has been facing temporary liquidity constraints arising from a slowdown in collections, increased working capital requirements, and timing mismatches in operational cash flows, this resulted into loss or inadequate profits.
2.	Steps taken or proposed to be taken for improvement	The Company has adopted the following measures to improve the profitability: 1. Modernisation of existing facilities to improve overall operating efficiency 2. Widening of customer base and better market penetration, especially in overseas market 3.Conscious effort to develop products/customers base in alternate market segments. 4. Focus on significant improvements in operating costs 5. Cost control in all areas 6. Deeper penetration in the replacement market in India & abroad
3.	Expected increase in the productivity and profits in measurable terms	It is difficult to forecast the productivity and profitability in measurable terms. However, the Company expects that productivity and profitability may improve and would be comparable with the industry average.

Further, as stipulated under Regulation 36 (3) of the Listing Regulations, 2015 and Para 1.2.5 of Secretarial Standard-2, brief profile of Mr. Hans Albert Lewis is provided below:

Age	40 years
Experience	He has more than 16 years of experience in the field of Mass Media and Advertisement.
Terms and Conditions of appointment	He is Appointed as Whole Time Director of the company w.e.f. 12 th December, 2022 on terms and conditions as mentioned in the draft letter of appointment as placed before the meeting
Details of remuneration	Remuneration details are mentioned above under Item No. 5 of the notice.
Date of first appointment	He is appointed since incorporation of the company w.e.f. 17 th July, 2017
Shareholding in the Company	13.06%
Relationship with other director/Manager and other KMP	None
Number of Board meetings attended during the year	Ten
Directorships of other Board	1. Jephersons Communications Private Limited 2. CCME World Services Private Limited
Membership/Chairmanship of Committees of other Board	Nil

As stipulated under Regulation 36 (3) of the Listing Regulations, 2015 and Para 1.2.5 of Secretarial Standard-2, brief profile of Mr. Paulson Paul Thazhathedath is provided below:

Age	42 years
Experience	He has more than 15 years of experience in the field of Mass Media and Advertisement.
Terms and Conditions of appointment	He is appointed as Managing Director of the company w.e.f. 12 th December, 2022 on terms and conditions as mentioned in the draft letter of appointment as placed before the meeting
Details of remuneration	39,00,000 per Annum
Date of first appointment	He is appointed since incorporation of the company w.e.f. 17 th July, 2017
Shareholding in the Company	17.77% out of which 4.71% is subject to invocation of pledge
Relationship with other director/Manager and other KMP	None
Number of Board meetings attended during the year	Ten
Directorships of other Board	1. Jephersons Communications Private Limited 2. CCME World Services Private Limited
Membership/Chairmanship of Committees of other Board	Nil

FOR DOCMODE HEALTH TECHNOLOGIES LIMITED

PAULSON PAUL THAZHATHEDATH
WHOLETIME DIRECTOR & CHAIRMAN
DIN: 02301881

Date: 29.08.2025
Place: Mumbai

ATTENDANCE SLIP
(to be presented at the entrance)

Members attending the Meeting are requested to complete the Attendance Slip and hand it over at the entrance of the meeting room.

I hereby record my presence at the 8th (Eighth) Annual General Meeting of the Company at 30th September, 2025, Tuesday, at 2.00 p.m., at the corporate office of the company situated at 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India.

Folio No/ DP ID No.: _____

Name of the Member(s): _____ Signature: _____

Name of the Proxy holder(s): _____ Signature: _____

Note:

- 1. Only Member(s)/ Proxy holder(s) can attend the Meeting.
- 2. Member(s)/ Proxy holder(s) should bring his/ her copy of the Notice for reference at the Meeting.

Form No. MGT - 11
PROXY FORM

[Pursuant to Section 105(6) of the Companies Act, 2013 and Rule 19(3) of the Companies (Management and Administration) Rules, 2014]

CIN: L74999MH2017PLC297413
Name of the Company: Docmode Health Technologies Limited
Registered Office: 307, Shivai Plaza, Marol Cooperative Industrial Estate Road, Sagbag, Marol, Andheri East, Mumbai – 400059, Maharashtra, India.

Name of the member(s):	
Registered address:	
E- Mail id.:	
Folio No. / Client Id.:	
DP ID.:	

I/We, being the member (s) of _____ shares of the above named company, hereby appoint

1. Name: _____
Address: _____
E-mail Id: _____

Signature: _____, or failing him

2. Name: _____
Address: _____
E-mail Id: _____

Signature: _____, or failing him

3. Name: _____
Address: _____
E-mail Id: _____

Signature: _____

as my/our proxy to attend and vote for me/us and on my/our behalf at the 8th (Eighth) Annual General Meeting of the Company, to be held on 30th September, 2025, Tuesday at 02.00 p.m. at the corporate office of the Company situated at 201, Kalpataru Plaza, Rambaug Off Chincholi Bunder Road, Malad West, Mumbai – 400064, Maharashtra, India, and at any adjournment thereof in respect of such resolutions as are indicated below:

Resolution No.

1. To receive, consider and adopt the Standalone Audited Balance Sheet for the period ended 31st March, 2025, the Profit & Loss Accounts as on that date together with reports of Directors and Auditors thereon;
2. To receive, consider and adopt the Consolidated Audited Balance Sheet for the period ended 31st March, 2025, the Profit & Loss Accounts as on that date together with Reports of Directors and Auditors Thereon;
3. To approve and recommend the reappointment of Mr. Paulson Paul Thazhathedath (DIN: 02301881), Whole Time Director, liable to retire by rotation at the 8th Annual General Meeting of the Company;
4. Approval of Related Party Transactions.
5. To consider the payment of remuneration to Mr. Hans Albert Lewis, Wholetime Director of the company.

Signed this 29th day of August, 2025

Affix Revenue
Stamp

Signature of shareholder

Signature of Proxy holder (s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

Route Map to the venue of Annual General Meeting

